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The purpose of this doctoral research is to develop a 
biosensor for the monitoring of heart failure (HF) in 
humans. Currently, there is no quantitative patient-
facilitated method to monitor HF, and the physical symptoms 
that result are a poor representation of the acute state of 
the disease. The biomarker of interest is N-terminal 
prohormone brain natriuretic peptide (NT-proBNP) which is 
secreted from the cardiac muscle tissue when the heart is 
experiencing decompensation. The concentration of NT-proBNP 
has a direct correlation to the severity of HF, and it is 
used as the antigen in a metalloimmunoassay, where two 
monoclonal antibodies are used to sandwich NT-proBNP. One 
is conjugated to a magnetic microbead via a streptavidin-
biotin interaction, and the other is conjugated to a 20 nm-
 vii 
diameter silver nanoparticle (AgNP) using a 
heterobifunctional cross-linker. The fully formed 
metalloimmunoassay is placed on a carbon screen-printed and 
Au electrodeposited sensing electrode to detect AgNP labels 
electrochemically. Ag charge collected from the assay is 
representative of the concentration of NT-proBNP in the 
sample. A phenomenon known as galvanic exchange (GE) is 
utilized in the detection of Ag. GE is a process that 
occurs when a zerovalent metal is immersed in a solution 
containing the oxidized form of a more noble metal. In this 
specific case, the exchange occurs between AgNP in the 
metalloimmunoassay and Au3+ generated on the sensing 
electrode. GE occurs because the standard reduction 
potential of Ag+ is slightly lower than Au3+. Significant 
findings of this project reveal that GE between AgNP and 
Au3+ is a process that results in only a partial exchange of 
AgNP with the Au3+ under physiologic conditions. It has also 
been found that, implementing two subsequent Au3+ 
electrogeneration steps improve the Ag collection 
efficiency and the reproducibility. Additionally, using 
heterobifunctional cross-linkers to covalently attach 
antibodies to AgNP and silver nanocubes (AgNCs) results in 
a lower limit of detection. These findings have led to the 
detection of NT-proBNP in buffer within clinically relevant 
ranges of 0.06-3.49 nM. 
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Chapter 1: Introduction 
1.1 Electrochemical biosensors 
A biosensor is a tool that takes a biological sample, pinpoints 
a specific biomarker via a capture assay or a labeled probe, and 
provides the user with either qualitative or quantitative 
analytical information about the concentration of the biomarker 
of interest.1 Some biosensors fall into a category known as 
point-of-care (POC) diagnostic devices in which rapid results 
are given to the user at the point of care. These devices can be 
constructed from glass,2,3 plastic,4,5 or paper4,6,7 and are often 
fabricated in the form of microfluidic or lateral-flow 
constructs.8,9 There are also hybrid designs which combine 
several different materials.10 Typically, the signal or response 
that is generated from the sensor is either in the form of a 
change in spectroscopic absorption,11 fluorescence emission,12,13 
or electrochemical current.14–17  The readout from the device is 
then usually correlated to a calibration curve so that the 
specific response can be measured. From there, the user, whether 
that is the patient, physician, or clinician, makes a decision 
about treatment based on the results provided.  
The unique, nearly equipment-free design of POC and point-





such as at home,18,19 in clinics,20–22 and in hospitals.23,24 The 
matrix in which the analyte is naturally present and stable in 
is a key element to consider when designing POC devices. 
Biomarkers and metabolites are found in an assortment of 
different matrixes such as urine,25 saliva,26–28 sweat,29,30 and 
whole blood.31,32 In some cases, these matrixes can be 
beneficial33,34 to detection, while in others can be 
detrimental.35,36 
An example of a POC electrochemical biosensor which became 
a pivotal tool in health care and in the disease management of 
diabetes was the blood glucose meter. In 1987, Matthews et al. 
constructed a pen-shaped sensor which used a paper test strip to 
electrochemically detect glucose levels in whole blood.37,38 This 
device eventually evolved into the more familiar and 
commercially available personal glucose meter, which was 
developed by Csöregi and coworkers.39 Another example of a 
momentous POC biosensor is the paper-based lateral flow device 
which detected the pregnancy hormone, human chorionic 
gonadotropin, in an enzymatic immunoassay.37 This laid the 
groundwork for the modern at-home pregnancy test. 
To construct a successful and useful POC device, several 
characteristics must be kept in mind. Specifically, these 





specificity, user-friendliness, and the tools also need to be 
rapid, robust, equipment free, and deliverable to the end-user 
according to the World Health Organization.40  To achieve all of 
these features in one POC test, a great deal of ingenuity needs 
to go into bioassay design. 
1.2 Designs of bioassays 
Designing a bioassay ultimately requires four parts: (1) 
recognition elements such as antibodies (Abs), nucleic acids, or 
aptamers to capture the biomarker or analyte of interest; (2) a 
signal amplification mechanism such as enzymes or nanoparticles 
(NPs) so that detection can be performed within clinically 
relevant concentration ranges; (3) a bioconjugation technique to 
immobilize the recognition element to the signal amplifier; and 
(4) a detection mechanism. All these pieces combine to create 
the everyday biosensors that are familiar to us today. In 
Illustration 1.1, the clinically relevant concentration ranges 
for different biomolecules, specifically small molecules, 
nucleic acids, and proteins are shown. This illustration 
illuminates the vast and wide concentration ranges that 






Illustration 1.1 Diagram showing the reference concentration 
ranges for the detection of different clinically relevant small 
molecules, nucleic acids, and proteins sorted by mass.41 Image 







1.2.1 Recognition elements 
Depending on the target biomolecule, several different 
recognition elements can be used in the bioassay. In this 
context, a recognition element refers to a material or process 
that can selectively extract the target molecule from its 
matrix. These elements can include Abs, nucleic acids, or 
aptamers. 
Monoclonal Abs are commonly the tool of choice when Abs are 
used as recognition elements. The primary characteristic that 
sets monoclonal Abs apart from polyclonal Abs is the presence of 
only one epitope on the Abs antigen-binding region. This feature 
plays a key role in the sensitivity and selectivity of the 
bioassay to the antigen. Polyclonal Abs have more than one 
epitope on the antigen-binding regions of the Ab, and depending 
on the purpose of the assay, this can be detrimental to the 
selectivity of the sensor because biomolecules other than the 
biomarker of interest can potentially bind to those regions. 
Typically, Abs are used in the form of a sandwich assay in which 
a capture Ab is immobilized on a surface, and a labeled 






Nucleic acid recognition elements involve a noncovalent 
interaction between bases of complimentary nucleic acid strands 
and is manifested by hybridization between an immobilized 
capture probe and a complementary sequence.43,44 This bioassay can 
be constructed as either a stem-loop or linear probe depending 
on the structure and length of the nucleic acid sequence.45 This 
mechanism can generate signal-ON46 and signal-OFF47 
electrochemical sensors when the target biomolecule is captured.  
Aptamers are nucleic acid ligands that are another commonly 
used recognition element used in biosensors. These work 
similarly to nucleic acid strands, except for that in contrast 
to the base paring exhibited by nucleic acid, aptamers can fold 
to form highly specific three-dimensional structures due to 
their self-annealing properties.48,49 This results in a 
selectivity and binding affinity similar to Abs, and these 
features can be tailored during the aptamer selection process. 
Aptamers also have the advantage of being highly robust in that 
they can survive numerous rounds of denaturation and 
renaturation on the sensor surface during the detection 
process.50–52  
1.2.2 Signal amplification 
Signal amplification is another key part of a successful 





biomolecule that is captured, an ideal sensor should generate 
more than just one unit of signal. This aspect of bioassay 
construction is usually accomplished by using fluorescent 
probes,53 NPs,54 or enzymatic labels;55 for example, in enzyme-
linked immunosorbent assays (ELISA). Enzymes such as horseradish 
peroxidase and alkaline phosphate are traditionally used in 
immunoassays and result in an obvious color change when the 
target biomolecule is captured and is exposed to oxidizing 
reagents. The use of metallic or semiconduction NPs for signal 
amplification is becoming increasingly more common. This is due 
to their generally higher stability, lower cost, and faster 
read-out times.41,56 Note that an immunoassay that uses an NP as a 
recognition element is referred to as a metalloimmunoassay. 
In Illustration 1.2, a general detection process involving 
noble metal NPs is shown. Due to the different electrochemical, 
optical, and piezoelectric properties of NPs, a variety of 
transduction methods have been reported. The Crooks group in 
particular has been pioneering the use of NPs as detection 
labels over the last 10 years. Specifically, the use of silver 
NPs (AgNPs) for detection of an assortment of biomolecules.57–59 
The idea here is that for every one target biomolecule that is 
captured and forms a sandwich assay, there are hundreds of 





within that one formed immuno-sandwich. For example, there are 
~250,000 Ag atoms in a 20 nm-diameter AgNP (Illustration 1.3). 
This means that for one sandwich assay, a signal amplification 
of up to 250,000-fold is possible.  
 
 
Illustration 1.2. Scheme showing the role of noble metal NPs in 










Illustration 1.3 Schematic of a detection method involving the 
use of a model composite containing streptavidin-coated magnetic 
microbead (MµBs) to immobilize AgNP-biotin conjugates to the 
bead surface. (a) Pre-concentration of formed model conjugate at 
the working electrode surface. (b) Chemical oxidate of the AgNP 
with KMnO4. (c) Electrodeposition of the Ag+. (d) Anodic 
stripping of the electrodeposited Ag0 from the electrode surface 
for quantification. Image sourced from Reference 61.61 
 
1.2.2 Bioconjugation techniques 
After the appropriate recognition elements have been selected 
for the bioassay, those elements usually require some type of 
attachment to a signal amplification mechanism. In the context 
of monoclonal Abs and metal NPs, there are two common methods: 
chemisorption (physisorption) and covalent linkage. 
Physisorption relies primarily on interactions between the NP 





approach is widely used due to it being fast and easy, however a 
main limitation to this approach is the fact that Abs are not 
well-oriented on the NP surface. This results in the antigen-
binding regions of the Abs having limited access to target 
molecules in a sample which reduces the activity of the Abs.  
 Covalent linkage of Abs to NP can be done in a controlled 
manner depending on the regions of the Ab that are targeted. 
There are two main regions of an Ab, the antigen-binding region 
and the fragment crystallizable (Fc) region. Ideally, 
conjugation techniques should avoid the antigen-binding region 
as much as possible to ensure that it is undamaged during 
modifications. Some examples of covalent-linking techniques 
include 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) and 
N-hydroxysuccinimide (NHS) mediated cross-linker conjugation.62 
These methods, however, also target the primary amines on the Ab 
which can be located in the antigen-binding region. 
1.3 Electrochemical detection  
When the bioassay is finally fully formed, the next step is 
detection. Electrochemical detection techniques can be 
classified into four main types including 
voltammetric/amperometric, impedimetric, conductometric, and 
potentiometric.63,64  Voltammetric and amperometric biosensors 





electrode and measure the current. The current arises from 
electrolysis by means of an electrochemical oxidation or 
reduction at the working electrode and is limited by the mass 
transport rate of the reactant molecules from the bulk solution 
to the electrode interface. Amperometric biosensors offer 
additional selectivity because their oxidation or reduction 
potential used in analysis is typically characteristic of the 
analyte species.63  
Electrochemical impedance spectroscopy is a technique that 
uses an AC source to perturbate a system and measure the 
response. The frequency is changed over a wide range to obtain 
an impedance spectrum. The in-phase and out-of-phase current 
responses are then measured to determine the resistive and 
capacitive components of the circuit.41,65 In the context of 
biosensors, a rate limiting component at high frequency is the 
migration rate of the redox species to the electrode surface. 
Due to this, analyte can block the electrode and this generates 
a frequency-dependent phase lag between the AC voltage and the 
current.63 
Conductometric biosensors measure changes in the electrical 
conductivity of a sample solution as the composition of the 
solution changes during a chemical reaction. These biosensors 





the ionic strength of the sample solution.64 Enzymes are also 
typically involved in potentiometric biosensors in which an ion-
selective membrane reacts with the charged ion of interest. 
Enzymes can catalyze the reaction that forms the ion, which can 
be detected by the underlying electrode. The selection of all of 
these techniques, however, can be different for each biosensor 
detection system. 
1.4 Research summary and accomplishments 
This dissertation focuses on a combination of the core concepts 
discussed in Section 1.2 and 1.3. These concepts were involved 
in the design of an electrochemical biosensor for the heart 
failure biomarker, N-terminal prohormone brain natriuretic 
peptide (NT-proBNP). In particular, the formation of 
metalloimmunoassay which includes the use of monoclonal Abs 
conjugated to AgNPs and MµBs, followed by electrochemical 
detection via galvanic exchange/anodic stripping voltammetry 
(GE/ASV). 
Specifically, Chapter 2 presents an in-depth investigation 
of the GE/ASV detection method using a model bioassay. The model 
assay is prepared with 110 nm AgNPs conjugated to a MµB surface 
via a streptavidin-biotin interaction. The morphology of the 
AgNPs are observed by scanning electron microscopy (SEM) after 





two GE cycles, a Au shell was formed on the surface of the 
AgNPs, which essentially prevent further GE in the system. 
Chapter 3 discusses the use of a heterobifunctional cross-
linker to properly orient monoclonal Abs on the surface of AgNPs 
in a controlled manner. The goal of this work is to preserve the 
activity of the Abs during their immobilization onto the AgNP 
surface. This involved the synthesis of two slightly different 
cross-linkers, each of which included a thiolated-end for the 
covalent linkage to the AgNP surface, and a hydrazide-end which 
attached to the Fc region of the Ab. This resulted in the 
conjugate of ~5 active Abs per AgNP, and these conjugates were 
stable for at least 2 weeks. 
Chapter 4 integrates the use of the heterobifunctional 
cross-linker (HBCL) into the metalloimmunoassay for NT-proBNP. 
This work compared the performance of the assay when a AgNP-Ab 
conjugate was formed via physisorption instead of the HBCL. A 
27-fold increase in Ag signal was found when the HBCL was used, 
and we determined that the NT-proBNP assay could be formed in 
undiluted serum with no detectable interferences from the serum 
components. The linear dynamic range for this bioassay was 0.58-
2.33 nM, which is only about 5-fold higher than the risk 





Chapter 5 investigates the effects of serum on assay 
formation, washing steps, and electrochemical detection methods. 
Specifically, the GE/ASV technique was targeted and, both a 
model and antigen-specific bioassay were used. This work 
revealed that serum has no detectable effect on the formation of 
these assays, however when no washing is performed after assay 
formation even 0.50% serum remaining in the sample renders the 
detection inaccurate. Additionally, chelation of Au3+ and surface 
absorption to AgNP by serum components significantly inhibit GE. 
Chapter 6 aims to further lower the limit of detection for 
the NT-proBNP metalloimmunoassay, which contains spherical 
silver nanoparticles (sAgNPs), by incorporating the use of 
silver nanocubes (AgNCs) into the assay. This work revealed that 
by using an optimal volumetric ratio of both NPs in a single 
assay that the total collected Ag charge could be increased by 
20%. The addition of the AgNCs in the assay also led to a 
threefold decrease in the limit of detection for a model assay, 
as well as a decrease of one order of magnitude in the antigen-
specific assay for NT-proBNP. This improvement allowed for the 
linear dynamic range of the NT-proBNP assay to overlap with the 
clinically relevance concentration range used by physicians to 






Chapter 2: Detection of Silver Nanoparticles by 
Electrochemically Activated Galvanic Exchange 
2.1 Synopsis 
This chapter presents on the seemingly simple process of 
galvanic exchange (GE) between electrogenerated AuCl4– and silver 
nanoparticles (AgNPs). The results were obtained in the specific 
context of using AgNPs as labels for bioassays in paper fluidic 
devices. Results obtained from a combined electrochemistry and 
microscopy study indicate that the GE process results in 
recovery of only ∼5% of the total equivalents of Ag present in 
the system. This low value is a consequence of two factors. 
First, after an initial fraction of each AgNP undergoes GE, a Au 
shell forms around the remaining AgNP core preventing further 
exchange. Second, to simulate a true biological fluid, the 
experiments were carried out in a Cl– -containing buffer. 
Consequently, some Ag+ formed during GE precipitates as AgCl, and 
it also serves to block additional GE. Following optimization of 
the GE process, it was possible to detect AgNP label 
concentrations as low as 2.6 fM despite these limitations. 
 
 Chapter 2 is based on previous publication: M. R. Kogan, N. E. Pollok, 
Crooks, R. M. Detection of Silver Nanoparticles by Electrochemically 
Activated Galvanic Exchange. Langmuir. 2018, 34, 15719–15726. MRK and NEP 
contributed equally to the work. RMC was the research advisor. MRK and NEP 







We recently reported the use of silver nanoparticle (AgNP) 
labels for electrochemical detection of biomolecules58,59,61,66 in 
paper microfluidic sensing devices.6,67–70  In this approach 
(Illustration 2.1), multiple AgNPs are linked to a single 
magnetic microbead (MµB) in the presence of a target.  This MµB-
AgNP conjugate is then drawn to an electrode surface by a 
magnetic force, and the number of AgNPs is analyzed 
electrochemically.  Because there is a one-to-one correspondence 
between the number of target molecules and the number of AgNPs, 
the presence of the target is amplified in proportion to the 
charge stored in each AgNP.57–59  
We have used two closely related electrochemical methods to 
detect the presence of the AgNP labels.  In both cases the AgNPs 
are chemically oxidized, the resulting Ag+ is electrodeposited 
onto the surface of an electrode, and then the amount of 
deposited Ag is determined by anodic stripping voltammetry.  The 
two methods vary only in the method of initial oxidation of the 
AgNPs.  In one case they are chemically oxidized using a 
chemical reagent such as permanganate (MnO4-),57,61 bromine,54,71 or 
hypochlorite (bleach),58 and in the other the oxidation is 
accomplished by a process known as galvanic exchange (GE).59,67,74–





the electrode surface, it is not possible to oxidize them 
directly.61 
GE, which is sometimes called galvanic replacement, has 
been used for decades to efficiently replace one metal with 
another.73,74,76  GE occurs when a zerovalent metal is immersed in 
a solution containing the oxidized form of a more noble metal 
(e.g., a higher standard potential).  The two metals undergo a 
spontaneous exchange of electrons, leading to oxidation of the 
less noble metal (e.g., Ag, E⁰ = 0.79 V) and reduction of the 
more noble metal (e.g., Au, E⁰ = 1.52 V).65  There have been a 
number of interesting fundamental and practical reports relating 
to GE.  For instance, Adzic and coworkers studied the 
electrocatalytic oxygen reduction reaction using nanoparticles 
(NPs) having Pt shells deposited onto different types of metal 
cores by GE.77,78  In another report, Xia and coworkers used AgNPs 
and Ag nanowires as templates to study the morphology of the 
materials resulting after addition of metal salts having higher 
reduction potentials.73,79–81  
Because AgNPs are available commercially in different sizes 
and shapes, and because Ag has a relatively low reduction 
potential, AgNPs are often used as templates for GE.73,74,82,83  For 
example, a number of groups have studied how the optical 





addition of HAuCl4.79,84–88  An important outcome of these studies 
is that, depending upon conditions, both AgCl and Ag+ can result, 
as shown in eqs 2.1 and 2.2.81,82,89–91 
 
4Ag + AuCl4- = 4AgCl + Au     (2.1) 
Ag + AuCl4- = Ag+ + Au + 4Cl-    (2.2) 
 
Importantly, eq 2.1 can lead to deposition of both a Au 
shell and/or an insoluble AgCl shell on the surface of the 
AgNPs, thereby blocking penetration of AuCl4- to the underlying 
AgNP that remains and preventing complete GE.91  As we will 
discuss later, this is an important consideration in our study.  
In the present chapter, we focus on the details of the GE 
processes represented by eqs 2.1 and 2.2.  The experiments are 
carried out using the approach displayed in Illustration 2.1, 
which, with one exception, is directly relevant to the detection 
scheme we have used in previous publications focused on chemical 
sensing.59,66  The one exception is that here we have used 110 nm 
AgNPs and in our prior studies the size was 20 nm.  We found it 
necessary to use the larger particles so that they could be 






Illustration 2.1 Galvanic exchange detection method. 
 
As shown in Illustration 2.1a, GE is implemented as 
follows.  First, a small amount of Au is electrodeposited onto a 
carbon paste working electrode.  Next, the MµB-AgNP conjugates 
are drawn to the electrode surface by a magnetic force.  At this 
point, a fraction of the Au is electrochemically oxidized to 





from left to right.  This results in formation of Ag+ 
(Illustration 2.1b), which is subsequently electrodeposited onto 
the electrode surface as zero-valent Ag (Illustration 2.1c).  A 
final anodic stripping voltammetry step makes it possible to 
determine the total Ag charge recovered from the GE reaction.  
Note, however, that Illustration 2.1 is a highly simplified 
representation of the GE process.  For example, it ignores the 
possibility of AgCl formation, incomplete GE, and mass transfer 
considerations.  The objective of the present study is to better 
define the complex nature of this seemingly simple process so 
that it can be used for electrochemical sensing applications. 
2.3 Experimental 
2.3.1 Chemicals and Materials 
All solutions were made using deionized (DI) water (>18.0 MΩ-cm, 
Milli-Q Gradient System, Millipore, Bedford, MA). NaCl, NaOH, 
HCl, HAuCl4, KNO3, citric acid monohydrate, 4-(2-hydroxymethyl)-
1-piperazineethanesulfonic acid (HEPES), Whatman Grade 1 
chromatography paper (180 µm thick, 20 cm x 20 cm sheets, linear 
flow rate of water = 0.43 cm/min), and siliconized low-retention 
microcentrifuge tubes were purchased from Fisher Scientific 
(Pittsburgh, PA).  Boric acid was purchased from EM Science 





were purchased from Ted Pella (Redding, CA).  A solution 
containing 0.10 M borate and 0.10 M NaCl (referred to henceforth 
as BCl) was prepared by dissolving appropriate amounts of boric 
acid and NaCl in DI water, and then adjusting the pH to 7.5 with 
NaOH.66  
 Conductive carbon paste (Cl-2042) was purchased from 
Engineered Conductive Materials (Delaware, OH).  Cylindrical 
neodymium magnets (1/16 in x ½ in, N48) were purchased from Apex 
Magnets (Petersburg, WV).  Streptavidin-coated MµBs (Dynabeads, 
M-270, 2.8 µm diameter) were obtained from Invitrogen (Grand 
Island, NY).  Lyophilized thiol-DNA-biotin (5’d thiol C6 SS-
ACATTAAAATTC-biotin 3’) was purchased from Biosearch 
Technologies (Petaluma, CA).  Before use, the DNA-biotin was 
hydrated with the appropriate amount of DI water to make a final 
concentration of 1.0 mM.   
2.3.2 Electrochemistry 
All electrochemical measurements were performed using a CH 
Instruments model 760B Electrochemical Workstation (Austin, TX).  
For all electrochemical procedures, the working electrode was 
stencil-printed carbon paste partially covered with 
electrodeposited Au (vide infra).  The counter and reference 
electrodes were a Pt wire and a saturated Hg/Hg2SO4 electrode 





The working electrodes were fabricated by patterning sheets 
of chromatography paper with wax using a Xerox ColorQube 8570DN 
printer.  After printing, the wax was melted through the 
thickness of the paper by placing it in an oven at 120 ⁰C for 
25.0 s.  Next, the paper was cut into 12 rectangles (5.0 cm. x 
6.5 cm.). A stencil for defining the 2.0 mm-diameter, disk-
shaped electrodes was created using CorelDRAW (Ottawa, ON), and 
then it was cut into a thin plastic sheet of transparency film 
using an Epilog laser engraving system (Zing 16).  Finally, the 
stencil was placed over the paper (wax side up), the electrodes 
were printed through the stencil using conductive carbon paste, 
and then the carbon paste was left to dry in air for 14 h. 
Au was electrochemically deposited onto the carbon paste 
electrodes using a polytetrafluoroethylene electrochemical 
cell.59,66 Au electrodeposition was carried out using a solution 
containing 300.0 µL of 6.0 mM HAuCl4 and 0.10 M KNO3.59,67,94  Au 
electrodeposition onto the carbon paste working electrode was 
initiated by stepping its potential from 0 V to -0.20 V vs. 
Hg/Hg2SO4 for 2.0 s.  This potential was chosen based on the 
AuCl4- reduction wave.59,66  During reduction, Au nucleated on the 
carbon paste electrode resulting in dispersed gold nanoparticles 
(AuNPs).67,95  This modified electrode will be referred to 





electrodeposition, the electrode was rinsed twice with DI water 
and dried with a Kimwipe.66  
 
Illustration 2.2 Description of the polylactic acid (PLA) 
electrochemical cell used for all Au oxidation, Ag 
electrodeposition, and anodic stripping voltammetry 
measurements. (a) Photograph of the cell showing the three 
electrodes connected. (b) Cross-sectional view with dimensions.  
This cell was printed using a Modified MakerBot Replicator 2s 3D 
printer using PLA.  A magnet was glued into the opening on the 
back side of the PLA cell, which held the MµB-AgNP conjugates on 
the electrode surface during galvanic exchange (GE). A layer of 
clear nail polish was painted on the interior of the PLA cell to 
prevent the BCl supporting electrolyte from leaking during 
electrochemical measurements.  The PLA cell employs three 
electrodes: a carbon/Au working electrode, a saturated Hg/Hg2SO4 
reference electrode, and a Pt wire counter electrode. MµB-AgNP 
conjugates were dropcast onto the working electrode, dried, slid 
into the 0.10 cm opening of the cell, and aligned in the center 
of the top opening of the PLA cell.  In this position, the 
magnet in the bottom opening of the cell is directly behind the 
working electrode.  To keep the working electrode in place, a 
binder clip was used to clamp the PLA cell and the 
chromatography paper together.  After all three electrodes were 
in place, 150.0 µL of BCl was pipetted into the opening of the 






The GE reactions and Ag anodic stripping voltammetry were 
carried out using an electrochemical cell printed with 
polylactic acid (PLA) using a Modified MakerBot Replicator 2s 3D 
printer.  This cell is referred to hereafter as the "PLA cell" 
(Illustration 2.2).  After the PLA cell was printed, a single 
coat of clear nail polish, obtained from Electron Microscopy 
Sciences (Hartfield, PA), was applied to the interior of the cell 
to seal it and prevent leakage of BCl electrolyte solution.  The 
charge corresponding to AgNP concentration was calculated by 
integrating the anodic stripping voltammetry peaks using Origin 
Pro8 SR4 v. 8.0951 (Northampton, MA). 
2.3.3 Preparation of the MµB-AgNP conjugate 
Biotinylated DNA was immobilized on 110 nm AgNPs using a 
previously reported fast, pH-assisted method.67,96,97  The 
biotinylated DNA immobilized on the AgNPs will henceforth be 
referred to as “AgNP-biotin”.  Next, 400 µL of the AgNP-biotin 
(2.4 x 109 AgNPs/mL) was mixed with 16 µL streptavidin-coated 
MµBs (6-7 x 108 MµBs/mL), and the solution was shaken (1400 rpm) 
for 30 min at 23 ⁰C.61,67,98  Following conjugation, the MµB-AgNP 
conjugates were washed three times by holding the 
microcentrifuge tube up to a magnet, removing the supernatant, 






2.3.4 Transmission electron microscopy (TEM) 
Size analysis of the AgNPs before and after biotin modification 
was carried out using a JEOL 2010F TEM having a point-to-point 
resolution of 0.19 nm.  Samples were prepared by pipetting 2.0 
µL of unmodified or modified AgNPs onto a carbon-coated Cu grid 
obtained from Electron Microscopy Sciences (Hartfield, PA).  The 
size distributions were determined using ImageJ software and 200 






Figure 2.1 TEM micrographs and size-distribution histograms of 
AgNPs before and after immobilization on MµBs. AgNPs (a) before 
and (b) after binding to DNA-biotin. A carbon-coated Cu grid was 
used for the TEM micrographs. SEM micrographs and size-
distribution histograms for AgNPs present as (c) the MµB-AgNP 
conjugate on a carbon-coated Ni grid and (d) the MµB-AgNP 
conjugate on a carbon/Au working electrode.  Each of the 






Energy-dispersive X-ray (EDX) analysis of the MµB-AgNP 
conjugates was performed using a JEOL 2010F TEM.  The samples 
for this analysis were prepared by removing the MµB-AgNP 
conjugates from the carbon/Au working electrode (after 
electrochemical analysis) using a micropippette.  The MµB-AgNP 
conjugates were then added to 100.0 µL of isopropylalcohol in a 
microcentrifuge tube, and sonicated for 10.0 min.  Next, the 
sample was pipetted onto a Si3N4 TEM grid (Ted Pella, Redding, 
CA) and dried for 15.0 min under a heat lamp.  Finally, a 200 
mesh carbon-coated Cu grid obtained from Electron Microscopy 
Sciences (Hartfield, PA) was laid on top of the sample to 
prevent the MµBs from adhering to the magnetic portions of the 
TEM instrument. 
2.3.5 Scanning electron microscopy (SEM) 
SEM micrographs were obtained using a Hitachi S5500 SEM 
instrument having an accelerating voltage of 30 kV, and a point-
to-point resolution of 0.4 nm.  Samples of the MµB-AgNP 
conjugates were prepared by drop casting 2.0 µL of the MµB-AgNP 
conjugates on a carbon-coated Ni grid (Electron Microscopy 
Sciences, Hartfield, PA) and then dried in air for ~12 h.  The 
size distribution of the AgNPs on the MµBs were also analyzed by 
randomly selecting 200 particles in ImageJ (Figure 2.1).  The 





of AgNPs present on the surface of the MµBs using ten different 
SEM micrographs (Figure 2.2). 
 
Figure 2.2 SEM micrographs showing representative AgNP 
distributions on the MµBs used in this study. Ten MµBs imaged on 
(a) a carbon-coated Ni grid and (b) a carbon/Au working 
electrode.  The samples were prepared as follows. 16 µL of the 
MµB-AgNP conjugates were formed following the procedure provided 
in the Experimental Section of Chapter 2, and then 2.50 µL of 
this solution were pipetted onto a carbon-coated Ni grid or 0.50 
µL were pipetted onto a carbon/Au working electrode.  Both types 
of samples were air dried for 14.0 h. The number of AgNPs/MµB, 
averaged over all 20 MµB, was 106 ± 100 AgNPs.  Due to the large 
standard deviation of the experimentally determined value, the 
number of AgNPs/MµB used to prepare the MµB-AgNP conjugates (94 






SEM micrographs of the carbon/Au working electrode before 
and after immobilization of the MµB-AgNP conjugates were 
obtained by removing the electrode from the PLA cell, cutting 
out a section of the electrode (3.0 x 5.0 mm), drying in air for 
12.0 h, and then attaching the electrode section to the stage of 
a Hitachi SEM Standard Holder with conductive carbon tape.  The 
AgNP size distrubtion (Figure 2.1) and coverage of the AgNPs on 
the MµBs (Figure 2.2) were both quantified as previously 
described.  EDX was carried out using Bruker ESPRIT imaging 
software (Billerica, MA).  The EDX detector was a Bruker XFlash 
4010 with a detector area of 10 mm2 and an energy resolution of 
129 eV at the Mn Kα peak. 
2.4 Results and Discussion 
2.4.1 Electron microscopy of the MµB-AgNP conjugates 
The primary goal of this project is development of a better 
understanding of the complex nature of the seemingly simple GE 
process between AuCl4- and AgNPs.73,74,82,97  As mentioned earlier, 
Illustration 2.1 neglects numerous potential subtleties that are 
important when using this labeling approach for biosensing 
applications.  Accordingly, to better understand this process, 







Figure 2.3 SEM micrograph of the MµB-AgNP conjugate on (a) a TEM 
grid and (b) dried onto a carbon/Au working electrode prior to 
electrochemical activation. 
 
Figure 2.3a is a representative SEM micrograph of a MµB-
AgNP conjugate dried onto a carbon-coated Ni grid prior to GE.  
EDX data (Figure 2.4) confirms that the NPs present on the MµBs 
are composed of Ag.  Qualitatively, it is clear that AgNPs 
sparsely cover the MµBs, and quantitative analysis of 20 MµBs 
(Figure 2.2) indicates the presence of 106 ± 100 AgNPs/MµB.  On 
the basis of the AgNP:MµB ratio used to prepare the conjugates, 
the maximum coverage should be 94 AgNPs per MµB.  We conclude, 
therefore, that essentially 100% of the AgNPs introduced to the 
MµBs are immobilized thereon.  Due to the variability in the 
number of MµB-AgNP conjugates measured experimentally, we adopt 







Figure 2.4 Microscopy and EDX analysis of the MµB-AgNP 
conjugates before electrochemistry. The MµB-AgNP conjugate was 
immobilized on the carbon/Au working electrode. (a) SEM 
micrograph of the MµB-AgNP conjugate and (b) EDX element map 
showing Fe (blue), Ag (red), and Au (green). (c) The micrograph 
in (a) with a pink line indicating the position of the line scan 
shown in (d). Fe is coincident with the magnetic core of the MµB 
and Ag is present on the periphery.  Au is only present at the 
background level.  Cl is also present. 
 
The size of the MµB-bound AgNPs is 131 ± 10 nm, which is 
larger than the size of AgNP conjugates prior to immobilization 
on the MµBs (106 ± 10 nm, Figure 2.1).  It is unlikely that this 
discrepancy is real, but rather it probably arises from the 
difficulty of accurately measuring the AgNP size after 





Figure 2.3b is a representative SEM micrograph of the MµB-
AgNP conjugates dried on the carbon/Au working electrode.  The 
shape (spherical) and size of the AgNPs before and after 
immobilization of the MµBs on the electrode (131 ± 10 nm vs. 128 
± 8 nm, respectively) are the same.  Additional SEM micrographs 
of the MµB-AgNP conjugates following immobilization onto the 
working electrode are provided in Figure 2.2b.  The main point 
of this initial assessment is that immobilization of the MµB-
AgNP conjugates onto the carbon/Au working electrode does not 
result in any significant alteration of their physical 
properties. 
One final point: the micrographs shown in Figures 2.1-2.4 
suggest that a small number of AgNPs may be in direct contact 
with the electrode surface.  However, control experiments 









Figure 2.5 Linear sweep voltammograms (LSVs) demonstrating that 
direct oxidation of AgNPs is below the electrochemical detection 
limit.  The black trace shows the LSV associated with direct 
electrochemical detection of AgNPs, and the red trace results 
from galvanic exchange. The black trace was obtained as follows.  
First, 0.50 µL of the MµB-AgNP conjugate, having a AgNP 
concentration of 25.0 fM, was dried at the carbon/Au working 
electrode.  Second, the electrode was placed into the PLA cell 
and 150.0 µL of BCl was added.  Third, the electrode potential 
was swept from -0.70 V to 0.20 V.  No AgNP oxidation was 
detected, and therefore we conclude that few AgNPs are in direct 
contact with the electrode surface.  The red trace was obtained 
following galvanic exchange, as described in the caption for 
Figure 2.17. In this case a substantial stripping current 
obtains.  In summary, current is only observed when the AgNPs 
are oxidized by galvanic exchange. Note that the scan rate for 
both traces 50 mV/s and sloping baselines in the original data 
were corrected. 
 
2.4.2 Galvanic exchange 
After ensuring the fidelity of the MµB-AgNP conjugates after 
adsorption onto the working electrode, we sought to understand 
how they change following GE.  These experiments were carried 





AgNP conjugates were pipetted onto the carbon/Au working 
electrode, and then the electrode was dried in air for 20.0 min.  
Given the number of MµBs in this volume of solution, the surface 
area of the electrode, and assuming the MµBs are in a hexagonal 
close-packed lattice, this would correspond to a coverage of 
about 1.5 monolayers of MµBs on the electrode.  Because the MµBs 
are not close-packed, however, this represents a lower limit on 
the thickness of the MµB layer. An optical micrograph of the 
MµBs on the electrode is provided in Figure 2.6. 
 
Figure 2.6 Micrographs of the MµB-AgNP conjugates dried on a 
carbon/Au working electrode. (a) An optical micrograph of the 
MµB-AgNP conjugates dried on the carbon/Au working electrode.  
(b) An expanded view (SEM micrograph) of the MµB-AgNP conjugates 
in (a).  The micrographs were obtained by pipetting 0.50 µL of a 
337 fM MµB-AgNP conjugate solution onto a carbon/Au working 
electrode and then drying in air for 20.0 min.  The results 
indicate that the distribution of conjugates is rather uniform, 
but that there are patches on the electrode surface where no 








Figure 2.7 Experiment showing the relationship between the 
percentage of Au oxidized from the carbon/Au electrode as a 
function of chloride concentration.  (a) Reduction of AuCl4- 
(black trace) and oxidation of Au (pink trace) from a carbon 
paste electrode.  (b) The percentage of Au oxidized from the 
carbon paste working electrode at different Cl- concentrations.  
The experiment was carried out as follows.  First, a carbon 
paste electrode was placed into a polytetrafluoroethylene 
electrochemical cell filled with 300.0 µL of 6.0 mM HAuCl4 and 
0.10 M KNO3.59,66  Next the electrode potential was swept from 
0.40 V to -0.40 V vs. Hg/Hg2SO4, resulting in reduction of AuCl4- 
as shown by the black trace in (a).  Second, the electrode was 
removed at the open-circuit potential and rinsed twice with DI 
water.  Third, the electrode was placed into the PLA cell with 
BCl electrolyte solutions having the NaCl concentrations 
indicated in (b).  Finally, the potential was swept from -0.40 V 
to 1.0 V to oxidize Au.  The areas under the peaks (charges) 
resulting from these experiments (e.g., Frame (a)) were 
obtained, and the percentage of Au oxidized as a function of the 
amount of deposited Au is displayed in (b). Each histogram 
corresponds to give independent replicates. The results indicate 
that, within error, the percentage of Au oxidized is independent 
of the chloride concentration. 
 
Second, the MµB-AgNP conjugate-covered electrode was placed 
into the PLA cell, and then 150.0 µL of BCl electrolyte solution 
was added.  The BCl electrolyte solution contained 0.10 M NaCl, 





working electrode (Figure 2.7).  Next, the working electrode 
potential was stepped from 0 to 0.60 V for 25.0 s.  This 
potential results in oxidation of a fraction of the previously 
electrodeposited Au thereby initiating GE.59,66 Moreover, on the 
basis of the diffusion coefficient calculated for AuCl4- (Figure 
2.8), 25.0 s is sufficient time for AuCl4- to reach all of AgNPs 
present in the vicinity of the electrode.65 Following GE, the 
electrode potential was immediately stepped from 0 V to -0.70 V 
for 100.0 s to electrodeposit Ag.  The combination of 
electrochemical oxidation of Au and subsequent deposition of Ag 
is referred to hereafter as “one GE cycle”.  Finally, the 
electrode was removed from the PLA cell at the open-circuit 












Figure 2.8 Electrochemical data used to calculate the diffusion 
coefficient of AuCl4-. The AuCl4- diffusion coefficient was 
determined using the current-time trace for AuCl4- reduction 
shown in Frame (a).  The Cottrell plot in Frame (b) was obtained 
using the current from 1.25 s to 2.00 s.  The values required to 
calculate the diffusion coefficient of AuCl4- are the AuCl4- 
concentration (6.0 x 10-6 mol/cm3), the area of the carbon paste 
working electrode (0.03 cm2), the number of electrons transferred 
(n=3.0), the Faraday constant (96,485 C/mol), and the slope of 
the Cottrell line in (b) (6.84 x 10-5 A s1/2).65  The calculated 
diffusion coefficient of AuCl4- is 4.9 x 10-5 cm2/s.  As discussed 
in the Results and Discussion section of Chapter 2, galvanic 
exchange is initiated by oxidation of Au present on the carbon 
electrode for 25.0 s.  Using the calculated AuCl4- diffusion 
coefficient, we determined that AuCl4- can diffuse ~500 µm from 
the surface of the carbon/Au working electrode. This distance is 
sufficient to reach the AgNPs on all MµBs concentrated at the 
working electrode.  These experiments were performed in the 
polytetrafluoroethylene electrochemical cell discussed in the 







Figure 2.9 SEM micrographs of MµB-AgNP conjugates imaged on the 
carbon/Au working electrode after one GE cycle.  (a) A low-
resolution view. (b,c) Expanded views of the regions highlighted 
by the red and blue boxes, respectively, in (a).  
 
The micrograph in Figure 2.9a shows the MµB-AgNP conjugates 
dried on the carbon/Au working electrode immediately following 
GE.  At the resolution of this micrograph, there are no 
significant changes in morphology of the AgNPs compared to the 
images obtained prior to GE shown in Figure 2.3.  Higher 
resolution images of the AgNPs (Figures 2.9b and 2.9c) are 





shows that some of the NPs maintain their size, smooth texture, 
and generally spherical shape even after GE (Figure 2.3).  In 
contrast, the AgNPs shown in Figure 2.9c exhibit a morphology 
change, probably resulting from GE.  
 
Figure 2.10 SEM micrographs of the MµB-AgNP conjugates after one 
GE cycle, but in the absence of Au. (a) MµB-AgNP conjugates 
after one GE cycle. (b) Expanded view of the boxed area in (a).  
The AgNPs appear identical before and after electrochemistry.  
We conclude that in the absence of GE, there is no change in 
morphology of the AgNPs.  
 
Note that when the same electrochemical program is applied, but 
in the absence of Au (Figure 2.10) the spherical shape and 
smooth texture of the imaged AgNPs are conserved.  This control 
experiment further implicates the GE process as being 
responsible for the morphological changes observed in Figure 
2.9c.  Indeed, it has been shown previously that GE between 
AgNPs and AuCl4- leads to changes in the shape of the parent 
AgNPs.  Specifically, AuAg alloys form with shapes that include 







Figure 2.11 (a) TEM micrograph of a portion of a MµB-AgNP 
conjugate after one GE cycle.  The white arc approximates the 
edge of the MµB, the red circle highlights one associated NP, 
and the white circle highlights a pair of closely spaced NPs. 
(b) An EDX element map of the NPs in the white circle in (a). It 
reveals a Ag core (red) surrounded by a Au shell (green). 
 
To further confirm that GE is responsible for the changes 
shown in Figure 2.9, the MµB-AgNP conjugates were analyzed by 
TEM and EDX following GE (Figure 2.11).  For this experiment, 
the MµB-AgNP conjugates were dried onto a freshly prepared 
carbon/Au working electrode.  Following one GE cycle, the MµB-
AgNP conjugates were removed from the electrode and prepared for 
TEM analysis as discussed in the Experimental Section.  Figure 
2.11a is a TEM micrograph of a portion of a MµB-AgNP conjugate 
after GE.  The edge of the MµB is outlined by the curved white 





with a red circle, and a pair of overlapping NPs is highlighted 
with a white circle.  The rough surface morphology of all three 
NPs resembles those shown in Figure 2.9c, and therefore we 
conclude that they have undergone GE.   
EDX analysis of the two NPs highlighted by the white circle 
are shown in Figure 2.11b.  Here, the green-colored shell 
corresponds to Au and the red-colored core corresponds to Ag.  
The width of the Au shell is ~10 nm and the two Ag cores are 25 









Figure 2.12 EDX analysis of NPs after one GE cycle.  The data 
were obtained for the NPs circled in white in Figure 2.11.  (a) 
EDX spectrum. (b) The atomic percentages of Ag and Au determined 
from the spectrum in (a).   
 
 
Figure 2.12 provides quantitative EDX data for the two NPs 
circled in white, and it shows that the Au shell comprises ~21 
atom% of the NPs.  Two conclusions can be drawn from Figure 
2.11b.  First, electrochemically initiated GE results in only 
partial exchange of Au for Ag for these ~110 nm-diameter AgNPs.  
Second, the Au shell that encapsulates the Ag core is probably 





Clearly, it is only possible to obtain TEM and EDX data for 
a few NPs following GE, but the foregoing results confirm that 
there is a correlation between the morphology of the NPs and 
whether they have undergone GE: rough morphologies correlate to 
GE, while smooth morphologies correlate to no GE.  This finding 
has allowed us to image many NPs using SEM, which has sufficient 
resolution to distinguish morphology, and hence determine a 
statistically meaningful value for the percentage of AgNPs that 
undergo GE.  A detailed explanation for how this analysis was 









Figure 2.13 Morphology of AgNPs after one GE cycle. The smooth 
morphology of the two AgNPs in (a) was unchanged after the GE 
cycle, indicating that they did not undergo GE. The morphology 
of the AgNP in (b) is much rougher than those in (a), indicating 
that it did undergo GE with AuCl4-. (c) The relative numbers of 
smooth (no GE) and rough (GE) NPs were marked as indicated in 
this image.  The blue numbers represent NPs that remained 















Briefly, we examined 547 NPs on 25 different MµBs and of these 
52% exhibited a morphological change correlated to at least 
partial GE. We now turn our attention to understanding why the 
GE reaction does not go to completion. 
2.4.3 The MµB-AgNP conjugates after oxidation by AuCl4- 
As discussed earlier, the time allotted for GE (i.e., the 
duration of the Au oxidation step shown in Illustration 2.1a) is 
sufficient for AuCl4- to diffuse well-beyond the layer of MµBs 
present on the electrode surface.  Hence, it is surprising that 
a higher percentage of the AgNPs do not undergo GE.  In this 
part of the study, we sought to address this issue by 
identifying phenomena that could limit GE.  This was 
accomplished using EDX analysis of the MµB-AgNP conjugates 
following just the first half of the GE cycle (described next).   
This experiment was carried out exactly as described in the 
previous section, except that it was halted immediately after 
oxidation of Au (e.g., only the steps shown in Frames a and b of 
Illustration 2.1 were carried out: no redeposition of Ag as in 
Frame c).  Specifically, the working electrode potential was 
stepped from 0 to 0.60 V for 25.0 s to initiate GE.  The 
electrode was then removed from the PLA cell at open circuit 







Figure 2.14 (a) SEM micrograph of MµB-AgNP conjugates on the 
carbon/Au working electrode after oxidation of Au.  The orange 
rectangle highlights salt around the MµB. (b) An element map of 
the MµB-AgNP conjugates in (a). The blue and green arrows point 
to the same MµB and Au nodule, respectively, in (a). 
 
Figure 2.14a is an SEM micrograph of the MµB-AgNP 
conjugates present on the electrode following oxidation of Au.  
The blue arrow points to a MµB and the green arrow points to a 
NP structure present on the electrode surface.  The area 
outlined by the orange box contains an unknown material that 
overlays multiple MµBs.  EDX analysis was performed to identify 
the composition of this material and to determine the identity 
of the NP indicated by the green arrow. 
Figure 2.14b is an EDX color map corresponding to the 
micrograph in Figure 2.14a.  The element map is focused on Fe, 
Au, Ag, and Cl because of the roles they play during GE.  
Specifically, Fe is present in the core of the MµBs (blue arrow 
in Figure 2.14a) and Cl- is present in the electrolyte.  The 





clearly identified as a nodule of Au that was electrodeposited 
during the fabrication of the electrode (green arrow in Figure 
2.14b).  The presence of this feature indicates that only a 
fraction of the Au originally deposited onto the carbon 
electrode is converted to soluble AuCl4- during the positive 
potential step (Figure 2.7).  It also indicates that Au 
electrodeposited onto the carbon electrode during device 
fabrication is randomly distributed as NPs on the carbon surface 
rather than being present as a conformal coating.66,93  Finally, 
the structure outlined with an orange box in Figure 2.14a is 
composed of Ag and Cl, suggesting that it is primarily AgCl.   
 
 
Figure 2.15 EDX spectrum obtained from the region shown in 
Figure 2.14.  The MµB-AgNP conjugates were prepared and 
processed as discussed in the Experimental section of Chapter 2.  
This spectrum compares the intensity of the Na, Au, Cl, Ag, and 






Figure 2.15 indicates that a small fraction of NaCl is present 
as well.  These findings indicate that AgCl (Ksp = 1.8 x 10-10)102 
is a product of GE (eq 2.1) under the conditions used in our 
experiment.81,82,89,91,103  Indeed, AgCl is a known byproduct of this 
GE reaction, and can lead to inefficient GE.82,89–91,99 
The results shown in Figure 2.14 suggest that AgCl 
encapsulates a significant fraction of the MµB-AgNP conjugates.  
This most likely reduces access of AuCl4- to the underlying AgNPs 
and hence reduces the GE efficiency.81,82,90,91,99,103  Importantly, 
and as shown in Figure 2.9, the mass of AgCl present in Figure 
2.14 (orange box in Figure 2.14a) is not visible after a 
complete GE cycle (all three steps shown in Illustration 2.1).  
Apparently, some or all of the AgCl is in direct contact with 
the electrode surface and is reduced to Ag0 during the second 
half of the GE cycle (Ag electrodeposition).59,66  
To summarize, there are two factors that prevent complete 
oxidation of the AgNPs.  First, the presence of a Au shell that 
prevents access of AuCl4- to underlying Ag (Figure 2.11).  








2.4.4 GE of remaining AgNPs 
As just discussed, AgCl is a byproduct of the GE reaction 
between AuCl4- and Ag0, when it is carried out in Cl--containing 
media, that prevents oxidation of about half the AgNPs 
immobilized on the MµBs.  For sensing purposes, we wish to 
oxidize all the AgNP labels and, in this section, we show that a 
second GE cycle results in at least partial GE of all the AgNPs 
present.  For these experiments, the potential of the working 
electrode was stepped from 0 to 0.60 V for 25.0 s and then to -
0.70 V for 100.0 s.  This program was then repeated.  At this 
point the electrode was removed from the PLA cell at open 






Figure 2.16 SEM micrographs of MµB-AgNP conjugates after two GE 
cycles imaged on the carbon/Au working electrode.  (a) A low-
resolution view. (b,c) Expanded views of the regions highlighted 
by the red and blue boxes, respectively, in (a).  
 
The micrograph in Figure 2.16a shows four MµB-AgNP 
conjugates present on a carbon/Au working electrode after two GE 
cycles.  The expanded views in Figures 2.16b and 2.16c 
correspond to the red and blue boxes in Figure 2.16a, 
respectively.  As discussed previously, the distorted surface 





A total of 547 NPs were examined following two GE cycles, and 
all of them resembled those in Figures 2.16b and 2.16c.  
Accordingly, we conclude that two potential cycles result in GE 
(or, more precisely, at least partial GE) of essentially all the 
AgNPs present on the electrode surface. 
2.4.5 Electrochemical detection of AgNPs after GE cycles 
Thus far we have shown that 52% and ~100% of AgNPs exhibit 
morphological changes after one and two GE cycles, respectively.  
We correlate these changes to full or partial GE between AuCl4- 
and Ag0. In this section, we compare these findings to 
quantitative electrochemical results obtained by Ag anodic 
stripping voltammetry.  
These experiments were carried out exactly as described in 
the previous sections for one, two, and three GE cycles, except 
rather than halting the experiment after Ag electrodeposition 
the potential was swept twice from -0.70 V to 0.20 V at 50 mV/s 
to oxidize Ag after the final GE cycle.  The charge under the 









Figure 2.17 Histogram of the average Ag charge measured at 12 
different working electrodes after one, two, and three GE 
cycles.  The MµB-AgNP conjugates were dried on the carbon/Au 
working electrode and rehydrated in 150 µL BCl to give a final 
AgNP concentration of 45 fM. 
 
Figure 2.17 presents histograms of the charge recovered for 
12 independently prepared electrodes for the indicated number of 
GE cycles.  The average Ag charge after one GE cycle was 0.5 ± 
0.6 µC.  After two and three GE cycles, the charge more than 
doubled to 1.3 ± 0.3 µC and 1.3 ± 0.4 µC.  On the basis of these 
results, we conclude that only two GE cycles are required to 
capture all of the accessible Ag charge. 
It is now possible to correlate the results obtained by 
microscopy to the electrochemical data in Figure 2.17.  Recall 





exhibiting morphological changes doubled after a second GE 
cycle.  Now we find that the electrochemical data in Figure 2.17 
are in near-quantitative accord with this finding, and therefore 
electrochemistry provides a good measure of the number of AgNPs 
present.  
On the basis of the AgNP concentration used in these 
experiments, detection of 100% of the Ag present in the AgNPs 
would correspond to 26.7 µC.  However, the experimental results 
indicate that just 5% of this charge is recovered after two GE 
cycles.  This low collection efficiency must, therefore, be 
attributed to the Au shell (Figure 2.11) that forms during the 
initial stages of GE.  A rough calculation based on data like 
that shown in Figure 2.11 suggests that ~85% of the total Ag 
present in the system is within the core of the Ag@Au NPs that 
form during GE.  The remainder of uncollected Ag (~15%) is 
likely present as AgCl that is not in direct contact with the 
electrode surface. 
2.4.6 Electrochemical detection of different AgNP concentrations 
Up to this point, we have only reported results for a single, 
average number density of AgNPs on the MµB-AgNP conjugates.  
Because we wish to use AgNPs as labels in bioassays, we now turn 
our attention to correlating the electrochemical charge recovery 





This provides a good model for understanding the dynamic range 
of this detection method.  These experiments were carried out as 
described for the two-cycle histogram shown in Figure 2.17, 
except for one minor change: Ag-oxidation voltammograms were 
obtained only after both GE cycles were complete, whereas 











Figure 2.18 (a) Anodic stripping voltammograms (ASVs) obtained 
by drying the MµB-AgNP conjugates onto the carbon/Au working 
electrode, rehydrating in 150 µL BCl, and then carrying out the 
ASV protocol described in the text.  The concentrations listed 
in the legend represent the total concentration of AgNPs in the 
150 µL volume.  The scan rate was 50 mV/s. (b) Expanded view of 
the ASVs for the lowest two AgNP concentrations in (a). (c) Plot 
of charge, determined by integrating the ASVs in (a), as a 
function of AgNP concentration. Each data point represents five 
replicate measurements obtained using independently prepared 
electrodes. Outliers were eliminated using the Grubb’s Test with 
a 95% confidence level.102 (d) Expanded view of the linear range 










The voltammograms in Figure 2.18a indicate that the Ag 
stripping current increases as a function of the concentration 
of the AgNPs. The concentrations listed in the legend of Figure 
2.18a represent the moles of AgNPs dried at the working 
electrode and rehydrated in 150 µL BCl. The voltammograms for 
the two lowest concentrations are expanded in Figure 2.18b. Note 
that concentrations below 2.6 fM could not be differentiated 
from the baseline.  The charges under voltammograms like that 
shown in Figure 2.18a were obtained by integration, and the 
results for five independent experiments per concentration are 
plotted in Figure 2.18c. These data show that the charge 
increases linearly from 2.6 fM to 337.0 fM AgNPs, and then it 
begins to saturate. The lower end of the linear range is shown 
on an expanded scale in Figure 2.18d. The point is that by 
understanding and optimizing this detection system, it has been 
possible to obtain a very low detection limit and a respectable 
linear range (two orders of magnitude).   
2.5 Summary and Conclusion 
To summarize, we have investigated the seemingly simple process 
of GE between AuCl4- and AgNPs conjugated to MµBs in Cl—-
containing buffer.  The study was carried out to develop a 





detection modality that we recently reported.59,66  The simplistic 
view of the detection system is summarized in Illustration 2.1, 
but after analysis of both SEM and TEM micrographs, we found 
that the reality of the situation is quite a bit more 
complicated.  For example, each AgNP label undergoes only 
partial GE due to formation of a ~10 nm Au shell that shields 
the remaining Ag that ends up in the core of the NP.  The 
formation of this core@shell structure is a consequence of the 
rather large AgNPs (110 nm) that were used in this study (to 
facilitate structure determination).  Because the Au shell is 10 
nm thick, however, it is likely that 20 nm AgNPs will undergo 
complete GE.  Therefore, in forthcoming biosensing applications, 
we plan to use AgNP labels in the 20 nm size range.   
 We also discovered that only about half the AgNPs undergo 
any detectable level of GE after one cycle, but that two GE 
cycles results in partial GE of essentially all AgNPs originally 
present.  This, we believe, is a consequence of precipitation of 
AgCl, which prevents cross-reaction between AuCl4- and AgNPs.  
 Finally, we established that this basic GE-based detection 
of AgNPs is both quantitative and sensitive.  The relevant 
metrics for biosensing detections are a 2.6 fM AgNP detection 
limit, and a linear range that spans two orders of magnitude. We 





detection strategy and a paper fluidic platform.6,67,69  The 






Chapter 3: Orientation-Controlled Bioconjugate of 
Antibodies to Silver Nanoparticles 
3.1 Synopsis 
Here we report on the use of heterobifunctional cross-linkers 
(HBCLs) to control the number, orientation, and activity of 
immunoglobulin G antibodies (Abs) conjugated to silver 
nanoparticles (AgNPs). A hydrazone conjugation method resulted 
in exclusive modification of the polysaccharide chains present 
on the fragment crystallizable region of the Abs, leaving the 
antigen-binding region accessible. Two HBCLs, each having a 
hydrazide terminal group, were synthesized and tested for 
effectiveness.  The two HBCLs differed in two respects, however: 
(1) either a thiol or a dithiolane group was used for attachment 
to the AgNP; and (2) the spacer arm was either a PEG chain or an 
alkyl chain. Both cross-linkers immobilized 5 ± 1 Abs on the 
surface of each 20 nm-diameter AgNP. Electrochemical results, 
obtained using a half-metalloimmunoassay, proved that Abs 
conjugated to AgNPs via either of the two HBCLs were 4 times 
more active than those conjugated by the more common 
physisorption technique.  This finding confirmed that the HBCLs 
exerted orientational control over the Abs. We also demonstrated 
that the AgNP-HBCL-Ab conjugates were stable and active for at 





HBCLs themselves was related to the nature of their spacer arms.  
Specifically, the results showed that the HBCL having the alkyl 
chain is chemically stable for at least 90 days, making it the 
preferred cross-linker for bioassays. 
  
 
 Chapter 3 is based on a previous publication: N. E. Pollok, C. Rabin, L. 
Smith, R. M. Crooks, Orientation-Controlled Bioconjugation of Antibodies to 
Silver Nanoparticles. Bioconjugate Chem. 2019, 30, 3078-3086. NEP and CR 
contributed equally to the work. LS collected experimental data. RMC was the 
research advisor. NEP and CR designed and performed the experiments. NEP, CR, 






In this chapter we demonstrate the use of heterobifunctional 
cross-linkers (HBCLs) to control the number and orientation of 
immunoglobulin G antibodies (Abs) conjugated to silver 
nanoparticles (AgNPs). Specifically, two HBCLs were synthesized, 
each bearing: (1) a hydrazide group for the specific targeting 
of the fragment crystallizable (Fc) region of Abs,104–107 (2) a 
thiol group for anchoring the HBCL to the AgNP,106,108–111 and (3) a 
tunable spacer arm to enhance the biocompatibility104 of the NP-
Ab conjugates. The key finding is that HBCLs improve the 
activity of the Abs on AgNPs by controlling their orientation 
compared to the more common physisorption method in which Abs 
are randomly arranged electrostatically in multi-layers.104,112 
Because AgNPs have become increasingly important as labels for 
bioassays113,114 in recent years, and because there are few prior 
reports relating to controlled-Ab immobilization on AgNPs,9,13 the 
present study is timely and relevant.  
While Au and Ag are both noble metals, Au has a 
significantly higher standard potential (E⁰ = 1.52 V) than Ag (E⁰ 
= 0.79 V).65 The increased stability of AuNPs relative to AgNPs 
makes them a prime candidate for bioconjugation applications. 
Indeed, there are numerous reports of Ab immobilization on 





to have optical113,114,118,119 and biological118,120,121 properties that 
can be beneficial to the development of a new category of 
molecular probes. For example, our group has used AgNPs as a 
signal amplifying label for detecting Abs in 
metalloimmunoassays,57,58,61 including for electrochemical 
detection of the heart-failure biomarker, N-terminal prohormone 
brain natriuretic peptide (NT-proBNP).59 In this specific 
metalloimmunoassay, simple physisorption was used to conjugate 
the detection Abs to the AgNP labels. The detection limit and 
reproducibility of this approach were not satisfactory, however, 
and therefore we sought an alternative immobilization method. 
Physisorption of Abs to metal NPs relies primarily on 
interactions between the NP surface and amine or thiol residues 
present on the Abs.104,122 While this approach for bioconjugation 
is fast and easy, it has four important limitations: (1) it 
requires a large excess of Abs;104,105,121 (2) the Ab coverage on 
the NP surface is not well-controlled;104 (3) the stability of 
the conjugate is poor due to weak electrostatic 
interactions;115,123,124 and (4) the lack of control over the 
orientation of the Abs reduces access of the target to the 
antigen-binding sites (Fab).104,115  For AuNPs, these points have 
been addressed by using HBCLs comprised of a thiol group at one 





Ag can also form dative bonds with thiol functional groups,67,111–
114,131–134 which provides a means for forming a stable bond between 
the Ag surface and the Fc region of the Abs. 
As mentioned earlier, the majority of reports pertaining to 
Ab immobilization on AgNPs does not rely on a controlled 
immobilization method.  For example, in 2007 Huang et al. used 
the affinity of thiols for AgNPs to link Abs to AgNPs via 
HBCLs.129 Specifically, they attached thiolated HBCLs to the 
surface of AgNPs, and then activated the carboxylic acid group 
at the distal end of the HBCLs using 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide. Exposure of these 
functionalized AgNPs to Abs resulted in a reaction between the 
activated acids and primary amines present on the latter. A 
related approach has also been reported in which activated 
carboxylic acids present on the Abs were reacted with 
thiol/amine HBCLs pre-attached to AgNPs.105  
Both of the foregoing approaches rely on the position of 
accessible amine or carboxylic acid groups within the Ab 
structure, which is strongly dependent of the Ab sequence. The 
main drawback of targeting amine and carboxylic acid groups is, 
therefore, the lack of control over the distribution of the 
functional groups on the Ab. Indeed, charged residues (NH3+ and 





Moreover, targeting amine groups has an even more deleterious 
effect upon binding activity of Abs because the N-terminus is 
located within the Fab region.104,112,130,131 This potentially puts 
the active site of the Ab in danger of being damaged or 
misoriented on the surface of the NPs. In these cases, like in 
the physisorption method, control over the orientation is not 
achieved.  
 






To overcome some of the deficiencies of these earlier 
approaches, we focused on controlling the orientation of the Abs 
to allow the Fab regions to be more accessible to antigens in 
solution while still maintaining a robust AgNP-Ab interaction. 
This can be done by targeting either the C-terminus of the Ab or 
the polysaccharide chains sequestered in the Fc region.104,105,132 
The C-terminus is generally recognized by specific 
protein/protein interactions with protein G112,116 or protein A,115 
but in both cases this is a reversible binding event.112,133 In 
contrast, the polysaccharide chains can either be targeted 
directly with boronic acid residues,105,134,135 or by following a 
mild oxidation step coupled with a hydrazide addition.104,131 
Because the boronic-polysaccharide complex is known to be 
unstable at physiological pH,135 we elected to use the hydrazone 
chemistry. Illustration 3.1 depicts the hydrazone method, in 
which the polysaccharide chains of the Ab are first converted to 
aldehyde groups with a mild oxidant, and then coupled to 
hydrazide-functionalized HBCLs. Note that a similar approach was 
reported by Kumar et al. in 2008 for AuNPs, and as we will show 
later AgNPs are as biocompatible as AuNPs using this approach.106   
In the present chapter, two HBCLs differing in spacer arm 
composition (PEG or alkyl chains) and sulfur group (thiol or 





AgNPs (Illustration 3.1). The same chemistry was carried out 
using AuNPs as a benchmark for comparison. The present study 
shows that: (1) a HBCL-mediated bioconjugation method can be 
used to efficiently functionalize AgNPs; (2) NPs can be 
functionalized with reproducible numbers of Abs; (3) HBCLs lead 
to Ab orientation on NP surfaces that results in improved 
binding of targets compared to physisorption; and (4) the 
binding efficiency to the target is constant over at least a 
two-week period for AgNP-HBCL-Ab conjugates, which is not the 
case for physisorbed conjugates.  
3.3 Experimental 
3.3.1 Chemicals and Materials 
All solutions were prepared using deionized (DI) water (>18.0 
MΩ-cm, Milli-Q Gradient System, Millipore, Burlington, MA). 
Tetrahydrofuran (THF) anhydrous, hydrazine monohydrate, 
hydrazine solution 1 M in THF, (±)-α-lipoic acid, methanol, 
dimethyl sulfoxide (DMSO) and DMSO-d6 were purchased from Sigma-
Aldrich (Milwaukee, WI). 4-Amino-3-hydrazino-5-mercapto-1,2,4-
triazole (Purpald), H2SO4, KMnO4, toluene, phosphate buffered 
saline (PBS) pH 7.4 (P3813), casein, superblock blocking buffer 
(SBB) (37515), siliconized low-retention microcentrifuge tubes, 





sheets, linear flow rate of water = 0.43 cm/min), and Costar 3590 
high-binding microtiter plates were purchased from Fisher 
Scientific (Pittsburgh, PA).  
 All PBS used was 1x concentration PBS. SH-PEG7-COOH was 
obtained from Polypure (Oslo, Norway). mPEG-SH 5 kDa was 
obtained from Nanocs (New York, NY). 1-Step Ultra TMB-ELISA 
Substrate Solution (34028) and sodium meta-periodate (NaIO4) were 
obtained from Thermo Scientific (Grand Island, NY). Citrate-
capped AgNPs and AuNPs (nominal 20 nm diameter) were purchased 
from nanoComposix (San Diego, CA). N-terminal prohormone brain 
natriuretic peptide (NT-proBNP) and monoclonal immunoglobulin G 
anti-NT-proBNP 13G12 (Ab) were obtained from HyTest (Turku, 
Finland). Polyclonal anti-mouse immunoglobulin G horseradish 
peroxidase-labeled secondary antibody (SAb) was obtained from 
Abcam (Cambridge, UK). Amicon ultra 0.5 mL centrifugal filters 
(10 K) were purchased from Millipore Sigma (Tauton, MA). 
Conductive carbon paste (Cl-2042) was purchased from Engineered 
Conductive Materials (Delaware, OH). All chemicals and reagents 
were used without further purification unless otherwise 
specified. 
3.3.2 Instrumentation 
1H and 13C NMR spectra were recorded with a Varian MR 400 MHz 





were recorded with an Agilent MR 400 MHz spectrometer. All 
spectra were measured using DMSOd6 as the solvent. Multiplicities 
are reported as follows: s=singlet, t=triplet, m=multiplet. 
Chemical shifts are reported in δ units to 0.01 ppm precision for 
1H and 0.1 ppm for 13C by using residual solvent as an internal 
reference.  
Absorbance measurements were obtained and pathlength 
corrected using a Synergy H4 Hybrid Multi-Mode Microplate Reader 
from BioTek (Winooshi, VT). A Sorvall Legend Micro 21R 
Centrifuge from Thermo Scientific was used for washing and 
separation steps during bioconjugation. A Mini Vortexer 945300 
from VWR International (Radnor, PA) was used to briefly mix 
solutions while a BioShake iQ from Quantifoil Instruments GmbH 
(Jena, Germany) was used for incubation steps during 
bioconjugation. Before analysis with the microplate reader, a 
centrifuge 5810 R from Eppendorf (Hamburg, Germany) was used to 
remove bubbles from the wells.  
3.3.3 Electrochemistry  
All electrochemical measurements were performed using a CH 
Instruments model 760B electrochemical workstation (Austin, TX), 
and a slightly modified, previously published protocol.127 
Specifically, all electrochemical materials, the working, 





stencil-printing carbon paste onto wax-patterned sheets of 
chromatography paper that had been printed using a Xerox 
ColorQube 8570DN printer. Following printing, the wax was melted 
through the thickness of the paper by placing it in an oven at 
120 °C for 25.0 s. Photopaper was glued to the back of the wax 
printed chromatography paper for rigidity, and then it was cut 
into 12 rectangles (2.0 cm × 5.0 cm). A stencil for defining the 
3.0 mm-diameter disk-shaped working electrode, hook-shaped 
carbon quasi-reference electrode, and counter electrode was 
created using CorelDRAW (Ottawa, ON).  The stencil was cut into 
a thin plastic sheet of transparency film using an Epilog laser 
engraving system (Zing 16). Finally, the stencil was placed over 
the paper (wax side up), the electrodes were printed through the 
stencil using conductive carbon paste, and then the carbon paste 









Illustration 3.2 Description of the electrochemical cell used 
for determining the activity of the Abs on the conjugates. Ag 
electrodeposition and anodic stripping voltammetry (ASV) were 
performed with this device. (a) Photograph of the electrodes and 
the electrochemical cell. (b) Photograph of the assembled cell. 
The white portion of the electrochemical cell incorporates metal 
prongs within the enclosure to provide ohmic contact between the 
carbon paste electrodes and the potentiostat.  Duct tape is 
placed across the orange platform of the cell to keep it stable 
during analysis. The electrodes were stencil printed with 
conductive carbon paste, as mentioned in the Experimental 
Section of Chapter 3. The regions printed in yellow wax are 
slightly more hydrophilic compared to the black wax regions, 
allowing for the sample solution to span all three carbon 
electrodes. The yellow region can hold an aqueous volume of 50-
80 µL. In the present chapter, 76 µL of sample solution were 










3.3.4 Synthesis of HBCL1 
To a solution of SH-PEG7-COOH (108 mg, 0.24 mmol) in methanol 
(2.00 mL) was slowly added a solution of hydrazine hydrate (1.40 
mL) in methanol (1.00 mL). The reaction medium was stirred for 
24 h at room temperature (RT) (22 ± 3 °C). The solvent was then 
co-evaporated with toluene under reduced pressure to yield HBCL1 
as a yellowish oil (113 mg, 100%). 1H NMR (400 MHz, DMSOd6), δ 
(ppm): 3.64 (t, J = 6.5 Hz, 2H, Hb), 3.57 (t, J = 6.7 Hz, 2H, 
Hd), 3.51 (s, 28H, Hc), 2.89 (t, J = 6.4 Hz, 2H, Ha), 2.34 (t, J 
= 6.7 Hz, 2H, He). 13C NMR (400 MHz, DMSOd6), δ (ppm): 173.7 (Cq, 
Ch), 69.8 (CH2, Cd), 69.6 (CH2, Ce), 69.5 (CH2, Cc), 68.6 (CH2, 
Cb), 67.3 (CH2, Cf), 37.9 (CH2, Ca), 36.3 (CH2, Cg). 2D NMR: COSY 







Figure 3.1 (top) 1H NMR (400 MHz, DMSOd6) and (bottom) 13C NMR 









Figure 3.2 (top) COSY (1H/1H) 2D NMR (400 MHz, DMSOd6) and 









3.3.5 Synthesis of HBCL2 
To a solution of (±)-α-lipoic acid (50 mg, 0.24 mmol) in 
anhydrous THF (3.00 mL) at 0 °C was slowly added a solution of 
hydrazine hydrate in THF (0.34 mL, 1 M). The reaction medium was 
stirred for 90 min at 0 °C. The solvent was then evaporated 
under reduced pressure below 30 °C to yield HBCL2 as a white 
solid (40 mg, 76%). 1H NMR (400 MHz, DMSOd6), δ (ppm): 3.59 
(hidden, determined by 2D NMR) (m, 2H, Hc), 3.12 (m, 2H, Ha), 
2.40 (m, 1H, Hb), 2.10 (t, J = 7.1 Hz, 2H, Hg), 1.86 (m, 1H, 
Hb’), 1.65 (m, 1H, Hd), 1.52 (m, 1H, Hd’), 1.48 (m, 2H, Hf), 
1.35 (m, 2H, He). 13C NMR (400 MHz, DMSOd6), δ (ppm): 175.2 (Cq, 
Ch), 56.5 (CH, Cc), 40.1 (hidden, determined by 2D NMR) (CH2, 
Cb), 38.5 (CH2, Ca), 34.4 (CH2, Cg), 34.1 (CH2, Cd), 28.6 (CH2, 
Ce), 24.7 (CH2, Cf). 2D NMR: COSY (1H/1H), HSQC (1H/13C). NMR 






Figure 3.3 (top) 1H NMR (400 MHz, DMSOd6) and (bottom) 13C NMR 
(400 MHz, DMSOd6) spectra of HBCL2. Note, the spectra of HBCL2 









Figure 3.4 (top) COSY (1H/1H) 2D NMR (400 MHz, DMSOd6) and 









3.3.6 Conjugating Abs to NPs 
Unless stated otherwise, all incubation steps were performed at 
RT at 600 rpm. To start, 5.0 µL of 6.7 µM Ab were incubated with 
5.0 µL of 50 mM NaIO4 for 30 min in the dark to oxidize the 

















Figure 3.5 Colorimetric determination of polysaccharide chain 
content of 13G12 anti-N-terminal prohormone brain natriuretic 
peptide antibody (Ab) by UV-vis spectroscopy using 4-amino-3-
hydrazino-5-mercapto-1,2,4-triazole (Purpald). This experiment 
was carried out by adding 4 µL of 5.4 µM Ab to 4 µL of 50 mM 
NaIO4, incubating the mixture in the dark for 30 min at 22 ± 3 
˚C, and agitating at 600 rpm to oxidize the polysaccharide 
chains of the Ab. Oxidation was quenched by adding 100 µL of 
1xPBS. 75 µL of a freshly prepared 68.4 mM solution of Purpald 
in 1 M NaOH were then added to the wells of a microtiter plate 
immediately prior to spectrophotometric analysis. The solution 
was monitored at 550 nm, which is characteristic of the Purpald 
hydrazone product resulting from the reaction between the 
oxidized polysaccharide chains of the Ab and Purpald. The 
spectrum corresponding to this experiment was recorded, and an 
absorbance intensity of ~0.15 a.u. was obtained (green 
spectrum), confirming the presence of the polysaccharide chains 
on the Ab. Several controls were also performed to ensure that 
the absorbance intensity at 550 nm was only due to the hydrazone 
formation. The black, red, and brown spectra were recorded 
without Purpald, and as expected there is no elevation in the 
baseline. The pink spectrum corresponds to Purpald in the 
presence of non-oxidized Ab, and it shows a slight increase in 
the baseline at 550 nm due to the background of Purpald 
degradation.106 The blue spectrum corresponds to Purpald in 
presence of NaIO4 and here again only the background signal of 






The oxidation reaction was quenched with 125 µL of PBS.  The 
oxidized Abs were then incubated with 5.0 µL of 5.0 mM of the 
desired HBCL solution for 2 h. HBCL1 was directly dissolved in 
DI water to give the desired concentration, while HBCL2 was 
first dissolved in DMSO and then diluted in DI water. The 
solution was transferred to an Amicon ultra 0.5 mL centrifugal 
filter (10 K) and was centrifuged for 25 min at 4 °C at 14,000 
g.  
The HBCL-modified Abs were then incubated with 500 µL of 
the desired NP solution (4.9 x 1011 AgNPs/mL or 7.4 x 1011 
AuNPs/mL) for 1 h. In this step, the microcentrifuge tubes were 
pre-blocked with SBB to prevent non-specific binding of Abs and 
NPs on the walls of the tubes. These tubes were covered with 
aluminum foil to protect the NPs from light. Following 
incubation, 50 µL of 10.0 µM mPEG-SH were added and incubated 
for another 20 min. Finally, three centrifugation (25 min, 4 °C, 
16,600 g) steps were performed to remove unbound material, 
followed by resuspension into 500 µL SBB. The percentage yields 






Figure 3.6 Histograms showing the percentage yield of (a) the 
AgNPs and (b) the AuNPs, after functionalization with Ab-HBCL1, 
Ab-HBCL2 and unmodified Abs. This experiment was carried out as 
follows. First, the absorbance intensity at λmax was measured for 
each conjugate (i.e. NP-HBCL1-Ab, NP-HBCL2-Ab and physisorbed 
conjugates). Second, the absorbance value was converted to a NP 
concentration (NPs/mL) using the calibration curve shown in 
Figure 3.8. Third, this concentration was divided by the 
concentration of NPs before bioconjugation and was multiplied by 
100. For all conjugates, the yields reflect those after the 
first (blue) and second (orange) centrifugation (conditions: 25 
min, 4 ˚C, 16,600 g). The absorbance at λmax is directly 
correlated to the number of NPs in solution, and a decrease is 
usually representative of NP aggregation.136 Therefore, this 
analysis provides a means for determining the extent of NP 
aggregation that results after Ab conjugation.  The data 
indicates that almost no aggregation of the conjugates occurs 
after the first centrifugation. In contrast, the NP-Ab 
conjugates aggregate significantly after the third 
centrifugation. Note that, the physisorbed conjugates aggregate 










Henceforth, the product of bioconjugation will be referred to as 
NP-HBCL-Ab conjugates (AgNP-HBCL-Ab when referring to Ag and 
AuNP-HBCL-Ab when referring to Au). The protocol for making the 
samples with physisorbed Abs can be found in the Appendix (A2). 
3.3.7 Quantifying the total number of Abs per NP 
The number of Abs per NP was determined using an indirect 
enzyme-linked immunosorbent assay (ELISA) with a SAb. Unless 
stated otherwise, all incubation steps were performed for 30 min 
at RT at 600 rpm and were followed by three washing steps with 
PBS. Briefly, 100 µL of 58.2 nM NT-proBNP in PBS were incubated 
for 14 h at 4 °C without shaking in a high-binding microtiter 
plate. Then, 400 µL of 2% (w/v) casein solution in PBS were 
added to block the wells for 30 min without shaking. Wells used 
for the calibration curve (Figure 3.7) were incubated with 
various known concentrations of unmodified Abs, while test wells 
were incubated with the supernatant obtained after the first 








Figure 3.7 UV-Vis spectrophotometric data collected at 450 nm in 
triplicate using an indirect enzyme-linked immunosorbent assay 
(ELISA) to determine the number of Abs per AuNP. (a) Calibration 
curve obtained via indirect ELISA of unmodified Abs. (b) 
Histogram showing the number of Abs bound per AuNP, which was 
determined by performing an indirect ELISA with the supernatant 
of the first washing step (first centrifugation) following 
bioconjugation of Abs to AgNPs.  The complete procedure for this 
experiment is described in the Experimental Section. 
 
Next, 100 µL of 6.7 µM SAb were added to each well and 
incubated. Finally, 100 µL of the 1-Step Ultra TMB solution were 
added and 50.0 µL of 2 M H2SO4 were used to quench the reaction 
after it reached the desired color intensity (~3 min). The 
number of Abs in the conjugates was obtained by subtracting the 
Ab content remaining in the supernatant after bioconjugation 
from the initial Ab solution. This value was divided by the 
number of NPs, which was determined with a calibration curve 






Figure 3.8 UV-Vis calibration data for quantification of Ag and 
Au NPs. (a) UV-Vis spectra of decreasing concentrations of AgNP.  
(b) AgNP calibration curve generated from the absorbance values 
at 395 nm.  (c) UV-Vis spectra of decreasing concentrations of 
AuNP.  (d) AuNP calibration curve generated from the absorbance 
values at 520 nm. These experiments were performed by diluting 
the stock solution of 20 nm-diameter, citrate-capped AgNPs and 
AuNPs with deionized water. 100 µL of each solution were added 
to the wells of a microtiter plate and the absorbance spectra 
were recorded. The error bars represent the standard deviation 










3.3.8 Monitoring the Ab activity of the conjugates 
The activity of the Abs on the AgNPs was determined 
electrochemically by forming a half-metalloimmunoassay, wherein 
the AgNPs were used as the detection label and the target was 
bound to a well. Unless stated otherwise, all steps were 
performed at RT at 600 rpm. Briefly, 100 µL of 0.60 µM of NT-
proBNP were bound to the wells of a high-binding microtiter 
plate for 14 h at 4 °C. After coating the wells, the plate was 
washed three times with PBS and blocked with SBB for 30 min 
without shaking. Next, 100 µL of the conjugates were added to 












Figure 3.9 Ag charge obtained for the conjugates in solution 
following electrochemical analysis. This experiment was 
performed by freshly preparing the conjugates, diluting them all 
to the same 0.23 µM AgNP concentration, incubating with 30 µL of 
0.20 mM KMnO4 for 15 min, and then carrying out the 
electrochemical protocol described in the Experimental Section. 
The Ag charges obtained for each conjugate for the same 
concentration of AgNP are, within error, equivalent.  This shows 
that the three AgNP functionalization protocols do not affect 
the electrochemical analysis. The error bars represent the 


















Figure 3.10 Electrochemical detection of unmodified, 20 nm-
diameter, citrate-capped AgNPs incubated with KMnO4 for the 
indicated times. The electrochemical procedure described in the 
Experimental Section was used. Briefly, however, 46 µL of 0.60 
µM AgNPs in 1xPBS were incubated with 30 µL of 0.2 mM KMnO4 for 
15 and 30 min at 1000 rpm in the wells of a microtiter plate. 
Note that, here no target was immobilized on the wells of the 
microtiter plate. The entire content of each well was then 
placed on an electrode and the electrochemical protocol 
described in Chapter 3 was performed. The resulting Ag charges 
are not statistically different with a p-value greater than 0.05 
(0.2380). This experiment proves that all of the AgNPs are 
oxidized within a 15 min incubation period. Thus, the 
experimental procedure used to obtain the ASV results discussed 
in Chapter 3 results in complete oxidation of the AgNPs. 
Therefore, the Ag charge detected corresponds to the binding 
activity of each conjugate for the immobilized target (N-
terminal prohormone brain natriuretic peptide) on the plate. The 
maximum amount of target immobilized on the plate during the Ab 
activity experiments corresponded to 0.60 µM, and therefore a 
molar equivalent of AgNPs were used for this control experiment. 
Note that, the KMnO4 solution was in excess, which was confirmed 







To prepare for electrochemical analysis, 46 µL of PBS and 
30 µL of 0.2 mM KMnO4 were added to the wells to denature the 
metalloimmunoassay and oxidize all bound AgNPs (Figure 3.9). 
After 15 min (a sufficient amount of time) of incubation at 1000 
rpm, the entire content of the well (in a single drop) was then 
placed on an electrode for electrochemical analysis (Figure 
3.10). Next, the working electrode was stepped from 0 to -0.70 V 
vs. a carbon quasi-reference for 800.0 s to electrodeposit Ag+ in 
solution to Ag0 on the electrode surface. After 
electrodeposition, anodic stripping voltammetry (ASV) was used 
to determine the Ag content on the working electrode surface. 
ASV was carried out by sweeping the working electrode potential 
from -0.70 to 0.20 V at 50 mV/s to oxidize Ag0. The ASV traces 









Figure 3.11 ASV results obtained using a solution containing 
only KMnO4 and PBS. The electrochemical protocol described in the 
Experimental Section in of this chapter was used for these 
experiments.  The electrochemical analysis was carried out in 
solutions containing: (black trace) 30 µL of freshly prepared 
0.20 mM KMnO4 and 46 µL of PBS; (red trace) 76 µL PBS. The 
purpose of this experiment was to evaluate the background 
current arising from the presence of KMnO4. The black background 
trace was subtracted from all ASV data presented in this 
chapter.  
 
The charge under the voltammogram was then determined by 
integration. It is important to note that this experiment was 
not intended to quantify total Ag from the assay since it relied 
solely on the diffusion of Ag+ to the electrode surface, 
nonetheless, a variation in the Ag charge was obtained for the 
three conjugates.65  This analysis was completed for identically 
prepared conjugate samples on days 0, 1, 2, 6, and 14, where day 





HBCL1, Ab-HBCL2, and unmodified Abs. The Ag content was then 
correlated to the Ab activity of the conjugates. The stability 
of the AgNP portion of the conjugates was also tested using UV-
vis spectroscopy, and these results can be found in Figure 3.12. 
 
Figure 3.12 Spectrophotometric data related to the stability of 
AgNPs and AuNPs. The absorbance spectra were measured at (a) 395 
nm for AgNPs and (b) 520 nm for AuNPs. This experiment was 
performed by freshly preparing the conjugates on day 0 and then 
analyzing the solutions on day 0, 1, 2, and 6. The NPs were 
suspended in SBB for analysis. 70 µL of each sample were added 
to the wells of a microtiter plate on each testing day and 
absorbance determined at the indicated wavelengths. The overall 
trend is that there is no change for either NP solution 
throughout the duration of the experiments. A decrease in 
intensity would be indicative of NP aggregation and because this 











3.4 Results and Discussion 
3.4.1 Characterization of the AgNP-Ab conjugates 
The hydrazone bioconjugation method has been used previously for 
preparing AuNP-Ab conjugates,106 but to the best of our knowledge 
there are no such reports of HBCL-modified Abs being conjugated 
to AgNPs. The main goal of the present chapter, therefore, is to 
show that hydrazone bioconjugation is possible with AgNPs and 
that it is a superior alternative to physisorption. To 
accomplish this, AgNPs were conjugated with Ab-HBCL1, Ab-HBCL2, 










Figure 3.13 Normalized UV-Vis spectra of the citrate-capped 
AgNPs (black) and the AgNPs after bioconjugation with Ab-HBCL1 
(red), Ab-HBCL2 (green), and unmodified Abs (physisorption, 
blue).  The inset is an expanded view of the maxima of the 
plasmon peaks: λmax = 395, 398, 398, and 400 nm for citrate-capped 
AgNPs, AgNP-HBCL1-Ab, AgNP-HBCL2-Ab, and physisorbed conjugates, 
respectively. The spectra are representative of three 
independent measurements, and λmax did not shift within precision 
of the measurement (accuracy within 1 nm) for the three trials.  
 
Figure 3.13 shows representative UV-Vis spectra for 
unconjugated 20 nm AgNPs and the three Ab conjugates. The 
characteristic plasmon band for the unmodified, citrate-capped 
AgNPs is present at λmax = 395 nm (black trace). After 
functionalization with Ab-HBCLs or unmodified Abs, the plasmon 
band undergoes a red-shift of 3 nm (red and green traces) and 5 





with a change in the refractive index of the environment 
surrounding the metallic NPs,136,137 which is characteristic of 
bioconjugation. Note that the spectra depicted in Figure 3.12 
are normalized to a λmax intensity of 1.0 to better highlight the 
red shift. The same experiments were carried out with AuNPs as a 













Figure 3.14 Normalized UV-Vis spectra of 20 nm-diameter citrate-
capped AuNPs before (black) and after bioconjugation with HBCL1-
modified Abs (red), HBCL2-modified Abs (green), and unmodified 
Abs (physisorption, blue).  The AuNP-HCBL-Ab conjugates were 
prepared using the procedure described in the Experimental 
Section of the main text.  The inset is an expanded view of the 
maxima of the plasmon peaks.  λmax = 520, 523, 523 and 525 nm for 
citrate-capped AuNPs, AuNP-HBCL1-Ab, AuNP-HBCL2-Ab and 
physisorbed conjugates, respectively.  The experiment was 
carried out by adding 100 µL of each solution (containing the 
NPs and SBB) to the wells of a microtiter plate. For clarity, 
only one spectrum of triplicate measurements is depicted here. 
λmax did not shift within the precision of the measurement 
(accuracy within 1 nm). The shift in the plasmon peak 
corresponds to a change in the refractive index of the 









In this case a similar red shift of 3 to 5 nm was observed. From 
these results, we conclude that the AgNPs have been successfully 
conjugated to the Abs.  In a subsequent section we will discuss 
the extent of conjugation. 
3.4.2 Quantification of the total number of Abs per AgNP 
It is usually not possible to directly quantify the number of 
Abs or proteins on a solid phase, such as a NP, because the 
solid phase can interfere with the analysis.104 To avoid such 
interferences, destructive techniques can be used.  These 
include dissolution of the metal NP to prevent fluorescence 
quenching,138–140,141,142 or complete digestion of the conjugate 
followed by high-performance liquid chromatography to determine 
the total protein content on the NP.143 However, we wanted to 
avoid destructive techniques so that it would be possible to 
compare every batch of conjugates without having to sacrifice 
samples. Thus, an indirect quantification method was used; that 
is, measuring the amount of unbound Abs remaining after 
bioconjugation. 
The number of unbound Abs for the three conjugates in this 
study were determined as follows.  First, the conjugation 
reaction was carried out.  Second, the supernatant resulting 
from the first centrifugation (washing) step, which contains the 





performed following the procedure described in the Experimental 
Section of this chapter. 
 
Figure 3.15 Histogram showing the number of Abs bound per AgNP 
for each of the conjugation methods.  The data were obtained 
using an indirect enzyme-linked immunosorbent assay (ELISA).  
The error bars represent the standard deviation of three 
independent measurements.   
 
Figure 3.15 is a histogram of the results from the indirect 
ELISA. The data represent results obtained from three 
independent reactions for each conjugate. Interestingly, the 
coverage is strongly dependent on the conjugation method. More 
specifically, using the hydrazone chemistry, 5 ± 1 Abs are 
reproducibly immobilized per AgNP for both HBCLs, while 





the AgNPs. These trends are similar to those we determined for 
AuNPs (Figure 3.7). 
 To ensure that the foregoing results are within a 
reasonable range, we calculated the approximate maximum Ab 
coverages for our materials. By considering typical dimensions 
for an Ab (14.5 nm x 8.5 nm x 4 nm),130 the surface area of a 
smooth 20.0 nm-diameter sphere (1260 nm2), and the orientation of 
the surface-confined Abs, it is possible to estimate maximum 
coverage. Using this approach, the maximum coverage for Abs 
oriented side-on is 10, while for end-on coverage it is 40. As 
shown in Figure 3.14, the coverage of physisorbed Abs on 20 nm 
AgNPs is 15 ± 2 Abs/NP, which is almost the same as we measured 
for physisorption onto AuNPs (13 ± 2 Abs/NP, Figure 3.7). This 
suggests that, independent of the metal, physisorbed Abs are 
present in both side-on and end-on orientations. There may also 
be Ab-Ab interactions that result in bilayer formation.  
 In contrast to physisorption, Abs immobilized via the 
hydrazone method should bind only in an end-on orientation due 
to the positioning of the HBCLs on the Fc region of the Ab.  
This configuration should result in higher activity.  Evidence 
for significant structural differences between physisorbed Abs 
and those linked via the HBCLs comes from dynamic light 





hydrodynamic diameter (H) of the physisorbed materials was found 
to be 24.6 ± 1.2 nm, while for the materials having HBCLs the H 
were 9.4 ± 0.7 and 7.1 ± 1.3 nm for AgNP-HBCL1-Ab and AgNP-
HBCL2-Ab, respectively.  
 
Sample 
Change in hydrodynamic 
diameter (ΔH)  
Physisorbed conjugate in SBB 24.6 ± 1.2 nm 
AgNP-HBCL1-Ab in SBB 9.4 ± 0.7 nm 
AgNP-HBCL2-Ab in SBB  7.1 ± 1.3 nm 
 
Table 3.1 Hydrodynamic diameter measurements obtained for 
various AgNP conjugates using dynamic light scattering 
spectroscopy (DLS). The experiment was performed as follow: 1 mL 
of 0.25 nM AgNP solution was added to a quartz cuvette through a 
PTFE 0.2 µm membrane. The DLS measurement was performed in 
triplicate. A change in the hydrodynamic diameter was reported 
in comparison to the hydrodynamic diameter of AgNP in SBB. All 
the quartz cuvettes were washed with aqua regia (3 HCl: 1 HNO3) 
prior to being used to get rid of any residual NPs. The HBCL 
itself was used as the “backfill” ligand in these experiments in 
place of the mPEG-SH. The mPEG-SH used in the conjugate protocol 
has a molecular weight of 5 kDa, which would generate false 
increased diameters with this technique. 
 
3.4.3 Comparison of the Ab activity of the conjugates 
To confirm the orientations of the Abs, our next step was to 
quantitatively compare their binding activity for a specific 
antigen, NT-proBNP. The basis for correlating antigen-binding 
activity to orientation is the well-known fact that only an 





Here, Ab activity was directly determined using the half-
metalloimmunoassay described in the Experimental Section.  
Briefly, the target, NT-proBNP, was adsorbed to the wells of a 
microtiter plate, then the AgNP-labeled Ab conjugates were 
introduced, and after washing, the amount of Ag present in each 
well was determined by anodic stripping voltammetry (ASV).  In 
this assay, only the active fraction of the Abs will bind to the 
immobilized target, and therefore the amount of Ag charge 











Figure 3.16 Anodic stripping voltammograms (ASVs) obtained by 
forming a half-metalloimmunoassay with the conjugates in a 
microtiter plate, adding KMnO4 to oxidize bound AgNPs, 
transferring the entire contents of each well to a carbon paste 
working electrode, and then carrying out the electrochemical 
protocol discussed in the text. The scan rate was 50 mV/s. For 
clarity, only one ASV trace is shown for each conjugate, but the 
measurements were carried out in triplicate.  The position of 
the ASV peaks varies due to the use of a quasi-carbon reference 
electrode.  
 
Figure 3.16 shows Ag ASV traces for the half-
metalloimmunoassay formed with the AgNP-Ab conjugates. Each 
trace is representative of three individually formed half-
metalloimmunoassays that were tested on three independently 
prepared electrodes. The blank for this experiment consisted of 
citrate-capped AgNPs suspended in SBB with no Abs present. Both 





average Ag charge of 1.68 ± 0.20 µC, while the physisorbed 
conjugate (blue trace) gave just 0.41 ± 0.06 µC.  
This experiment clearly proves the superiority of the 
hydrazone conjugation method compared to the more common 
physisorption technique. Specifically, despite a low quantity of 
immobilized Abs (5 vs. 15 for the HBCL and physisorbed 
conjugates, respectively), the higher charge obtained for the 
AgNP-HBCL-Ab conjugates is evidence of the orientation control 
exerted by the cross-linker. On the other hand, the lower charge 
resulting from the physisorbed conjugates can be related to 
misorientation of the Abs on the AgNP surface. Additionally, the 
weak electrostatic interactions might not have been sufficient 
to keep the Abs on the AgNP surface during formation of the 
metalloimmunoassay. The key point is that HBCLs help to 
circumvent these drawbacks.  
3.4.4 Determination of the stability of the Abs 
To more fully characterize the AgNP-HBCL-Ab conjugates, their 
stability (Figure 3.12) and that of the Abs on the AgNP were 
examined. The stability of the Ab portion of the conjugates was 
determined electrochemically using the protocol described in the 
previous section.  The only difference being that the assay was 









Figure 3.17 Ag charge obtained for the conjugates using the same 
electrochemical protocol as in Figure 3.16, but performed on 
days 0, 1, 2, 6, and 14. Day 0 indicates the day the conjugates 
were prepared. Each data point represents the standard deviation 
from the mean for three replicate measurements obtained using 
independently prepared electrodes. 
 
Figure 3.17 is a plot of the Ag charge resulting from the ASV 
analysis of the half-metalloimmunoassays as a function of time.  
The AgNP-HBCL1-Ab and AgNP-HBCL2-Ab conjugates, shown in red and 
green respectively, display the same average activity throughout 
the 14-day study. This is an important result, because typically 





stability of the NPs is reported). The outcome of this stability 
study is beneficial for many applications, because it is 
important to know how reliable the NP-Ab conjugates are in 
solution for a given amount of time. In contrast to the HBCL 
conjugates, the physisorbed conjugates (blue) underwent a nearly 
60% decrease in activity between day 0 and day 1. This decrease 
from 0.41 ± 0.06 µC to 0.17 ± 0.02 µC is in accord with the poor 
stability of other physisorbed conjugates reported in the 
literature.115,123,124 Specifically, the electrostatic interactions 
between Abs and NPs are weak and lead to desorption over time.104 
Additionally, it is well-known that protein-surface interactions 
may induce conformational changes in Abs after some time. This 
is due to the physisorbed Abs slowly reconfiguring their packing 
to reach equilibrium. This process may also cause the protein to 
unfold and lose activity.144   
3.4.5 Investigation of the stability of the HBCLs 
This part of our study focused on the relative stability of the 
two HBCLs. The preceding results have demonstrated that despite 
differences in their chemical compositions, HBCL1 and HBCL2 are 
equivalent in terms of conjugation efficiency and Ab stability. 
On the other hand, assays performed with HBCL1 tended to produce 
irreproducible results over a time period of a few months (data 





potentially be caused by a time-dependent change at either end 
(thiol or hydrazide) of the cross-linker resulting in poor 
attachment of the HBCL to the NP or the Ab, respectively. Thus, 
an NMR stability study was performed on HBCL1 and HBCL2 to 
identify possible structural changes. Note: this part of the 
study was focused on just the cross-linkers, not the conjugates. 
 
Figure 3.18 Stability study of HBCL1 (just the linker, not the 
full conjugate) as a function of time.  The 1H and 13C NMR (400 
MHz, DMSOd6) spectra of HBCL1 are shown at (a) day 0 and (b) day 
90. The cross-linker was stored in DI water during the 90-day 
period.  He and Cg peaks are denoted by an asterisk.  Figure 3.1 
provides complete labeling of the spectra. (c) The 1H and 13C NMR 
(400 MHz, DMSOd6) spectra of SH-PEG7-COOH. 
 
Figure 3.18 presents the 1H and 13C NMR spectra and chemical 
shifts for the methylene group closest to the hydrazide-end of 
HBCL1, marked as (*), resulting from a 90-day study. In Figure 





and 90, respectively. Figure 3.18c presents the spectra of SH-
PEG7-COOH, a possible degradation product of HBCL1. After 90 
days, the protons of the methylene group (*) underwent a strong 
deshielding from 2.34 to 2.42 ppm, meanwhile the carbon 
underwent a slight shielding from 67.3 to 66.4 ppm. This means 
that the composition of the adjacent carbo-hydrazide group was 
altered. The chemical shifts obtained at day 90 correspond 
perfectly to the signature shifts of SH-PEG7-COOH. The 
correlation of the NMR shifts confirms the transformation of 
HBCL1 into a non-reactive form.  
Finally, no evidence of chemical shifts was observed for 
HBCL2 over the 90-day test duration, which confirms that HBCL2 
is chemically stable within this time frame in aqueous solution 
(Figure 3.3). We attribute the increased stability to the 
difference in the composition of the spacer arms (PEG vs. alkyl 
chains). Presumably, the PEG residues affect the solubility of 
the molecule and bring a water-rich environment close to the 
hydrazide, while the alkyl chain will have the opposite effect. 
All in all, these findings show that HBCL2 is the more 






3.5 Summary and Conclusion 
To summarize, the goal of this study was to develop a nearly 
universal route for conjugating Abs to AgNPs. We elected the 
hydrazone bioconjugation method, because it provides control 
over the orientation of the Abs by targeting the Fc region of 
Abs. We also took advantage of the affinity of the thiol 
endgroup for the AgNP surface. Using this generalized format, 
two novel HBCLs were synthesized with each bearing a hydrazide 
group for forming the hydrazone bond with the Abs, and a thiol 
group for forming a dative bond with the AgNP surface. The 
results showed that the AgNP-HBCL-Ab conjugates are reproducible 
and consist of an average of 5 ± 1 Abs per AgNP.  
Using a half-metalloimmunoassay, it was possible to show 
that the hydrazone bioconjugation method significantly improves 
the activity of the conjugated Abs compared to the more common 
physisorption technique. Moreover, the AgNP-HBCL-Ab conjugates 
are stable for at least 14 days, while the physisorbed 
conjugates exhibit a sharp decrease in stability one day after 
preparation. Finally, we found that the spacer arm of the HBCLs 
plays an important role in the stability of the hydrazide group 
of the cross-linker. More specifically, an alkyl chain spacer 






 In conclusion, the method reported here provides a viable 
route for conjugation of AgNPs to Abs.  This finding is 
significant given the recent interest in using AgNPs as 
electrochemical57,58,61 and spectroscopic113,114,118,119 labels for 
bioassays. Indeed, we are currently using the AgNP-HBCL2-Ab 
conjugate as a key component of a point-of-care electrochemical 
sensor for heart failure.59  The results of that work will be 





Chapter 4: Electrochemical Detection of NT-proBNP using 
a Metalloimmunoassay on a Paper Electrode Platform 
4.1 Synopsis 
In this chapter we demonstrate an electrochemical method for 
detection of the heart failure biomarker, N-terminal prohormone 
brain natriuretic peptide (NT-proBNP).  The approach is based on 
a paper electrode assembly and a metalloimmunoassay; it is 
intended for eventual integration into a home-use sensor.  
Sensing of NT-proBNP relies on the formation of a sandwich 
immunoassay and electrochemical quantification of silver 
nanoparticle (AgNP) labels attached to the detection antibodies 
(Abs).  There are four important outcomes reported in this 
chapter.  First, compared to physisorption of the detection Abs 
on the AgNP labels, a 27-fold increase in signal is observed 
when a heterobifunctional cross-linker is used to facilitate 
this labeling.  Second, the assay is selective in that it does 
not cross-react with other cardiac natriuretic peptides.  Third, 
the assay forms in undiluted human serum (though the 
electrochemical analysis is carried out in buffer). Finally, and 
most important, the assay is able to detect NT-proBNP at 





the critical NT-proBNP concentration threshold often used by 
physicians for risk stratification purposes: ~0.116 nM. 
  
 
 Chapter 4 is based on a pervious publication: N. E. Pollok; C. Rabin, C. T. 
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NT-proBNP Using a Metalloimmunoassay on a Paper Electrode Platform. ACS 
Sensors 2020, 5, 853-860. NEP designed the experiments. RMC was the research 
advisor. IR contributed to the generation of ideas and experimental design. 






Here, we report on the detection of the cardiac biomarker, N-
terminal prohormone brain natriuretic peptide (NT-proBNP) using 
a metalloimmunoassay adapted to a paper-based electrochemical 
sensor.  There are four important outcomes of this study.  
First, the use of a heterobifunctional cross-linker (HBCL), 
instead of the more common physisorption technique, for the 
bioconjugation of monoclonal immunoglobulin G antibodies (Abs) 
to silver nanoparticle (AgNP) labels improves the limit of 
detection and reproducibility of the assay. Second, the assay is 
selective in that there is no cross-reactivity with other 
cardiac natriuretic peptides, such as brain, atrial, and C-type 
natriuretic peptides (BNP, ANP, and CNP, respectively).145–147 
Third, detection of NT-proBNP is not impacted by matrix 
effects148,149 in that the sandwich assay forms in undiluted human 
serum prior to analysis. Finally, and most important, the assay 
is able to detect NT-proBNP at concentrations between 0.58-2.33 
nM with an overall relative standard deviation of <15%. These 
findings represent a notable contribution to current efforts 
aimed at detecting NT-proBNP using a state-of-the-art system 
that is evolving toward home-use applications.150–153 
 NT-proBNP is a peptide that is secreted by ventricular 





volume overload. 154,155 Stretching of these heart muscle cells 
results in secretion of the prohormone brain natriuretic peptide 
(proBNP), which is enzymatically cleaved into BNP and NT-proBNP 
before being released into the bloodstream.155,156 The primary 
function of natriuretic peptides, such as BNP, ANP, and CNP, are 
to lower the blood pressure by increasing natriuresis and 
diuresis (reducing excess salt and water retention), inhibit the 
production and action of vasoconstrictor peptides, and promote 
vascular relaxation.157 The overall effect of this cascade of 
events is to reduce cardiac output and central venous pressure.   
Because they both originate from proBNP, BNP and NT-proBNP 
are initially present in equal concentrations in the body.  The 
biological function of NT-proBNP is unknown, but for a number of 
reasons it is used as a proxy for BNP in clinical settings to 
track the progression and severity of HF. Specifically, the 
circulation half-life of NT-proBNP in the body is six times 
longer than BNP (120 min vs. 20 min, respectively), making it a 
more desirable biomarker for HF.158  
The critical NT-proBNP concentration threshold used by 
physicians for risk stratification purposes is 1000 pg/mL (116 
pM).159–162  This threshold allows physicians to identify HF 
patients as being at a high or low risk of hospitalization or 





peptide concentration values can vary greatly depending on co-
morbidities, race, disease severity, and the age of the 
patient.162–167 Due to this variability, it would be desirable for 
HF patients to be able to monitor their HF status at home, 
because this could reduce the likelihood of decompensation and 
hospitalization.168–170  This is the motivation for the study 
presented here. 
 There are numerous analytical methods for detecting NT-
proBNP, such as enzyme-linked immunosorbent assays (ELISA),55,171 
immunofluorescence,172,13 and electrochemiluminescence (ECL).14–17 
These methods typically require some type of immunological or 
aptameric173,174 technique to capture the peptide, and also a 
signal amplification mechanism.41 For example, in 2017, Shi et 
al. developed a sandwich-type (immunoassay) ECL sensor for 
detecting clinical levels of NT-proBNP, in which the 
concentration of NT-proBNP in diluted human serum was correlated 
to the ECL quenching efficiency.14 In another example, an 
immunochromatographic assay consisting of monoclonal Abs labeled 
with a genetically engineered fluorescent protein was used to 
capture NT-proBNP on nitrocellulose paper, and then the assay 
was quantified fluorometrically.13 While these methods provide 






Illustration 4.1. Scheme of the galvanic exchange method used to 
detect Ag following formaiton of the assay. 
 
Our group previously reported on electrochemical detection 
of NT-proBNP using a metalloimmunoassay consisting of a capture 
Ab conjugated to a magnetic microbead (MµB) and a AgNP-labeled 





process, which has its roots in a method reported by Limoges and 
coworkers,54 proceeds as follows.  First, the peptide is captured 
by the Ab pair in solution, and then the MµB is brought to the 
electrode surface by a magnetic force for detection 
(Illustration 4.1a). In this case, and in our previous 
reports,57,58,61 the detection Ab is physisorbed to a AgNP label. 
Second, a process known as galvanic exchange (GE) is used to 
detect the AgNPs electrochemically.127,66 GE takes advantage of a 
difference in the standard potentials of two metals such that 
they undergo a redox process. In our detection system 
(Illustration 4.1b) the metals are Au and Ag (E⁰ = 1.52 and 0.79 
V, respectively).65 The more noble Au0 is pre-electrodeposited on 
an electrode and then is electrochemically oxidized to Au3+ which 
subsequently diffuses to the AgNPs and then spontaneously 
exchanges with the less noble, zerovalent AgNP labels. This 
results in oxidation of the AgNPs to Ag+, which, in a third step, 
is subsequently electrodeposited onto the working electrode 
(Illustration 4.1c). Finally, anodic stripping voltammetry (ASV) 
is used to quantify the amount of Ag on the electrode surface. 
The resulting charge is directly related to the amount of target 
originally present in the sample. 
The predominant means for immobilizing Abs on metal 





physisorption relies primarily on interactions between the 
surface of a metal, and thiol and amine residues present on 
Abs.62,112 While this bioconjugation method is quick and simple, 
the active orientation of the Abs on the nanoparticle surface is 
not well controlled unless the Ab is specifically engineered to 
bind in a particular way.179 Misorientation of the detection Ab 
can result in poor activity of the Ab in a metalloimmunoassay.115 
An additional disadvantage of physisorption is that there is a 
likelihood that other biomolecules present in real biological 
matrixes will effectively compete for the metal nanoparticle 
surface, thereby dislodging the detection Abs.62,123,148,149 For 
these reasons, we sought to control the orientation of the Abs 
on the AgNP surface with a hydrazide- and dithiolane-containing 
HBCL, which has previously been reported by our group180 to have 
a positive effect on the capture efficiency of Abs on the 
surface of AgNPs by targeting the fragment crystallizable (Fc) 
region.106 
 The primary goal of the present chapter is to report a 
bioassay that can be integrated into an electrochemical 
detection workflow on a paper-based, point-of-need device. 
Accordingly, we report on a metalloimmunoassay for NT-proBNP 
using a HBCL to bioconjugate AgNPs to the detection Ab rather 





possible to detect NT-proBNP near the risk stratification 
threshold in buffered solution. Additionally, the assay is 
selective for NT-proBNP compared to other cardiac natriuretic 
peptides, and it resists matrix effects associated with human 
serum.  
4.3 Experimental 
4.3.1 Chemicals and Materials 
All solutions were prepared using deionized (DI) water (>18.0 
MΩ-cm, Milli-Q Gradient System, Millipore, Burlington, MA). 
Phosphate buffered saline (PBS) pH 7.4 (P3813), casein, 
superblock blocking buffer containing PBS (SBB) (cat. no. 
37515), siliconized low-retention microcentrifuge tubes, H2SO4, 
HAuCl4, KNO3, Whatman grade 1 chromatography paper (180 μm thick, 
20 cm × 20 cm sheets, linear flow rate of water = 0.43 cm/min), 
and Costar 3590 high-binding microtiter plates were purchased 
from Fisher Scientific (Pittsburgh, PA). A horseradish 
peroxidase (HRP) conjugate kit (cat. no. LNK002P) was purchased 
from Bio-Rad (Richmond, CA). 
All PBS concentrations were 1x. The 5 kDa mPEG-SH was 
obtained from Nanocs (New York, NY). 1-Step Ultra TMB-ELISA 
Substrate Solution (34028) and sodium meta-periodate (NaIO4) were 





capped AgNPs (nominal 20 nm diameter) were purchased from 
nanoComposix (San Diego, CA). N-terminal prohormone brain 
natriuretic peptide (NT-proBNP), monoclonal immunoglobulin G 
anti-NT-proBNP 13G12 detection Ab, biotinylated monoclonal 
immunoglobulin G anti-NT-proBNP 15C4 capture Ab (15C4-biotin), 
and non-biotinylated monoclonal immunoglobulin G anti-NT-proBNP 
15C4 capture Ab were obtained from HyTest (Turku, Finland). 
Polyclonal anti-mouse immunoglobulin G HRP-labeled secondary 
antibody (SAb) and prohormone brain natriuretic peptide (proBNP) 
were obtained from Abcam (Cambridge, UK). Atrial natriuretic 
peptide (ANP), C-type natriuretic peptide (CNP), brain 
natriuretic peptide (BNP), and polyoxyethylene (20) sorbitan 
monolaurate (Tween-20) were purchased from Sigma-Aldrich (St. 
Louis, MO). Human chorionic gonadotropin (hCG) was purchased 
from Fitzgerald (Acton, MA). Streptavidin-coated magnetic 
microbeads (MµBs) having a diameter of 1.0 µm (cat. no. 65601) 
were obtained from Life Technologies (Grand Island, NY).   
Amicon ultra 0.5 mL centrifugal filters (10 K) and normal 
human serum were purchased from Millipore-Sigma (Taunton, MA). 
Conductive carbon paste (Cl-2042) was purchased from Engineered 
Conductive Materials (Delaware, OH). Cylindrical neodymium 





(Petersburg, WV). All chemicals and reagents were used without 
further purification unless otherwise specified. 
4.3.2 Instrumentation 
Absorbance measurements were obtained and path length corrected 
using a Synergy H4 Hybrid Multi-Mode Microplate Reader from 
BioTek (Winooshi, VT). A Sorvall Legend Micro 21R centrifuge 
from Thermo Scientific (Grand Island, NY) was used for washing 
and separation steps during bioconjugation. A tube revolver 
(cat. no. 88881001), also from Thermo Scientific, was used for 
incubation steps during the conjugation of Abs to MµBs. A Mini 
Vortexer (945300) from VWR International (Radnor, PA) was used 
to briefly mix solutions while a BioShake iQ from Quantifoil 
Instruments GmbH (Jena, Germany) was used for incubation steps 
during bioconjugation. A magnetic bead separation block (cat. 
no. VP771HH-Rz) was purchased from V&P Scientific (San Diego, 
CA) and was used for washing steps involving MµBs. 
4.3.3 Electrode fabrication 
A slight modification of a previously published procedure was 
used to fabricate the electrodes.127 Specifically, they were 
fabricated by stencil-printing carbon paste onto wax-patterned 
sheets of chromatography paper that had been printed using a 
Xerox ColorQube 8570DN printer. Following printing, the wax was 





oven at 120 °C for 25.0 s. Photopaper was glued to the back of 
the wax-printed chromatography paper to improve rigidity, and 
then it was cut into 12 rectangles (2.0 cm × 5.0 cm, each). A 
stencil for defining the 3.0 mm-diameter disk-shaped working 
electrode, hook-shaped carbon quasi-reference electrode, and 
counter electrode was created using CorelDRAW (Ottawa, ON).  The 
stencil was cut into a thin plastic sheet of transparency film 
using an Epilog laser engraving system (Zing 16). Finally, the 
stencil was placed over the paper (wax side up), the electrodes 
were printed through the stencil using the conductive carbon 
paste, and then they were left to dry in air for 14 h 












Illustration 4.2 Description of the paper electrochemical 
platform used for determining the amount of Ag charge obtained 
from the metalloimmunoassay for NT-proBNP. Electrode fabrication 
steps such as Au pre-electrodeposition on the working electrode 
and anodic stripping voltammetry were performed using this 
device. (a) Photograph of the electrodes before Au was 
electrodeposited on the working electrode. (b) Photograph of the 
cell which contains a magnet and holds the paper device. (c) 
Computer-aided design image of the fully assembled cell 
featuring the Au electrodeposited working electrode. The white 
portion of the cell (b) incorporates metal contacts within the 
enclosure to provide ohmic contact between the carbon paste 
electrodes and the potentiostat. Duct tape is placed across the 
orange platform of the cell to hold it in place during analysis. 
As discussed in the Experimental Section of this chapter, the 
electrodes were stencil printed with conductive carbon paste. 
When the device is fully assembled, the magnet is located behind 
the working electrode. The regions printed in yellow wax (c) are 
more hydrophilic compared to the gray wax regions, thus allowing 
for the sample solution to span all three carbon electrodes. The 
yellow region can hold an aqueous volume of 50-80 µL. In the 













The working electrode was further modified by 
electrodepositing Au onto the carbon paste. This step was 
performed on-chip and was carried out by placing a.0 µL droplet 
of a solution consisting of 6.0 mM HAuCl4 and 0.10 M KNO3 on the 
electrode region of the sensor.  Because the region of the 
sensor incorporating the electrodes is hydrophilic relative to 
the rest of the paper assembly, the deposition solution was 
confined to just the electrode region and hence no additional 
electrochemical cell was required. Next, the potential of the 
working electrode was stepped from 0 V to -0.60 V (unless 
otherwise stated, all potentials are vs. a carbon quasi-
reference electrode, CQRE) for 2.0 s.127 This process results in 
islands of Au (not a conformal coating) on the surface of the 
carbon.127 The electrode was then rinsed twice with DI water, and 
dried with a Kimwipe (Illustration 4.2). 
4.3.4 Electrochemical detection 
All electrochemical measurements were performed using a CH 
Instruments model 760B electrochemical workstation (Austin, TX). 
A previously published electrochemical protocol was used to 
determine the charge resulting from the process illustrated in 
Illustration 4.1.127 Briefly, to initiate GE, the potential of 
the working electrode was stepped from 0 to 0.80 V for 12.0 s to 





0.70 V for 50.0 s to reduce Ag+ to Ag0 onto the electrode. These 
two steps were carried out twice, and then the potential was 
swept two times from -0.70 to 0.20 V at a scan rate of 50.0 mV/s 
to oxidize Ag0.  The charge resulting from the last ASV scan was 
obtained by integration and represents the output signal of the 
sensor.66,127 All electrochemical measurements were performed in a 
PBS solution. 
4.3.5 Assessing Ab cross-reactivity 
The cross-reactivity of the 13G12 and 15C4 Abs was determined 
using an indirect, half ELISA and a full capture ELISA.  The 
13G12-HRP Ab was prepared using a kit and protocol provided by 
the manufacturer.181 Unless stated otherwise, all incubation 
steps were performed for 30 min at 600 rpm at room temperature 
(RT) (22 ± 3˚C) and were followed by three washing steps with 
PBS. Briefly, 100 µL of 58.2 nM NT-proBNP, proBNP, BNP, ANP, 
CNP, or hCG in PBS were incubated for 14 h at 4 °C without 
shaking in a high-binding microtiter plate.  Second, the wells 
were blocked by adding 400 µL of 2% (w/v) casein solution in PBS 
for 30 min without shaking.  Third, 100 µL of 6.7 µM of 13G12 Ab 
were added to each well and incubated. The same process was 
carried out with the 15C4 Ab. Fourth, 100 µL of 6.7 µM SAb (the 
secondary Ab) were added to each well and incubated. Finally, 





added and 50.0 µL of 2 M H2SO4 were used to quench the reaction 
after it reached the desired color intensity (~3 min), and then 
the absorbance was measured at 450 nm. The degree of cross-
reactivity was determined quantitatively. That is, if the Abs 
were cross-reactive with the different targets on the plate, a 
color change would be observed. Positive controls were also 
performed to ensure all the assay components were functioning 
properly. Specifically, hCG and CNP were detected using an anti-












Figure 4.1 Enzyme-linked immunosorbent assay (ELISA) results 
obtained by forming a half indirect ELISA with human chorionic 
gonadotropin (hCG) or C-type natriuretic peptide (CNP) and their 
appropriate monoclonal Abs. This experiment was performed 
similarly to those described in the Experimental Section.  
Specifically, all the incubation steps were performed at room 
temperature (RT) (22 ± 3 °C) for 30 min at 600 rpm, and then 
were followed by washing three times with 1x phosphate buffered 
saline (PBS). This experiment was carried out by first 
immobilizing the antigens by adding 100 µL of 58.2 nM of hCG or 
CNP to the wells of a microtiter plate. Second, 100 µL of 6.7 µM 
of monoclonal anti-hCG or monoclonal anti-CNP were added. Third, 
100 µL of 6.7 µM of the HRP-labeled polyclonal secondary Ab were 
added to each well. Finally, 100 µL of the 1-Step Ultra TMB-
ELISA Substrate solution were added and 50.0 µL of 2.0 M H2SO4 
were used to quench the reaction after it reached the desired 
color intensity (~3 min). These results show that for both hCG 
and CNP, a color change was detected, confirming that the 









A complementary cross-reactivity experiment, similar to 
that described in the previous paragraph, was also performed. In 
this case, a full capture ELISA for NT-proBNP was prepared in 
the presence of all the potentially cross-reactive species. 
Specifically, this experiment was carried out by first 
immobilizing the anti-NT-proBNP capture Ab by adding 100 µL of 
6.7 µM of the 15C4 Ab to the wells of a microtiter plate. Next, 
a 100 µL mixture containing 58.2 nM of each of the following was 
introduced: NT-proBNP, BNP, CNP, and ANP. Next, 100 µL of 6.7 µM 
13G12-HRP detection Ab were added to each well. Finally, 100 µL 
of the 1-Step Ultra TMB-ELISA Substrate solution were added and 
50.0 µL of 2 M H2SO4 were used to quench the reaction after it 
reached the desired color intensity (~3 min). The blank for this 
experiment was prepared following the same procedure, however, 
SBB was added to the wells in place of the antigen mixture.   
An advantage of the Abs used for this assay is that they 
target amino acids at the ends of the NT-proBNP peptide. This is 
important, because post-translational modifications of peptides, 
such as glycosylation, can hinder the ability of Abs to 
recognize a specific target. Indeed, endogenous NT-proBNP is 
known to have several locations on its amino acid sequence where 





the middle of the peptide: amino acids 28-60.182 These regions 
are avoided by the Ab pair used in this study.147,183 
4.3.6 Preparing assay components 
The 13G12 Ab was conjugated to the AgNPs using a previously 
published protocol, and a more detailed version can be found in 
the Appendix (A3).47,48 Briefly, the 13G12 Ab was modified by 
bioconjugating it to a HBCL. The modified Ab was then added to 
500 µL of AgNPs (4.9 x 1011 AgNPs/mL) and incubated for 1 h, 
followed by back-filling with mPEG-SH for 20 min at 600 rpm at 
RT. Excess conjugation reagents were then removed by 
centrifugation for 30 min at 16,600 g at 4 ˚C. The formed 
conjugate was washed three times by centrifugation and then 
resuspended in 500 µL of SBB. Henceforth, this will be referred 
to as the AgNP-HBCL-Ab conjugate.  The protocol for preparing 
the physisorbed conjugate (denoted as AgNP-Ab), used for 
comparison, is provided in the Appendix (A2). 
The 15C4-biotin Ab was conjugated to streptavidin-coated 
MµBs using the protocol provided by the manufacturer.184 In 
short, 50.0 µL of MµBs (~7–10 × 109 MµBs/mL) were added to a SBB-
blocked tube and washed by magnetic separation four times with 
PBS. Next, 30.0 µL of 4.6 µM 15C4-biotin Ab and 20.0 µL of PBS 
were added to the tube and incubated for 30 min at 40 rpm at RT, 





washed by magnetic separation five times with SBB and 
resuspended to a final volume of 50.0 µL. Henceforth, this will 
be referred to as the MµB-Ab conjugate. A more detailed protocol 
is provided in the Appendix (A4).  
4.3.7 Step-wise formation of the NT-proBNP metalloimmunoassay 
Once all the assay components were prepared, they were used in 
the full metalloimmunoassay for NT-proBNP. This assay was formed 
in SBB-blocked wells of a microtiter plate as follows. First, 
2.0 µL of the MµB-Ab conjugate were placed in each well along 
with 100 µL of a known concentration of NT-proBNP in SBB. These 
components were incubated for 30 min at 1000 rpm at RT. Next, 
the partially formed assay was washed to remove unbound peptide. 
Washing was performed by magnetic separation wherein the MµBs 
were collected at the bottom of the wells, the supernatant was 
removed, and the half-formed conjugate was resuspended in 0.1% 
(v/v) Tween-20 and PBS solution. This washing step was performed 
three times. Next, 20.0 µL of the AgNP-HBCL-Ab conjugate and 
80.0 µL of SBB were added. This mixture was incubated using the 
procedure stated in the previous section and then washed by 
magnetic separation. The fully formed assay was resuspended in a 
final volume of 50.0 µL of PBS and then transferred to the 
paper-based electrode. The MµBs were focused onto the working 





electrochemical analysis was performed as discussed earlier. For 
experiments involving assays formed in undiluted human serum, 
the same protocol was followed, except the NT-proBNP samples and 
the assay components were diluted into serum rather than SBB. 
4.4 Results and Discussion 
4.4.1 Determining Ab cross-reactivity 
One of the most important aspects of any bioassay is its 
specificity. That is, the degree to which the assay can 
distinguish the target molecule from all other possible 
components of a biological sample. In our case, other 
natriuretic peptides can be considered good model cross-
reactants for the NT-proBNP-targeting Abs used in this study. 
Accordingly, we carried out two sets of cross-reactivity studies 
using NT-proBNP, proBNP, BNP, ANP, CNP, and hCG. The first set 
used an indirect half ELISA to specifically check for individual 
antigen cross-reactivity for each Ab of the assay, while the 
second set used a full capture ELISA to perform a mixed-antigen 
cross-reactivity experiment (described in the Experimental 
Section of this chapter). Briefly, for the half indirect ELISA, 
the model cross-reactants were immobilized in different wells of 
a microtiter plate, and then either the unmodified 13G12 





followed by a SAb. In the case of the mixed-antigen cross-
reactivity experiment, the 15C4 capture Ab was immobilized on 
the plate, followed by the addition of the antigen mixture 
(including NT-proBNP) to the wells of the plate, and then a 
13G12-HRP signaling Ab. The degree of reactivity was determined 







Figure 4.2 Histograms representing the cross-reactivity 
absorbance results obtained using an indirect enzyme-linked 
immunosorbent assay (ELISA). Results for the anti-NT-proBNP Ab 
pair including, (a) the 13G12 detection Ab and (b) the 15C4 
capture Ab. (c) Full capture ELISA results from the assay 
prepared with a mixed antigen solution containing 58.2 nM of 
each of the following: NT-proBNP, BNP, CNP, and ANP, prepared in 
2% (w/v) casein-PBS. The error bars represent the standard 






Figures 4.2a and 4.2b show the results of the foregoing 
experiments obtained using the 13G12 detection Ab and the 15C4 
capture Ab, respectively. The histograms indicate that these two 
Abs are not cross-reactive with the other natriuretic peptides 
tested, or with hCG. A positive control experiment was also 
performed (Figure 4.1), which further validates this conclusion. 
Figure 4.2c displays the results for the mixed-antigen 
cross-reactivity experiment. These results show that even in the 
presence of multiple antigens that are related to NT-proBNP, NT-
proBNP is captured to the same degree as when the potential 
interferants are omitted. It is important to note that because 
NT-proBNP originates from proBNP, the Ab pair also recognizes 
proBNP (which was omitted in this mixed antigen experiment). 
This has little impact on the bioassay, however, because most 
commercial assays capture both NT-proBNP and proBNP, and the 
latter is almost ten times lower in concentration than NT-proBNP 
in HF patient samples.146   
4.4.2 Comparing physisorbed and HBCL-modified conjugates 
After ensuring that the Ab pair used for the analysis are not 
cross-reactive with the other tested natriuretic peptides, two 
different bioconjugation routes were explored to determine the 
best technique for immobilizing the detection Ab on the AgNP 





were carried out by preparing both the physisorbed AgNP-Ab and 
the AgNP-HBCL-Ab conjugates, as described in the Experimental 
section, and then using them to electrochemically detect a 
single concentration of NT-proBNP in the full metalloimmunoassay 
(detection of multiple concentrations is discussed in the next 
section). Specifically, the metalloimmunoassay was formed with 
100 µL of 0.58 nM of NT-proBNP and 2.0 µL of the MµB-Ab 
conjugate. The detection Ab, which was in excess, was either 
physisorbed to the AgNP label (AgNP-Ab conjugate) or covalently 
attached using the HBCL (AgNP-HBCL-Ab conjugate). After assay 











Figure 4.3 Histograms representing the amount of Ag charge 
obtained by forming the full metalloimmunoassay for a single 
concentration of NT-proBNP (0.58 nM) using either the AgNP-Ab 
physisorbed conjugate or the AgNP-HBCL-Ab conjugate. The 
electrochemical experiment was carried out in PBS. The error 
bars represent the standard deviation of five independent 
measurements performed using five independently prepared paper 
electrodes. 
 
Figure 4.3 is a histogram comparing the Ag charge obtained 
using the two different conjugation methods. These data 
represent three independently prepared assays analyzed on 
independently prepared paper electrodes. The magnitude of the 
signal arising from the AgNP-HBCL-Ab conjugate is 27-fold higher 
than that of the AgNP-Ab (physisorbed) conjugate. Specifically, 
the charge arising from the AgNP-HBCL-Ab conjugate was 1.90 ± 
0.18 vs. 0.07 ± 0.01 µC for the conjugate formed by 





correlation between the measured charge and the amount of 
peptide captured in the assay, which means that the HBCL leads 
to an increased target peptide capture and a lower limit of 
detection. 
Physisorption is widely used in the literature as a simple 
means for immobilizing Abs on NP surfaces; however, this 
technique has limitations. As noted previously, one of these is 
that there is usually (but not always)179 limited control over 
the orientation of the Ab on the surface of the particle.  This 
is a consequence of the fact that conjugation by physisorption 
does not target a specific region of the Ab.62 The advantage of 
the HBCL, and specifically the hydrazone chemistry used in this 
study, is that it exclusively targets the polysaccharide groups 
residing in the Fc region of the Ab.  This ensures that the 
antigen-binding fragment (Fab) regions of the Ab are completely 
accessible to the target molecule.106,180 Indeed, the results in 
Figure 4.3 suggest that the 13G12 detection Ab is more 
effectively oriented for capturing NT-proBNP.  Additionally, we 
have previously shown that the Ab is also more strongly attached 
to the NP when the HBCL is used instead of physisorption.180 








4.4.3 Detecting multiple concentrations of NT-proBNP 
 
After determining that the HBCL-modified detection Ab performs 
better than the physisorbed AgNP-Ab conjugate, the latter was 
used for preparing a dose-response curve. The assay was prepared 
in SBB using a step-wise procedure as described in the 
Experimental Section. Briefly, 2.0 µL of the MµB-Ab conjugates 
were added to the wells of a pre-blocked microtiter plate, and 
then 100 µL of varying concentrations of NT-proBNP were added. 
Following incubation and washing, an excess of the AgNP-HBCL-Ab 
conjugate was added to the wells. Once the assay was fully 
formed, the entire content of the well was transferred to the 
paper electrode, and the electrochemical protocol was carried 






Figure 4.4 Electrochemical results for detection of NT-proBNP 
using the full metalloimmunoassay in PBS on a paper electrode. 
(a) Anodic stripping voltammograms (ASVs) for the concentrations 
of NT-proBNP indicated in the legend. For clarity, only one ASV 
trace is shown for each concentration. The position of the ASV 
peaks vary slightly due to the use of a carbon quasi-reference 
electrode (CQRE). (b) Calibration curve showing the correlation 
between Ag charge (obtained by integrating ASVs like those in 
(a)) and the concentration of NT-proBNP. Note that for clarity 
the ASV for 7.0 nM of NT-proBNP is not shown in (a).  The linear 
regression value is 0.99, and the scan rate is 50 mV/s. Each 
data point represents the average of five measurements carried 
out using independently fabricated electrodes. The error bars 
represent the standard deviation of those five measurements. 






Figure 4.4 shows the results of this experiment. The 
voltammograms in Figure 4.4a indicate that the AgNP oxidation 
current increases as a function of the concentration of NT-
proBNP used to form the bioassay. The charges under the 
voltammograms were obtained by integration, and the results for 
five independent experiments per concentration are plotted in 
Figure 4.4b. These data demonstrate that the charge increases 
linearly from 0.58-2.33 nM of NT-proBNP and then it begins to 
saturate (the data point for 12.0 nM is not shown in Figure 
4.4b, but it is about the same as the point for 7.0 nM). Note 
that concentrations below 0.58 nM could not be differentiated 
from the blank and are thus not shown in Figure 4.4. An 
additional important feature of Figure 4.4b is that the overall 
relative standard deviation of this assay is <15%.  
To put the linear range of the bioassay into perspective, 
the critical concentration used by physicians to identify HF 
patients who are at risk of poor outcomes is 1000 pg/mL (116 
pM).159,160 Accordingly, the results in Figure 4.4b indicate that 
the performance of the bioassay is approaching the risk 
stratification threshold.  Clearly, additional work is required 
to further reduce the limit of detection, but to the best of our 





reported for detection of NT-proBNP using a simple, paper-based 
device.59 
4.4.4 Forming the metalloimmunoassay in undiluted serum 
 
The primary goal of the present chapter is to report on a 
bioassay that can be easily integrated into a point-of-need 
device. In part, this means an assay having the ability to 
capture NT-proBNP from a serum matrix. Accordingly, the full 
metalloimmunoassay for NT-proBNP was prepared exactly as 
described in the previous section, but in this case one set of 
replicates was prepared in SBB and another in undiluted human 
serum, both spiked with 0.58 nM NT-proBNP. The assays were 
formed in their respective matrixes, washed with 0.1% (v/v) 
Tween-20 and PBS, resuspended in PBS, and transferred to the 








Figure 4.5 Anodic stripping voltammograms (ASVs) obtained by 
forming the full metalloimmunoassay for NT-proBNP in either a 
superblock blocking buffer matrix (SBB) or an undiluted human 
serum matrix. The scan rate was 50 mV/s. For clarity, only one 
ASV trace is shown for each conjugate, but the measurements were 
carried out in triplicate using independently fabricated 
electrodes. The position of the ASV peaks varies due to the use 
of a carbon quasi-reference electrode (CQRE). 
 
Figure 4.5 displays the ASVs for the assays formed in both 
SBB and human serum. The blank for this experiment was the assay 
formed in serum with no NT-proBNP present. The Ag charge 
obtained from this experiment was 0.60 ± 0.10 µC, regardless of 
whether the assay was formed in SBB or undiluted human serum. 
This means that the serum matrix has no detectable adverse 





4.5 Summary and Conclusion 
To summarize, the goal of this study was to describe a bioassay 
that can be integrated into an electrochemical detection 
workflow on a paper-based, point-of-need device for the 
detection of NT-proBNP. The detection limit of 0.58 nM of NT-
proBNP is promising at this stage for such a simple 
immunological sensor.  Indeed, we found that a 27-fold increase 
in detection efficiency is observed by just improving the 
linking chemistry between the detection Ab and the AgNP label. 
We attributed this result to the controlled orientation of the 
detection Ab on the surface of the AgNP label.106,180 This advance 
made it possible to detect NT-proBNP near the risk 
stratification threshold with a relative standard deviation of 
<15%. Additionally, using both an indirect and a full-capture 
ELISA, we showed that the Ab pair selected for this bioassay was 
not cross-reactive with other cardiac natriuretic peptides. 
Finally, the bioassay could be formed in undiluted human serum 
with no change in signal (compared to buffer). 
The detection method reported in this chapter provides a 
simple means for detecting an important HF marker that may be 
relevant in the evolving at-home, personal medicine 
environment.55,150,174,185  There is, however, much more work to do.  





detection, eliminate all off-chip reagents and manipulations, 
and test the device using human blood samples.  All of these 
tasks are underway in our lab, and the results will be reported 






Chapter 5: Effect of Serum on Electrochemical Detection 
on Bioassays having Ag Nanoparticle Labels 
5.1 Synopsis 
The effect of serum on electrochemical detection of bioassays 
having silver nanoparticle (AgNP) detection labels was 
investigated. Both a model assay and an antigen-specific 
sandwich bioassay for the heart-failure marker NT-proBNP were 
examined. In both cases, the AgNP labels were conjugated to a 
detection antibody. Electrochemical detection was carried out 
using a galvanic exchange/anodic stripping voltammetry method in 
which Au3+ exchanges with AgNP labels. The assays were carried 
out using a paper-based electrode platform. The bioassays were 
exposed to different serum conditions prior to and during 
detection. There are three important outcomes reported in this 
article. First, both the model and antigen-specific assays could 
be formed in undiluted serum with no detectable interferences 
from the serum components. Second, to achieve the maximum 
possible electrochemical signal, the highest percentage of serum 
that can remain in an assay buffer during electrochemical 
detection is 0.25% when no washing is performed. The assay 
results are rendered inaccurate when 0.50% or more of serum is 
present. Third, the factors inhibiting galvanic exchange in 





the AgNP labels, chelation of Au3+ by serum components, or both. 
The results reported here provide general guidance for using 
metal NP labels for electrochemical assays in biofluids. 
  
 
 Chapter 5 is based on a manuscript accepted for publication: N. E. Pollok, 
Y. Peng, C. Rabin, I. Richards, R. M. Crooks, Effect of Serum on 
Electrochemical Detection of Bioassays having Ag Nanoparticle Labels. ACS 
Sensors 2021, Accepted. NEP and YP contributed equally to the work. CR 
assisted in data collection. IR contributed to discussion and experimental 






There are three key steps to executing a typical bioassay: 
capture of the analyte of interest, removal (washing) of excess 
reagents, and detection. At each of these steps the detection 
medium can either play an advantageous186,187 or a detrimental188 
role. In the present study, we evaluated the effect of serum on 
a previously reported method for detecting AgNP labels that 
combines galvanic exchange (GE) and anodic stripping voltammetry 
(ASV). Illustration 5.1 illustrates the GE/ASV method. In the 
first step (Illustration 5.1a), Au pre-deposited onto the 
working electrode (WE) is oxidized and then itself oxidizes 
AgNPs in the vicinity of the electrode surface. During the 
second step (Illustration 5.1b), the resulting Ag+ is 
concentrated onto the electrode surface by electrodeposition and 
then detected by ASV. Though we examined the effect of serum on 
this GE/ASV detection method, the results are generally 








Illustration 5.1 Schematic of the galvanic exchange/anodic 
stripping voltammetry (GE/ASV) detection method. 
 
 Electrochemical biosensors are powerful tools used to 
monitor medical conditions at home,18,19 in clinics,20–22 and in 
hospitals.23,24 Human biomarkers for point-of-care and point-of-
need sensors are found in matrixes including sweat,29,30 saliva,26–
28 and whole blood31,32 (among others).25 Serum is another common 
matrix used for bioassays. It is the fluid and solute component 
of whole blood that does not play a role in clotting. It 
includes all proteins not used in clotting, all electrolytes, 
antibodies (Abs), antigens, hormones, and exogenous 
substances.189,190  Human serum albumin  is the most abundant 
protein in human blood plasma, and it constitutes about 50% of 
the proteins in serum.189 Due to the relatively high abundance of 





example, both the oxidized and reduced forms of bovine serum 
albumin (BSA) exhibit reversible electron transfer when strongly 
adsorbed to a hanging mercury drop electrode through the 
interaction of exposed disulfide bonds with the mercury 
surface.188  
 Signal amplification is often a key component of bioassays. 
Amplification is usually accomplished using enzyme labels; for 
example, in enzyme-linked immunosorbent assays (ELISA).55,171 Over 
the past 20 years, however, there has been growing interest in 
using metallic or semiconducting nanoparticles (NPs) for signal 
amplification due to their generally higher stability, lower 
cost, and faster read-out times.41,54 More specifically, AgNPs and 
gold nanoparticles (AuNPs) conjugated to recognition elements, 
such as Abs,42,57,59,142,180,191 nucleic acids,66,95,127 or aptamers,173 
are becoming increasingly common. To ensure the stability of the 
metal label in complex media, many protocols include surface-
modification steps; for example, addition of thiolated 
polyethylene glycol.192 Furthermore, although a relatively 
complex matrix, serum can also work as an effective NP 
stabilizing agent and a conductive medium for electrochemical 
analysis.33,34,186,193 In fact, in 2009, Murawala et al. described a 
simple and convenient one-step, room-temperature method for the 





easily dispersible in water and could withstand dynamic salt 
conditions, all of which are important characteristics of NPs 
used in bioassays.33 
 Previous work from our group has shown that 
metalloimmunoassays can be formed in undiluted human serum,191 
but that the GE/ASV detection process is inhibited. In the 
present chapter we aim to elucidate the factors leading to 
inhibition.  Specifically, we will show that: (1) both a model 
and an antigen-specific metalloimmunoassay can be formed in 
serum; (2) systematic analysis of washing steps reveal the 
maximum amount of serum that can remain during detection to 
yield full recovery of the Ag signal; and (3) there are 
differences in detectability when serum or filtered serum are 
used. These findings should be of broad interest to those 
interested in carrying out electrochemical bioassays on analytes 
found in serum. 
5.3 Experimental 
5.3.1 Chemicals and materials 
NaCl, NaOH, HCl, KNO3, NaIO4, Whatman grade 1 chromatography 
paper (180 µm thick, 20 cm x 20 cm sheets, linear flow rate of 
water = 0.43 cm/min) and siliconized low-retention 





(Pittsburgh, PA). HAuCl4, AgNO3, phosphate-buffered saline (PBS, 
pH=7.4, P3813), superblock blocking buffer containing PBS (SBB) 
(cat. no. 37515), polyoxyethylene (20) sorbitan monolaurate 
(Tween-20), 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
(HEPES), and bovine serum albumin (BSA) were purchased from 
Sigma Aldrich (St Louis, MO). Unfiltered human serum (hereafter, 
just "serum") was purchased from Millipore-Sigma (Taunton, MA). 
In some cases, the human serum was filtered using 10 kDa 
molecular weight cut-off spin filters (also from Millipore-
Sigma), and this is hereafter referred to as "filtered serum"). 
The 5 kDa methoxy poly(ethyleneglycol) thiol(mPEG-SH) was 
obtained from Nanocs (New York, NY). 
 Conductive carbon paste (Cl-2042) was purchased from 
Engineered Conductive Materials (Delaware, OH). Streptavidin-
coated, 1.0 µm-diameter magnetic beads (MµBs, Dynabeads, MyOne 
Streptavidin T1, 10 mg/mL) were obtained from Invitrogen (Grand 
Island, NY). Stock citrate-capped AgNPs (nominal 20 nm diameter, 
0.18 mM Ag, 4.5×1011 NP/mL) were purchased from nanoComposix (San 
Diego, CA). N-terminal prohormone brain natriuretic peptide (NT-
proBNP), monoclonal immunoglobulin G anti-NT-proBNP 13G12 
detection (Ab), and 15C4 capture Ab were obtained from HyTest 
(Turku, Finland). The biotinylated polyclonal anti-mouse 





Abcam (Cambridge, UK). All solutions were made using deionized 
(DI) water (>18.0 MΩ-cm, Milli-Q Gradient System, Millipore, 
Burlington, MA). All PBS concentrations were 1X unless otherwise 
noted. 
5.3.2 Instrumentation 
The UV-vis spectroscopic measurements were performed using a 
Hewlett-Packard HP8453 spectrometer with a micro quartz cuvette 
(50 µL, Hellma, Müllheim, Germany). A tube revolver (cat. no. 
88881001, Thermo Scientific) and a BioShake iQ from Quantifoil 
Instruments GmbH (Jena, Germany) were used for incubation steps 
during bioconjugation. Neodymium magnets were purchased from K&J 
Magnetics (Pipersville, PA) and were used for washing and 
separating steps involving magnetic microbeads (MµBs). 
5.3.3 Electrochemistry 
Electrochemical measurements were performed using a CH 
Instruments model 760B electrochemical workstation (Austin, TX). 
The fabrication of paper electrodes and electrodeposition of Au 
onto the WE are described in the Appendix (A1) and are based on 
a previous publication.127 A previously published electrochemical 
protocol was used to detect the AgNP labels.59,66,127,191 Briefly, to 
initiate GE, the potential of the WE was stepped from 0 to 0.80 
V for 12.0 s to oxidize Au0 to Au3+. Following GE, the potential 





the electrode. These two steps were carried out twice, and then 
the potential was swept twice from −0.70 to 0.20 V at a scan 
rate of 50.0 mV/s to oxidize Ag0. The charge resulting from the 
last ASV scan was obtained by integration and represents the 
output signal of the sensor. All electrochemical measurements 
were performed in 1× PBS, unless stated otherwise, and all 
potentials are reported vs. a carbon quasi-reference electrode 
(CQRE). 
5.3.4 Preparation of assay components 
The 13G12 Ab was conjugated to the AgNPs using a previously 
published protocol180 that is also discussed in more detail in 
the Appendix (A3). Briefly, the 13G12 Ab was modified by 
bioconjugating it to a heterobifunctional cross-linker. The 
modified Ab was then added to 500 µL of AgNPs (4.9 × 1011 
AgNPs/mL) and incubated for 1 h, followed by back-filling with 
mPEG-SH for 20 min at 600 rpm at room temperature (RT, 22 ± 3 
°C). Excess conjugation reagents were then removed by 
centrifugation for 30 min at 16,600g at 4 °C. The formed 
conjugate was washed three times by centrifugation and then 
redispersed in 500 µL of SBB. Henceforth, this will be referred 
to as the AgNP−Ab conjugate.  
For the model assay, the biotinylated SAb was conjugated to 





manufacturer.184 Specifically, 100 µL of MµBs (∼7−10 × 109 
MµBs/mL) were aliquoted and washed. Washing was performed by 
magnetic separation wherein the MµBs were collected on the wall 
of the tube, the supernatant was removed, and the conjugate was 
redispersed in PBS. This was done three times within a SBB-
blocked microcentrifuge tube. Next, 40.0 µL of 6.67 µM SAb were 
added and the resulting solution was incubated for 30 min at 40 
rpm at RT using the tube revolver. Finally, the conjugated MµBs 
were washed by magnetic separation five times with 100 µL of 
PBS-BSA solution (1% w/v in PBS) and redispersed in a final 
volume of 100 µL of the PBS-BSA solution. The resulting product 
is referred to as MµB-SAb.  
In the case of the antigen-specific assay components, the 
15C4 capture Ab was biotinylated using a kit and the protocol 
provided by the manufacturer.194 After biotinylating the 15C4 
capture Ab, the modified Ab was then conjugated to the 
streptavidin-coated MµBs using the same procedure as described 
for the MµB-SAb, wherein 40.0 µL of the 6.67 µM biotinylated 
15C4 capture Ab were incubated with 100 µL of the streptavidin-
coated MµBs for 30 min at 40 rpm at RT on the tube revolver. 
After incubation, the conjugate was washed by magnetic 






5.3.5 Formation of the metalloimmunoassay 
Following preparation of the assay components, two different 
metalloimmunoassay were prepared: the model assay and the 
antigen-specific assay. The model assay was formed by 
bioconjugating MµB-SAb and AgNP-Ab through the attached Abs. 
Specifically, 16.0 µL of the as-prepared MµB-SAb were added to 
100 µL of AgNP-Ab having the desired concentration and then 
incubated for 1.0 h in the tube revolver at 30 rpm. The 
components were washed with the 0.1% (v/v) Tween-20 and PBS 
solution five times using magnetic separation, and then they 
were redispersed in 16.0 µL of PBS. This conjugate will be 
referred to henceforth as the MµB-AgNP model composite. 
 A step-wise conjugation approach was used for the antigen-
specific assay. More specifically, this assay was formed in a 
SBB-blocked microcentrifuge tube as follows. First, 16.0 µL of 
the MµB−15C4 conjugate was placed in a tube along with 100 µL of 
a known concentration of NT-proBNP in undiluted normal serum (or 
PBS). These components were incubated for 30 min at 30 rpm at 
RT. Next, the partially formed assay was washed three times by 
magnetic separation with 0.1% (v/v) Tween-20 and PBS solution to 
remove unbound peptide. Finally, 100 µL of the AgNP−Ab conjugate 
were added. This mixture was incubated for 30 min at 30 rpm and 





antigen-specific assay was resuspended in a final volume of 16.0 
µL of PBS. 
 For analysis, both the model and the antigen-specific 
assays were prepared in a similar way in that 2.0 µL aliquots of 
the desired assay were combined with 48 µL of PBS in a tube to 
yield a final sample volume of 50.0 µL. These diluted samples 
were then transferred to the paper-based electrode, the fully 
formed assays were focused onto the WE (∼30.0 s) by the magnet, 
and the electrochemical procedure was performed as discussed 
earlier.  
5.3.6 Assay washing procedures 
Two washing procedures were used: (1) washing of the MµB-AgNP 
model composite; and (2) washing following dispersion of the 
formed MµB-AgNP model composite in different percentages of 
serum prior to electrochemical detection. The latter washing 
protocol is described next.  
After formation of the MµB-AgNP model composite, initial 
electrochemical measurements were performed by dispersing 2.0 µL 
of the MµB-AgNP composite into 48.0 µL of the diluted serum 
matrix to yield a final sample volume of 50.0 µL, and a final 
AgNP concentration of 100 pM. The percentages of serum were 
100.0%, 50.0%, 20.0%, 10.0%, 5.0%, 2.0%, 1.0%, 0.50% and 0.25%, 





50.0 µL of these solutions were transferred onto the paper-
electrode, and then the GE/ASV detection process was carried 
out. The first GE/ASV assay was carried out directly on these 
samples with no washing steps. 
Following the foregoing initial electrochemical detection 
experiments, identical experiments were undertaken after 
washing. For the first washing step, the MµB-AgNP model 
composites were separated from the serum samples identified in 
the previous paragraph using a magnet. Next, they were 
redispersed in 50.0 µL of PBS, and then the electrochemical 
assay was carried out using this solution. The second and third 
washing steps were performed the exact same way.  
5.3.7 Ag+ electrodeposition 
To better understand the impact of serum on the GE/ASV detection 
process, we examined the Ag+ electrodeposition step in the 
presence of serum or filtered serum. The filtered serum was 
prepared by centrifuging 500.0 µL of serum for 10 min at 10,000 
g using a 10 kDa molecular weight cut-off spin filter. The 
filtrate was collected and used without further treatment.  
The three test solutions used in this experiment contained 
the following components: (1) 1.0 mM AgNO3 + 0.10 M KNO3 in DI 
water, (2) 1.0 mM AgNO3 + 0.10 M KNO3 in 20.0% serum diluted with 





serum diluted with DI water. The Ag+ electrodeposition 
experiments were carried out as follows. First, 50.0 µL of the 
desired test solution was placed on the WE. Second, the WE 
potential was stepped from 0 V to -0.70 V (vs. CQRE) for 50 s to 
reduce Ag+ onto the electrode surface. Third, the 
electrodeposited Ag0 was anodically stripped from the electrode 
surface for two times by scanning the potential from -0.70 V to 
0.20 V at a scan rate of 50 mV/s. The ASV data obtained from the 
second scan was collected and used for quantification. 
5.3.8 GE in bulk solution 
GE of AgNPs by HAuCl4 in bulk solution (no electrode) was studied 
by UV-vis spectroscopy. Before performing these experiments, the 
AgNPs were capped with mPEG-SH (hereafter referred to as Ag-
mPEG) to yield AgNPs similar to those in the MµB-AgNP composite. 
The experiments were carried out by combining DI water, Ag-mPEG, 
HAuCl4, and either serum, or filtered serum in a 1.5 mL 
microcentrifuge tube. The resulting solution were then mixed 
using a vortexer for ~30 s. The total volume for the solutions 
was 100.0 µL. The specific reagent usages for each experiment 
















DI Water Notes 
50.0 µL - - 50.0 µL 
Control pair in 
DI water 50.0 µL - 3.0 µL 47.0 µL 
50.0 µL 20.0 µL - 30.0 µL 
Pair in 20.0% 
serum 50.0 µL 20.0 µL 3.0 µL 27.0 µL 
50.0 µL 20.0 µL FS - 30.0 µL 
Pair in 20.0% 
FS  50.0 µL 20.0 µL FS  3.0 µL 27.0 µL 
50.0 µL 10.0 µL - 40.0 µL 
Pair in 10.0% 
serum 50.0 µL 10.0 µL 3.0 µL 37.0 µL 
50.0 µL 5.0 µL - 45.0 µL 
Pair in 5.0% 
serum 50.0 µL 5.0 µL 3.0 µL 42.0 µL 
50.0 µL 20.0 µL(10% S) - 30.0 µL 
Pair in 2.0% 
serum 50.0 µL 20.0 µL(10% S) 3.0 µL 27.0 µL 
50.0 µL 10.0 µL(10% S) - 40.0 µL 
Pair in 1.0% 
serum 50.0 µL 10.0 µL(10% S) 3.0 µL 37.0 µL 
50.0 µL 5.0 µL(10% S) - 45.0 µL 
Pair in 0.50% 
serum 50.0 µL 5.0 µL(10% S) 3.0 µL 42.0 µL 
50.0 µL 2.5 µL(10% S) - 47.5 µL 
Pair in 0.25% 
serum 50.0 µL 2.5 µL(10% S) 3.0 µL 44.5 µL 
Table 5.1 Reagents used for GE in different percentages of serum 










A series of experiments were performed in which the percentage 
of serum or filtered serum was varied in the presence of a 
constant charge equivalent ratio of HAuCl4 to Ag (because we do 
not necessarily know the speciation of oxidized Au in solution, 
we hereafter refer to all forms of oxidized Au as Au3+). In all 
cases, the extent of GE was determined by transferring a portion 
of each sample to a 50.0 µL cuvette having a 1.00 cm pathlength, 
and then analyzing the solutions by UV-vis spectroscopy. 
5.4 Results and Discussion 
5.4.1 Effect of serum on assay formation 
A key step in biosensing is the formation of the assay, or, in 
other words, capture of the target molecule. Depending on the 
complexity of the matrix and the specificity of the capture 
molecules, this step can be challenging. Here, two different 
assays, the MµB-AgNP model composite and the antigen-specific 
assay for NT-proBNP, were prepared in different matrixes and 
then they were analyzed electrochemically.  Each of the assays 
was formed in either PBS or serum. In all cases, the MµB-AgNP 
model composite contained 200 pM of AgNPs. The antigen-specific 
assay was prepared using a step-wise approach with 2.0 nM of NT-





three times as described in the Experimental Section, 
transferred to the paper electrode, and analyzed by GE/ASV. 
 
Figure 5.1 Histograms representing the Ag charge obtained when 
the (a) MµB-AgNP model composite (prepared using 200 pM AgNP) 
and (b) the antigen-specific assay for NT-proBNP (prepared using 
2.0 nM NT-proBNP) were formed in either PBS or serum. Following 
assay formation, the samples were both washed and aliquoted, as 
described in the Experimental section of this chapter, and 
transferred to the paper-electrode for analysis in 50.0 µL of 
PBS. The error bars represent the standard deviation from the 
mean for five independent measurements. 
 
 Figure 5.1a is a histogram showing the results of the 
foregoing experiment for the MµB-AgNP model composite. The 
results clearly indicate that, within experimental error, the 
total charge collected for the MµB-AgNP model composite is 
independent of whether the assay is formed in serum or PBS. An 
identical conclusion obtains for the antigen-specific assay 
(Figure 5.1b). We conclude that that the matrix in which the 





detection method. To be clear, however, while the assays were 
formed in either serum or PBS, the actual electrochemical 
detection was carried out in aqueous PBS following washing of 
the assays with the 0.1% (v/v) Tween-20 and PBS. 
5.4.2 Effect of serum on electrochemical detection 
After confirming that the serum matrix has no detectable impact 
on the formation of the two metalloimmunoassays, the impact of 
serum on electrochemical detection was studied. In this 
experiment the MµB-AgNP model composite was prepared in PBS and 
then exposed to different percentages of diluted serum for >1 
min. In all cases, the concentration of AgNPs was 100 pM. The 
preformed assays were then washed up to three times with PBS 
prior to analysis, and the resulting charge was determined using 










Figure 5.2 Histograms representing the amount of Ag charge 
collected from the preformed MµB-AgNP model composite after it 
was exposed to various percentages of serum for >1 min and 
washed 0-3 times via magnetic separation. After washing, the 
samples were transferred to the paper electrode and the GE/ASV 
detection protocol was carried out using 50.0 µL of PBS. The 
error bars represent the standard deviation from the mean for 
three independent measurements.  
 
Figure 5.2 presents histograms showing the total charge 
recovered from the analysis of the MµB-AgNP model composite as a 
function of the number of washing steps and the percentage of 
serum. The black histograms correspond to the charge detected 
from the as-prepared model composite (no washing steps after 
exposure to the indicated percentages of serum). At serum 
percentages >5.0%, no Ag charge is detected, but for lower 
percentages there is a gradual increase. For the smallest 
percentage of serum, 0.25%, a limiting charge of 10.6 ± 1.2 µC 





the protocol, the presence of even 0.50% serum renders the assay 
inaccurate. 
The remaining histograms represent the charge recovered 
after the MµB-AgNP model composite was washed once, twice, or 
three times with PBS to remove residual serum prior to the 
electrochemical analysis. Specifically, after exposure to serum, 
50.0 µL of the MµB-AgNP model composite was washed using 
magnetic separation and then redispersed in 50.0 µL PBS before 
electrochemical detection. The trends in Figure 5.2 are quite 
clear: lower percentages of serum require less washing steps to 
achieve limiting charge detection, and more washing steps result 
in detection of higher charge.  In fact, three washing steps 
result in limiting charge detection even after the model 
composite is exposed to 100% serum. This same experiment was 
performed with two other washing buffers (1× PBS + 1.0% Tween-20 
and HEPES), and in both cases the charge collected was lower 






Figure 5.3 (a) Histograms representing the amount of Ag charge 
collected from the preformed MµB-AgNP model composite after it 
was exposed to 100% serum for >1 min and washed by magnetic 
separation 0-3 times using either 1× PBS, 1× PBS + 1.0% Tween-
20, or 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
(HEPES) buffer. After washing, the samples were transferred to 
the paper electrode and the GE/ASV detection protocol was 
carried out using 50.0 µL of 1× PBS. (b) Histograms representing 
the amount of Ag charge collected when the preformed MµB-AgNP 
model composite was not exposed to serum.  In this case the 
GE/ASV detection protocol was carried out in 50.0 µL of either 
1× PBS, 1× PBS + 1.0% Tween-20, or HEPES. The results indicate 
that Tween-20 significantly suppresses electrochemical 
detection.  The error bars for all data represent the standard 
deviation from the mean for three independent measurements. 
 
On the basis of the foregoing results, we conclude that 
even after exposure to relatively small amounts of serum, 
limiting charge detection cannot be obtained in the absence of 
washing. The question then remains: what exactly is the effect 
of serum on the GE/ASV electrochemical detection method and, by 







5.4.3 Effect of serum on Ag+ electrodeposition 
Inhibition of electron and mass transfer by biofilms is a common 
problem in biosensing applications,195,196 although there are some 
notable exceptions.197–200 Accordingly, we evaluated the effect of 
serum on the GE/ASV detection method by isolating the 
electrodeposition step. This was achieved by eliminating the 
analyte and AgNPs from the assay and simply carrying out Ag+ 
electrodeposition in solutions containing serum. Specifically, 
electrodeposition was performed in bulk solutions containing 1.0 
mM of AgNO3, 0.10 M KNO3, and different percentages of serum. The 
electrochemistry itself was carried out by stepping the WE 
potential from 0 V to -0.70 V for 50 s, and then the potential 
was swept twice from -0.70 V to 0.20 V. The second ASV was 







Figure 5.4 Effect of serum on Ag+ electrodeposition. (a) ASVs 
obtained following electrodeposition of Ag+ from 50.0 µL 
solutions (DI water, 20.0% serum, or 20.0% filtered serum) 
containing 1.0 mM AgNO3 and 0.10 M KNO3. Electrodeposition was 
carried out for 50 s at -0.70 V (vs. CQRE) on the paper-
electrode platform. The ASV scan rate was 50 mV/s.(b) Histograms 
representing the amount of Ag charge obtained by integrating the 
traces in (a). The error bars represent the standard deviation 







Figure 5.4a shows three representative ASV traces collected 
using DI water, 20.0% serum, and 20.0% filtered serum. Filtering 
removes components of the serum having molecular weights larger 
than about 10 kDa, principally, human serum albumin, globulin, 
and other large biomolecules. The obvious immediate observation 
is that even the presence of 20.0% serum dramatically reduces 
the ASV charge. This conclusion is reinforced by the histograms 
shown in Figure 5.4b, which indicate a 20-fold decrease in 
charge for the serum solution.  As an aside, it seems counter 
intuitive that filtered serum would have a more dramatic effect 
on ASV than the serum (Figure 5.4b), and except for pointing out 
that this observation is reproducible we are unable to offer an 
explanation for this finding.  
We propose that the underlying reason for the dramatic 
effect of serum on Ag+ electrodeposition may relate to either of 
the following two factors. First, it has previously been 
reported that Ag+ is chelated by albumin which is present in 
serum.201 Chelation shifts the redox potential of ions to more 
negative potentials in proportion to the strength of 
binding.65,187 A second possible effect of serum on 
electrodeposition relates to electrode passivation by 
biomolecules.  Passivation can hinder electron transfer, mass 







Figure 5.5 Effect of serum on mass transfer and electron 
transfer. (a) Representative cyclic voltammograms (CVs) collected 
with 1.0 mM K3Fe(CN)6 in only PBS (black trace) and in PBS plus 
20.0% serum (red trace). (b) Representative CVs collected with 
1.0 mM ferrocenedimethanol (Fc(MeOH)2) in only PBS (black trace) 
and in PBS plus 20.0% serum (red trace). The working electrode 
was glassy carbon, the reference electrode was Ag/AgCl (sat’d 
NaCl), and the counter electrode was a Pt wire. The scan rate 
was 50 mV/s. In (a), a pair of redox peaks for Fe(CN)63-/4- were 
observed in PBS, but this pair of redox peaks was suppressed in 
the presence of 20.0% serum. Because Fe(CN)63-/4- undergoes an 
inner-sphere electron-transfer reaction, the redox molecule must 
make contact with the electrode surface.  Accordingly, the 
absence of redox peaks in the presence of serum shows that serum 
inhibits mass transfer to the electrode surface.35,36 In (b), a 
pair of redox peaks for Fc(MeOH)2 is observed in PBS with or 
without 20.0% serum. Because the redox of Fc(MeOH)2 is an outer-
sphere electron-transfer reaction, which does not require direct 
contact with the electrode, the existence of the redox peaks in 
serum suggests that serum does not present a barrier to mass 










5.4.4 Impact of serum on GE in bulk solution 
Apart from the Ag+ electrodeposition step, the other important 
reaction in the GE/ASV detection process is GE. Therefore, in 
this section we examine the impact of serum on GE.  
As shown in Illustration 5.1a, detection in the 
electrochemical assay is initiated by first generating Au3+ by 
electrooxidation of metallic Au pre-deposited on the paper 
electrode. Because this step is necessary for GE, we 
investigated it in the presence of serum first. As shown in 
Figure 5.6, the result is that there is no statistically 
significant difference in the charge recorded for Au oxidation 
when using PBS or PBS plus 20.0% serum. Accordingly, we conclude 











Figure 5.6 Effect of serum on the electrooxidation of Au. These 
experiments were carried out by stepping the potential from 0 to 
0.80 V vs. CQRE for 12 s using the type of paper-based, carbon 
paste (CP) working electrode described in this chapter.  For the 
data represented in the red and green traces and histograms, Au 
was electrodeposited onto the CP electrode prior to analysis. 
(a) Representative chronoamperometric curves and (b) the 
corresponding integrated charges. The integrated charges derived 
from the chronoamperometric curves are 73±9 and 61±8 µC measured 
in PBS only and PBS with 20.0% serum, respectively. This 
suggests that the presence of serum has no significant impact on 
Au electrooxidation. The error bars represent the standard 






After determining that the Au3+ electrogeneration step is 
unhindered by serum, the GE reaction between Au3+ and Ag-mPEG was 
analyzed in bulk solution (Illustration 5.1a). Ag-mPEG was used 
as the model AgNP label because of its similarity to the Ag 
labels in the MµB-AgNP model composite. Recall, that in this 
composite the Ab-modified AgNPs are back-filled with mPEG-SH to 
improve NP stability. Accordingly, the only difference between 
Ag-mPEG and the AgNP-Ab bioconjugate is the presence of the MµBs 
and the Abs present in the latter.  
The GE experiments were performed by combining DI water; 
Ag-mPEG; Au3+; and serum, or filtered serum in a microcentrifuge 
tube and vortexing for ~30 s. Following mixing, the solutions 
were analyzed by UV-vis spectroscopy. It should be noted that 
Au3+ was introduced into the system with increasing equivalents 
of charge. For example, one charge equivalent of Au3+ corresponds 






Figure 5.7 Representative UV-vis spectra of Ag-mPEG before 
(black trace) and after (red trace) the addition of about one 
charge equivalent of Au3+ relative to Ag in (a) DI water, (b) 
20.0% serum, and (c) 20.0% filtered serum. The peak at ~400 nm 






The black trace in Figure 5.7a is an absorbance spectrum of 
Ag-mPEG in DI water. It exhibits an SPR peak at ~400 nm arising 
from the AgNPs. When one charge equivalent of Au3+ is introduced 
into this solution, the red trace results after just 1 min. The 
loss of the SPR peak indicates that Ag-mPEG was converted to Ag+ 
via GE.  One might expect the presence of a new AuNP SPR peak in 
the red spectrum following GE, and in fact a peak at 535 nm does 
emerge after 4 h (Figure 5.8). 
 
Figure 5.8 Representative UV-vis spectra of Ag-mPEG (black 
traces) and upon the addition of one charge equivalent of Au3+ in 








When the foregoing experiment is carried out in a matrix 
containing 20.0% serum instead of DI water (Figure 5.7b), there 
is no change in the absorbance of the SPR peak following the 
addition of Au3+. This finding indicates that even 20.0% serum 
completely inhibits GE. The results of additional experiments in 
which the percentage of serum was varied are presented in Figure 








Figure 5.9 Representative UV-vis spectra of Ag-mPEG (black 
traces) and upon the addition of one charge equivalent of Au3+ 
(red traces) in solutions containing different percentages of 
serum. (a) 10.0%, (b) 5.0%, (c) 2.0%, (d) 1.0% and (e) 0.50% and 
(f) 0.25%.
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Interestingly, as shown in Figure 5.7c, when the serum 
was filtered through a 10 kDa molecular weight cut-off 
filter, the intensity of the peak decreased by 87% 
indicating that the extent of GE is only slightly affected 
in this case. This indicates that biomolecules having 
molecular weights >10 kDa are principally responsible for 
inhibition of GE. In addition to the decrease in the 
magnitude of the absorbance peak, the peak position shifts 
from ~400 nm to ~480 nm. This change suggests that the 
products of the GE may be different depending on whether 
the reaction is carried out in 20.0% filtered serum or DI 
water.202 
Taking into account the foregoing discussion, we 
conclude there are two possible explanations for the 
inhibition of GE by serum. First, biomolecules may adsorb 
to the surface of the Ag-mPEG NPs and prevent penetration 
by Au3+, thereby inhibiting GE by limiting mass transfer. 
The second possibility is that biomolecules present in 
serum chelate Au3+, which would shift its redox potential 
into a regime that hinders GE.65,187 At present we are unable 
to determine if one or both of these mechanisms is 
responsible for suppression of GE. 
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5.5 Summary and Conclusion 
To summarize, the goal of this study was to determine the 
effect of serum on electrochemical bioassays that use AgNPs 
as detection labels. Using a GE/ASV detection method 
previously developed in our group,66 we confirmed that both 
a model and an antigen-specific assay for NT-proBNP could 
be formed in undiluted serum with no detectable adverse 
effects from the matrix. In addition to assay formation, we 
also performed a systematic analysis of the washing steps. 
This part of the study revealed that there is a high degree 
of signal inhibition in the absence of washing if even 
0.50% of serum remains in solution.  
Inhibition of electron and mass transfer by biofilms 
is a common issue in biosensing applications, and therefore 
this study offers generally useful insights into how this 
problem affects electrochemical detection of NP labels. 
Accordingly, the results are likely to be valuable to many 
in the field of chemical sensing. The findings described 
here will be applied to the ongoing development of a 
biosensor for heart failure that is currently underway in 
our lab. The results of that work will be reported in due 
course. 
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Chapter 6: Dual-Shaped Silver Nanoparticle Labels 
for Electrochemical Detection of Bioassays 
6.1 Synopsis 
In this chapter we demonstrate the use of dual-shaped 
silver nanoparticles (AgNPs) as detection labels for 
electrochemical bioassays.  The key finding is that by 
using AgNP labels having two different shapes 
simultaneously, the limit of detection (LOD) for the assays 
is lowered compared to using either of the two shapes 
separately. The two shapes were silver nanocubes (AgNCs) 
having edge lengths of 40 ± 4 nm and spherical AgNPs 
(sAgNPs) having diameters of 20 ± 3 nm.  Two different 
bioassays were examined.  In both cases the Ag labels were 
functionalized with antibodies.  In the one assay, the 
labels are directly linked to a second antibody immobilized 
on magnetic beads.  In the second assay, the antibodies on 
the AgNP labels and the antibodies on the magnetic beads 
are linked via a peptide.  The peptide is N-terminal 
prohormone brain natriuretic peptide (NT-proBNP), which is 
a heart failure marker.  The efficacy of the two 
electrochemical assays as a function of the ratio of the 
two labels was investigated using a galvanic 
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exchange/anodic stripping voltammetry method. The key 
finding is that by optimizing the ratio of the two types of 
AgNP labels, it is possible to decrease the LOD of the 
assays without compromising the dynamic range compared to 
using either of the two labels independently.  This made it 
possible to achieve the clinically relevant range for NT-
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Here, we report on the simultaneous use of two different Ag 
nanoparticle (NP) shapes as detection labels for 
electrochemical bioassay signal amplification. The two 
shapes, cubes (AgNCs) and spheres (sAgNPs), are responsive 
to different concentration ranges of the assay.  
Accordingly, the novelty of this work is that by combining 
the two shapes into a single assay, the dynamic range is 
expanded compared to using either of the two shapes 
individually.  Specifically, both NPs were functionalized 
with a monoclonal antibody and tethered to a magnetic 
microbead (MµB) surface prior to electrochemical detection. 
Using a previously reported galvanic exchange and anodic 
stripping voltammetry (GE/ASV) detection method,127 the 
optimal ratio of these particles on the MµB surface was 
systematically investigated.  
 Compared to a single label, simultaneous use of both 
the sAgNP and AgNC labels leads to the following results. 
First, there is a three-fold decrease in the limit of 
detection (LOD) for a model immunoassay. Second, the total 
amount of Ag charge collected increases by 20%. Third, the 
LOD for a metalloimmunoassay for the heart failure 
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biomarker N-terminal prohormone brain natriuretic peptide 
(NT-proBNP) decreases by an order of magnitude.  This 
decrease results in the metalloimmunoassay overlapping with 
the clinically relevant concentration range and risk 
stratification threshold for NT-proBNP.159–162  This latter 
goal could not be achieved using either of the two AgNP 
shapes individually.191  
NPs differing in composition,203,204 size,205 shape,206 and 
surface modifications207–209 have been applied to a variety of 
assays and bioassays.191,59,210 Due to their robust 
characteristics, the optical,107,113,118,119 magnetic,211 and 
electrochemical57–59,191,207 properties of metal NPs have been 
utilized for immunological assays in the biosensor field in 
place of the more common enzymatic,55,171 fluorescent,13 and 
radioactive212 labels.213,214 Gold NPs are the most commonly 
used metallic labels for bioassays, primarily due to their 
stability and their desirable optical properties.215–218 While 
AgNPs also have useful optical properties, they are 
significantly less stable than AuNPs.66 This is a 
consequence, in part, of the fact that Ag has a much lower 
standard potential (E° = 0.79 V) than Au (E° = 1.52 V).65 
For many applications, this large difference in standard 
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potentials is a drawback, but as we have shown previously 
it can also be an advantage.59,66,127  
 
Illustration 6.1 Schematic of the galvanic exchange/anodic 
stripping voltammetry (GE/ASV) detection method involving 
(a-c) sAgNPs or (d-f) AgNCs. 
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Our group has previously combined GE with ASV to 
detect the heart failure marker NT-proBNP using sAgNPs.191,59  
Illustration 6.1a-c displays how sAgNP labels are detected 
in these studies.   As shown in Illustration 1a, metallic 
Au pre-deposited on the detection working electrode (WE) is 
first oxidized.  The resulting Au3+ (here representing all 
species of oxidized Au) diffuses to the sAgNPs and 
partially oxidizes them to Ag+ by GE. Next, as shown in 
Illustration 6.1b, the resulting Ag+ is electrodeposited 
onto the surface of the WE.  This can be thought of as a 
preconcentration step.  Finally, the surface-bound Ag is 
electrochemically oxidized by ASV.  The charge resulting 
from the ASV step corresponds to the detection signal. The 
GE step is essential in this approach because the distance 
between the sAgNP labels (which are linked to the ~1.0 µm-
diameter MµBs) and the WE, precludes direct oxidation of 
the sAgNPs.  A intrinsic drawback of the GE process is 
that, depending on their size, a Au shell may form around 
the sAgNPs thereby preventing complete oxidation 
(Illustration 6.1c).219,220  
In an effort to circumvent the foregoing partial sAgNP 
oxidation problem, and thereby lower the LOD for GE/ASV 
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assays, we recently introduced the idea of replacing sAgNPs 
with AgNC labels.221  AgNCs are known to form a more porous 
Au shell during GE with Au3+ (Illustration 6.1d-
f),79,82,90,222,223 and we reasoned that this would result in a 
higher ASV charge and thus a lower LOD for the NT-proBNP 
assay. Illustration 6.1c-f shows the general conclusions 
from these earlier reports as they relate to the present 
study.  Comparison of Illustration 6.1c and 6.1f 
demonstrates the key point: GE is prematurely terminated by 
formation of the Au shell in Illustration 6.1c, but the 
porous Au shell of the AgNCs (Illustration 6.1f) permits 
more complete GE.79,82,84,90,221,223 
In this chapter, a combination of AgNC and sAgNP 
labels were used to detect both a model assay and an 
antigen-specific assay for NT-proBNP. As alluded to 
earlier, previous results from our lab showed that sAgNP 
labels yield a broad dynamic range but an insufficient 
lower LOD for this assay.191,59  Conversely, AgNC labels 
result in a limited dynamic range but a superior LOD. 
Accordingly, we hypothesized that by combining the two 
types of NPs it would be possible to access the clinically 
relevant range for NT-proBNP detection.159–162 The key point 
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is that this hypothesis is proven correct by the results 
presented herein. 
6.3 Experimental 
6.3.l Chemicals and materials 
NaCl, NaOH, HCl, KNO3, NaIO4, ethylene glycol (EG), sodium 
citrate, Whatman grade 1 chromatography paper (180 µm 
thick, 20 cm x 20 cm sheets, linear flow rate of water = 
0.43 cm/min) and siliconized low-retention microcentrifuge 
tubes were purchased from Fisher Scientific (Pittsburgh, 
PA). HAuCl4, AgNO3, phosphate-buffered saline (PBS, pH=7.4, 
P3813), NaSH, CF3COOAg, superblock blocking buffer 
containing PBS (SBB) (cat. no. 37515), polyvinylpyrrolidone 
(PVP, MW~55,000 g/mol), and polyoxyethylene (20) sorbitan 
monolaurate (Tween-20) were purchased from Sigma Aldrich 
(St Louis, MO). The 5 kDa methoxy poly(ethyleneglycol) 
thiol(mPEG-SH) was obtained from Nanocs (New York, NY). 
 All solutions were made using deionized (DI) water 
(>18.0 MΩ-cm, Milli-Q Gradient System, Millipore, 
Burlington, MA). The PBS concentrations were 1X unless 
otherwise noted. Conductive carbon paste (Cl-2042) was 
purchased from Engineered Conductive Materials (Delaware, 
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OH). Streptavidin-coated, 1.0 µm-diameter magnetic beads 
(MµBs, Dynabeads, MyOne Streptavidin T1, 10 mg/mL) were 
obtained from Invitrogen (Grand Island, NY). Stock citrate-
capped sAgNPs (nominal 20 nm diameter, 0.18 mM Ag, 4.5×1011 
NP/mL) were purchased from nanoComposix (San Diego, CA). 
The biotinylated polyclonal anti-mouse immunoglobulin G 
secondary antibody (SAb) was obtained from Abcam 
(Cambridge, UK). N-terminal prohormone brain natriuretic 
peptide (NT-proBNP), monoclonal immunoglobulin G anti-NT-
proBNP 13G12 detection (Ab), and 15C4 capture Ab were 
obtained from HyTest (Turku, Finland).  
6.3.2 Electrochemistry 
Electrochemical measurements were performed using a CH 
Instruments model 760B electrochemical workstation (Austin, 
TX). The fabrication of paper electrodes and 
electrodeposition of Au onto the WE are provided in the 
Appendix (A1) and are based on methods described in a 
previous publication.127 A previously published 
electrochemical protocol was used to detect the AgNP 
labels.59,66,127,191 Briefly, to initiate GE, the potential of 
the WE was stepped from 0 to 0.80 V (all potentials are vs. 
a carbon quasi-reference electrode, CQRE) for 12.0 s to 
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oxidize Au0 to Au3+. Following GE, the potential was stepped 
from 0 to −0.70 V for 50 s to reduce Ag+ to Ag0 onto the 
electrode. These two steps were carried out twice, and then 
the potential was swept twice from −0.70 to 0.20 V at a 
scan rate of 50.0 mV/s to oxidize Ag. The charge resulting 
from the last ASV scan was obtained by integration and 
represents the output signal of the sensor. All 
electrochemical measurements were performed in 1X PBS 
unless stated otherwise. 
6.3.3 Preparation of the Ag-Ab conjugates 
The 13G12 Ab was conjugated to the sAgNPs and AgNCs using 
previously published protocols.180,221 Briefly, the 13G12 Ab 
was bioconjugated to a heterobifunctional cross-linker 
(HBCL). The modified Ab was then added to 500 µL of sAgNPs 
(4.9 × 1011 sAgNPs/mL) and incubated for 1 h, followed by 
back-filling the AgNP surface with mPEG-SH for 20 min at 
600 rpm at room temperature (RT, 22 ± 3 °C). Excess 
conjugation reagents were then removed by centrifugation 
for 30 min at 16,600g at 4°C. The formed bioconjugate was 
washed three times by centrifugation and then redispersed 
in 500 µL of SBB. Henceforth, this will be referred to as 
the sAgNP−Ab conjugate.  
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The procedure for synthesizing the AgNCs is provided 
in the Appendix (A5).221 The AgNC-Ab conjugates were 
prepared as follows.  First, the AgNCs were washed with a 
Tween-20 solution (0.01% w/v in water) by centrifugation at 
12,000g and then dispersed in a Tween-20 solution.  Second, 
500 μL of a AgNC solution (6.02 × 1010 particles/ mL) was 
added to 25.0 μL of 1.33 μM HBCL-modified Ab and incubated 
for 1 h in the dark. Third, excess reagents were removed by 
centrifugation for 25.0 min at 12,000g at 4°C, and then the 
conjugates were resuspended in 500 μL of the Tween-20 
solution.  
6.3.4 Preparation of the MµB-Ab conjugates 
For the model assay, the biotinylated SAb was conjugated to 
streptavidin-coated MµBs using the protocol provided by the 
manufacturer.184 Specifically, 100 µL of MµBs (∼7−10 × 109 
MµBs/mL) were aliquoted and washed. Washing was performed 
using magnetic separation wherein the MµBs were collected 
on the wall of a SBB-blocked microcentrifuge tube with a 
neodymium magnet, the supernatant was removed, and the 
conjugate was redispersed in PBS. This process was carried 
out three times. Next, 40.0 µL of 6.67 µM SAb were added to 
the tube and the resulting solution was incubated for 30 
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min at 40 rpm at RT using the tube revolver. Finally, the 
conjugated MµBs were washed using magnetic separation five 
times with 100 µL of SBB and then redispersed in a final 
volume of 100 µL of SBB. The resulting conjugate is 
referred to as MµB-SAb.  
For the NT-proBNP assay, the 15C4 capture Ab was 
biotinylated using a kit and the protocol provided by the 
manufacturer.194 Next, the modified Ab was conjugated to the 
streptavidin-coated MµBs using the same procedure as 
described for the MµB-SAb, wherein 40.0 µL of the 6.67 µM 
biotinylated 15C4 capture Ab were incubated with 100 µL of 
the streptavidin-coated MµBs for 1 h at 30 rpm at RT on the 
tube revolver. After incubation, the conjugate was washed 
by magnetic separation. The resulting product is referred 
to as the MµB-15C4 conjugate. 
6.3.5 Formation of the metalloimmunoassay 
Following preparation of the assay components, two 
different metalloimmunoassay were prepared: the model 
composite assay and the NT-proBNP assay. The model 
composite assay was formed by bioconjugating MµB-SAb and 
sAgNP-Ab (or the AgNC-Ab) by interaction of the two Abs. 
Specifically, 16.0 µL of the as-prepared MµB-SAb were added 
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to 100 µL of a mixture of sAgNP-Ab and AgNC-Ab having the 
desired ratio and then incubated for 30.0 min in the tube 
revolver at 30 rpm (Table 6.1). The product of the 
conjugation reaction was washed with 0.1% (v/v) Tween-20 
and PBS solution five times using magnetic separation, and 
then it was redispersed in 16.0 µL of PBS. These composites 
will be referred to henceforth as the MµB-sAgNP model 
composite when prepared with sAgNP-Ab, and the MµB-AgNC 










100:0 100.0 - 100.0 
0:100 - 100.0 100.0 
50:50 50.0 50.0 100.0 
70:30 70.0 30.0 100.0 
30:70 30.0 70.0 100.0 
80:20 80.0 20.0 100.0 
20:80 20.0 80.0 100.0 
90:10 90.0 10.0 100.0 
10:90 10.0 90.0 100.0 
*Initial buffer volume of MµBs (16.0 µL) was 
removed prior to sAgNP-Ab and AgNC-Ab 
additions, which left only the MµBs in the tube 
and an initial volume of zero. 
Table 6.1 Preparation of the different NP ratios used to 
form the metalloimmunoassay. 
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A step-wise conjugation approach was used for the NT-
proBNP assay. More specifically, this assay was formed in a 
SBB-blocked microcentrifuge tube as follows. First, 16.0 µL 
of the MµB−15C4 conjugate was placed in the tube along with 
100 µL of a desired concentration of NT-proBNP in SBB. 
These components were incubated for 30 min at 30 rpm at RT. 
Next, the partially formed assay was washed three times 
using magnetic separation with 0.1% (v/v) Tween-20 and PBS 
solution to remove unbound peptide. Finally, 100 µL of the 
desired ratio of the sAgNP-Ab and AgNC-Ab conjugates were 
added (Table 6.1). This mixture was incubated for 30 min at 
30 rpm and was then washed using magnetic separation. The 
fully formed NT-proBNP assay was resuspended in a final 
volume of 16.0 µL of PBS. 
 For analysis, both the model and the NT-proBNP assays 
were prepared in a similar way in that 2.0 µL aliquots of 
the desired assay were combined with 48 µL of PBS in a tube 
to yield a final sample volume of 50.0 µL. These diluted 
samples were then transferred to the paper-based electrode, 
the fully formed assays were focused onto the WE (∼30.0 s) 
by the magnet, and the electrochemical procedure was 
performed as discussed earlier. 
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6.4 Results and Discussion 
6.4.1 Electrochemical analysis of the sAgNP-Ab and AgNC-Ab 
conjugates  
 
The first step for comparing the efficacy of the sAgNP-Ab 
and AgNC-Ab conjugates was to determine a figure-of-merit 
that could remain constant for both of them. These two 
types of NPs are similar in that they are both composed of 
Ag and they both have HBCL-modified Abs bioconjugated to 
their surface. There are, however, some differences. 
Specifically, these NPs differ in size (20 vs. 40 nm 
diameter for sAgNP and AgNC, respectively), surface ligands 
(PEG vs. PVP for sAgNP and AgNC, respectively), and GE 
efficiency. Accordingly, the best figure-of-merit is the 
total Ag charge collected after the GE/ASV detection method 
is performed on the model composites. Briefly, the MµB-
sAgNP and MµB-AgNC model composites were prepared as 
described in the Experimental Section using different 
concentrations of just the sAgNP-Ab or just the AgNC-Ab 
conjugates. These formed composites were then transferred 
to the paper-electrode platform for electrochemical 
analysis. The goal for this first experiment was to 
determine a concentration of both composites that would 
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lead to the same amount of charge collected by GE/ASV. The 
results would then provide a context for comparing the 
labels in subsequent experiments. 
 
Figure 6.1 Histograms representing the amount of Ag charge 
obtained by forming the model composite assay with either 
sAgNP-Ab or AgNC-Ab conjugates (100 pM and 60.8 pM, 
respectively). These model composites were prepared using 
the MµB-SAb conjugate and either only the sAgNP-Ab 
conjugate, to make the “MµB-sAgNP” model composite, or only 
the AgNC-Ab conjugate, to make the “MµB-AgNC” model 
composite. Following assay formation, the samples were both 
washed and aliquoted, as described in the Experimental 
Section, and transferred to the paper electrode for 
analysis in 50.0 µL of PBS. The error bars represent the 





 Figure 6.1 is a histogram comparing the Ag charge 
obtained using 100 pM of just the MµB-sAgNP model composite 
or 60.8 pM of just the MµB-AgNC model composite.  The 
results indicate that at these concentrations there is no 
statistical difference in the charge collected using the 
two different model composites. Specifically, both model 
composites, which were prepared with Ag particles having 
different sizes, shapes, and surface ligands, resulted in a 
Ag charge of ~25.0 µC.  
6.4.2 Optimization of the NP ratio 
After establishing an appropriate context for comparing the 
sAgNP-Ab and AgNC-Ab conjugates (Figure 6.1), the model 
composite was systematically prepared using a mixture of 
the sAgNP-Ab and AgNC-Ab conjugates.  The different 
volumetric ratios of the two conjugates were prepared using 
a 100 pM solution of the MµB-sAgNP model composite and a 
60.8 pM solution of the MµB-AgNC model composite.  These 
solutions were prepared as described in the Experimental 
Section and in accordance with Table S1. The key point is 
that the concentrations of the two composites (100 pm or 
60.8 pm) used individually yield the same detection signal 
(Figure 6.1).  Henceforth, we refer to this as "Ag charge 
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equivalence".  Therefore, when the two labels are mixed in 
different ratios, it is possible to determine if a 
particular ratio leads to an optimal dynamic range and LOD 







Figure 6.2 Histograms representing the amount of Ag charge 
collected from the model composite when it was prepared 
using different volumetric ratios of 100 pM sAgNP-Ab and 
60.8 pM AgNC-Ab conjugates (Table 6.1).(a) NP ratios 
containing more sAgNPs than AgNCs (sAgNP:AgNC)and (b) NP 
ratios containing more AgNCs than sAgNPs (AgNC:sAgNP).(c) 
Same experiment as in (a), but the concentration of the 
model composite was diluted by 50%. The dashed line 
represents the expected Ag charge based on the result for 
the Ag charge equivalence in (a). The error bars represent 
the standard deviation from the mean for five independent 
measurements. 
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The histograms in Figure 6.2a correspond to the Ag 
charge collected when the model composite was formed with 
volume ratios that included more sAgNPs than AgNCs in the 
mixture. For example, for the 70:30 model composite, 70.0 
µL of the sAgNP-Ab conjugate and 30.0 µL of the AgNC-Ab 
conjugates were added to 16.0 µL of MµB-SAb (Table 6.1). 
This result, and the other ratios, are compared to the “Ag 
charge equivalence” (first histogram in Figure 6.2a). 
Recall, that the Ag charge equivalence is the Ag charge 
resulting from the model composite yielding the same Ag 
charge but comprising only sAgNPs or only AgNCs (Figure 
6.1). The results in Figure 6.2a show that the 90:10 NP 
ratio generated a Ag charge which was ~20% higher than when 
the model composite is formed with only the sAgNPs or only 
the AgNCs.  
The histograms in Figure 6.2b were obtained exactly as 
discussed for Figure 6.2a, except for NP ratios that 
included more AgNCs than sAgNPs. The results indicate that 
when there are more AgNCs than sAgNPs present in the 
labeling mixture, the Ag charge collected after the GE/ASV 
detection method is significantly lower than the Ag charge 
equivalence results. The results in Figure 6.2b indicate 
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that NP ratios that include more AgNCs than sAgNPs are not 
optimal for sensing applications.  
Up to this point, a relatively high concentration of 
the sAgNPs-Ab and AgNC-Ab conjugates (various percentages 
having concentrations of 100 pM and 60.8 pM, respectively) 
was used to form the model composite. The next step in the 
optimization process was to reduce the NP concentration by 
50% (Figure 6.2c) to ensure that the same trends are 
observed over a range of concentrations (as would be 
encountered in a bioassay). An additional 98:2 ratio was 
also included in this part of the study. The dotted line in 
Figure 6.2c represents the expected Ag charge if the 
initial Ag concentration was diluted by 50%. For example, 
the benchmark value used in this experiment was the Ag 
charge equivalence, which resulted in ~25.0 µC of charge 
(Figure 6.1), therefore the expected Ag charge when the 
concentration is reduced by 50% is ~12.5 µC. The data in 
Figure 6.2c show that even when the concentration is 
reduced, the 90:10 sAgNP:AgNC ratio still results in a 20% 
increase in the expected Ag charge. On the basis of these 
results, the 90:10, sAgNP:AgNC ratio was used for the 
remaining experiments. 
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6.4.3 Calibration curve for the 90:10 sAgNP:AgNC model 
composite 
 
After confirming that the 90:10, sAgNP:AgNC ratio is 
optimal for one concentration of Ag, this same ratio was 
applied to a series of different Ag concentrations. 
Accordingly, the model composite was prepared as described 
in the Experimental Section using a 90:10 volumetric ratio 
of the sAgNP-Ab and AgNC-Ab conjugates at total Ag NP 
concentrations ranging from 2.07 to 100 pM. The formed 
model composites were then washed using magnetic separation 








Figure 6.3 Electrochemical results for detection of the 
model composite formed using the 90:10 sAgNP:AgNC 
volumetric ratio and the GE/ASV detection protocol. (a) 
Representative ASVs for the total concentration of AgNPs 
(sAgNPs + AgNCs) indicated in the legend. For clarity, 
representative ASVs for only half of the concentrations 
used to construct the calibration curve in (b) are shown.  
The other half are provided in Figure 6.4. The position of 
the ASV peaks varies somewhat because the references 
electrode is a CQRE. (b) Calibration curve showing the 
correlation between the Ag charge (obtained by integrating 
ASVs like those in (a)) and the total AgNP concentrations 
(sAgNPs + AgNCs). This plot contains data shown in (a) and 
in Figure 6.4. The LOD, 2.07 pM, was calculated using the 
standard deviation of the linear regression line and the 
slope of the calibration curve. The linear regression value 
is 0.99 and the scan rate was 50 mV/s. Each data point 
represents the average of five measurements carried out 
using independently fabricated electrodes. The error bars 
represent the standard deviation of these five 
measurements. Outliers were eliminated using the Grubb’s 





Figure 6.3 shows the results of this experiment. 
Specifically, the representative voltammograms in Figure 
6.3a indicate that the Ag oxidation current increases as a 
function of the total concentration of AgNPs used to form 
the model composite assay. The inset includes an expanded 
view of the voltammogram for the blank (black trace).  This 
solution contained AgNPs that were not bioconjugated to 
Abs, and it demonstrates that the assay has an intrinsic 
zero background.  The inset also shows data for the lowest 






Figure 6.4 Representative ASVs for the total concentration 
of AgNPs (sAgNPs + AgNCs) indicated in the legend.  ASVs 
for these concentrations were omitted from Figure 6.3a of 
this chapter for clarity.  These data are for the 90:10 
sAgNP:AgNC ratio. The position of the ASV peaks varies 
somewhat because the references electrode is a CQRE. The 








Figure 6.5 Calibration curve for the model composite formed 
using only the sAgNP-Ab conjugate. Specifically, this model 
composite was prepared by adding 100.0 µL of different Ag 
concentrations of the sAgNP-Ab conjugate to 16.0 µL of the 
MµB-SAb conjugate. The prepared model composite was washed 
using magnetic separation, and 50 µL were transferred to 
the paper-electrode for electrochemical analysis. (a) ASVs 
for the concentrations of sAgNPs indicated in the legend. 
For clarity, only one ASV trace is shown for each 
concentration. The position of the ASV peaks varies 
slightly because of the use of a CQRE. (b) Calibration 
curve showing the correlation between the Ag charge 
(obtained by integrating ASVs like those in (a)) and the 
sAgNP concentration. The linear regression value is 0.98 
and the scan rate was 50 mV/s. Each data point represents 
the average of five measurements carried out using 
independently fabricated electrodes. The error bars 
represent the standard deviation of these five 
measurements. Outliers were eliminated using the Grubb’s 
test with a 95% confidence level. These results show a 
linear dynamic range of 6.6-322 pM. This assay has an LOD 
that is three-fold higher than when the model composite 
assay is prepared using an optimized mixture of sAgNP-Ab 






The charges under voltammograms like those shown in 
Figure 6.3a, plus voltammograms obtained at other 
concentrations (Figure 6.4) were obtained by integration, 
and the results for five independent experiments per 
concentration are plotted in Figure 6.3b. These data 
demonstrate that the charge increases linearly from 2.07 to 
100.0 pM of total AgNPs (sAgNPs + AgNCs) and then begins to 
saturate. Note that concentrations below 2.07 pM could not 
be differentiated from the blank and thus are not shown in 
Figure 6.3. Nevertheless, the LOD of 2.07 pM represents a 
threefold decrease compared to the same assay carried out 
using only sAgNPs (Figure 6.5).  Another important aspect 
of Figure 6.3b is that the relative standard deviation of 
the combined dataset is <11%.  
6.4.4 Dose-response curve for the NT-proBNP 
metalloimmunoassay  
 
The ultimate goal in this dual-shaped AgNP investigation is 
to ensure that the results leading up to this point can be 
translated to the NT-proBNP metalloimmunoassay, which is 
the main focus of our sensor-related research. Accordingly, 
the NT-proBNP bioassay was prepared in SBB using the step-
wise procedure described in the Experimental Section. 
Specifically, 16.0 µL of the MµB-15C4 conjugate were added 
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to a SBB blocked microcentrifuge tubes, and then 100 µL of 
different concentrations of NT-proBNP were added. Following 
incubation and washing, an excess of the 90:10, sAgNP:AgNC 
conjugate ratio was added to the tubes. The fully formed 
assay was then transferred to the paper-electrode, and the 
electrochemical detection protocol was carried out in PBS. 
 
 
Figure 6.6 Electrochemical results obtained for detection 
of NT-proBNP using the 90:10 sAgNP:AgNC volumetric ratio 
and the GE/ASV detection protocol. (a) Anodic stripping 
voltammograms (ASVs) were obtained by aliquoting 2.0 µL of 
the formed assay, diluting it with 48.0 µL of PBS, and then 
carrying out the GE/ASV protocol described in the text. The 
concentrations listed in the legend represent the 
concentrations of NT-proBNP used to form the 
metalloimmunoassay. The scan rate was 50 mV/s. (b) 
Calibration curve showing the correlation between the Ag 
charge (obtained by integrating ASVs like those in (a)) and 
the concentration of NT-proBNP used to form the immuno-
sandwich. Additionally, for clarity, the ASV for 5.82 nM of 
NT-proBNP is not shown in Figure 6.6a. The error bars 
represent the standard deviation obtained using five 
independent measurements. Outliers were eliminated using 
the Grubb’s test with a 95% confidence level. 
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Representative ASV curves for this experiment are 
shown in Figure 6.6. The voltammograms in Figure 6.6a 
indicate that the Ag stripping current increases as a 
function of the concentration of the NT-proBNP used to form 
the assay. Note, however, that concentrations below 0.06 nM 
could not be differentiated from the background. The 
charges under voltammograms like those shown in Figure 6.6a 
were obtained by integration, and the results for five 
independent experiments per concentration are plotted in 
Figure 6.6b. These data show that the linear dynamic range 
for this assay is 0.06-3.49 nM of NT-proBNP, and then the 
calibration curve begins to saturate at 5.82 nM. The 
average relative standard deviation for the points on the 
linear part of the calibration curve is <21%. 
Earlier we stated that the lowest LOD we have been 
able to achieve for the NT-proBNP metalloimmunoassay formed 
using only the sAgNP-Ab conjugate was about five-fold 
higher than the clinically relevant minimum value.  
Specifically, the lowest LOD heretofore achieved was 0.58 
nM,191 but the minimum clinical concentration used by 
physicians to identify heart failure patients who are at 
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risk of poor outcomes is 0.116 nM.159–162 Using the dual-
shaped AgNP conjugates, the risk stratification threshold 
for this bioassay is 0.06 nM, well below the target of 
0.116 nM. We attribute this lower LOD to the incorporation 
of the AgNC-Ab conjugates to the Ag detection labels used 
in this bioassay. Recall that according to previously 
published literature, the AgNCs perform more efficiently 
during the GE process than the sAgNPs because the Au shell 
formed around the AgNCs is more porous, and therefore more 
exchange can occur.79,82,84,90,221,223 
6.5 Summary and Conclusion 
The overall goal of the present chapter was to develop an 
assay for the heart failure biomarker NT-proBNP that could 
perform within the clinically relevant concentration range. 
This range includes the risk stratification threshold used 
by physicians to determine next steps in the care of a 
patient. We have previously reported on this specific assay 
in which only sAgNPs were used as detection labels.191 The 
use of only the sAgNP labels resulted in an LOD which was 
still five-fold higher than the clinically relevant minimum 
concentration of NT-proBNP. In an effort to reduce the LOD 
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of the assay, AgNCs were introduced as an additional 
detection label.  This decision was made because prior 
literature indicated that AgNCs experience more efficient 
GE with Au3+ than sAgNPs.79,82,84,90,221,223 Specifically, instead 
of a Au shell forming around the exterior of the NPs, as 
occurs for sAgNPs,219,220 a porous Au layer forms. The porous 
Au layer results in more exchange during the GE 
process.79,82,84,90,221,223    
 The optimal volumetric ratio of the two labels was 
found to be 90:10 sAgNP:AgNCs.  Using both types of lables 
simultaneously, we achieved a threefold decrease in the LOD 
for the model metalloimmunoassay. We attribute this result 
to the presence of the of the AgNCs, which undergo more 
efficient GE than the sAgNPs. The findings for the model 
assay translated well to the antigen-specific assay for NT-
proBNP. In particular, the LOD for the metalloimmunoassay 
for NT-proBNP decreased by an order of magnitude, but the 
high end of the dynamic range was not affected by the 
presence of the AgNCs.191 Accordingly, the NT-proBNP assay 
overlaps with the clinically relevant concentration range 
and risk stratification threshold for NT-proBNP in 
buffer.159–162 The next steps for this NT-proBNP assay include 
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transitioning it into a serum matrix with the dual-shaped 
AgNP detection labels.  The results of this work will be 
reported in due course. 
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Chapter 7: Summary and Conclusion 
 In this dissertation, the evolution of an 
electrochemical POC device for the detection of the heart 
failure biomarker, NT-proBNP was presented and discussed. 
Much like any biosensor, sensitivity and signal 
amplification were a few of the most important aspects that 
went into the design of this bioassay. Several other 
components came into play during the development process as 
well. Specifically, the sample matrix, the size of the 
biomarker of interest, the critical concentration range 
needed to determine the next steps in patient care, the 
frequency of use, and who the target consumer was.  
 All in all, the initial designs and fundamental 
research that starts at a laboratory bench must encompass 
all the above criteria, almost simultaneously. The 
fundamental mechanism of the detection method needs to be 
understood to the best of our ability, such as the 
investigation of the GE/ASV detection method described in 
Chapter 2. To facilitate a high-level of sensitivity and 
selectivity of the system, bioconjugation methods need to 
be optimal, such as the method described in Chapter 3. This 
optimization can also ensure that reagents are not being 
 208 
wasted or used in extreme excess. This is largely because 
reagent waste can potentially increase the overall cost of 
the POC device, which would essentially negate one of the 
primary characteristics of the POC: low-cost. 
 Making the leap from one matrix to another is a 
critical component during development. In this case, 
transitioning the fully formed metalloimmunoassay from a 
simple buffer system to a more complex serum system, much 
like the processes discussed in Chapters 4 and 5. 
Additionally, piggybacking on that work to push the LOD of 
the sensor as close as possible to the risk stratification 
threshold, by simply changing the shape of the detection 
label to enhance signal amplification, such as the work 
described in Chapter 6.  
We have made several significant and recent 
advancements with this biosensor, however there is much 
more work to be done. In general, transitioning all the 
off-chip manipulation steps to on-chip processes which 
could occur within a lateral flow or microfluidic setup. I 
am hopeful that this POC biosensor can eventually bring 
better patient care and peace of mind to individuals 
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currently struggling to maintain control of their own 




A1. Electrode fabrication 
A slight modification of a previously published procedure 
was used to fabricate the electrodes.127 Specifically, they 
were fabricated by stencil-printing carbon paste onto wax-
patterned sheets of chromatography paper that had been 
printed using a Xerox ColorQube 8570DN printer. Following 
printing, the wax was melted through the thickness of the 
paper by placing it in an oven at 120 °C for 25.0 s. 
Photopaper was glued to the back of the wax-printed 
chromatography paper to improve rigidity, and then it was 
cut into 12 rectangles (2.0 cm × 5.0 cm, each). A stencil 
for defining the 3.0 mm-diameter disk-shaped working 
electrode, hook-shaped carbon quasi-reference electrode, 
and counter electrode was created using CorelDRAW (Ottawa, 
ON). The stencil was cut into a thin plastic sheet of 
transparency film using an Epilog laser engraving system 
(Zing 16). Finally, the stencil was placed over the paper 
(wax side up), the electrodes were printed through the 
stencil using the conductive carbon paste, and then they 
were left to dry in air for 14 h. 
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 The working electrode was further modified by 
electrodepositing Au onto the carbon paste. This step was 
performed on-chip and was carried out by placing a 50.0 µL 
droplet of a solution consisting of 6.0 mM Au3+ and 0.10 M 
KNO3 onto the electrode region of the sensor. Because the 
region of the sensor incorporating the electrodes is 
hydrophilic relative to the rest of the paper assembly, the 
deposition solution was confined to just the electrode 
region, and hence, no additional electrochemical cell was 
required. Next, the potential of the working electrode was 
stepped from 0 to −0.60 V (unless otherwise stated, all 
potentials are vs a carbon quasi-reference electrode, CQRE) 
for 2.0 s.127 This process results in islands of Au (not a 
conformal coating) on the surface of the carbon.127 The 
electrode was then rinsed twice with DI water and dried 
with a Kimwipe. 
 
A2. The physisorption of Abs to NPs 
Using a microcentrifuge tube blocked with Superblock 
blocking buffer (SBB), 500 µL of nanoparticle (NP) stock 
solution (4.9 x 1011 AgNPs/mL or 7.4 x 1011 AuNPs/mL) were 
added to 5 µL of 6.7 µM Ab. The mixture was incubated for 
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30 min at RT and 1400 rpm. Unbound Abs were removed with 
one centrifugation step (25 min, 4 ˚C, 16,600 g,), after 
which the supernatant was removed to leave behind only 5.0 
µL of the initial solution (so as not to disturb the 
pellet).  The NP pellet was then resuspended into a total 
volume of 500 µL of SBB. This solution was stored in the 
dark at 4 ˚C.  
 
A3. Preparation of the AgNP-HBCL-Ab conjugate 
Unless stated otherwise, all incubation steps were 
performed at RT at 600 rpm. To start, 5.0 µL of 6.7 µM Abs 
were incubated with 5.0 µL of 50.0 mM sodium meta-periodate 
(NaIO4) for 30 min in the dark to oxidize the polysaccharide 
chains on the fragment crystallizable (FC) region of the 
Ab. The oxidation reaction was quenched with 125 µL of PBS.  
The oxidized Abs were then incubated with 5.0 µL of 5.0 mM 
of the heterobifunctional cross-linker (HBCL) solution for 
2 h. The HBCL was first dissolved in dimethyl sulfoxide 
(DMSO) and then diluted in deionized (DI) water prior to 
being used. The modified Ab solution was transferred to an 
Amicon ultra 0.5 mL centrifugal filter (10 K) and was 
centrifuged for 25 min at 4 °C at 14,000 g. The HBCL-
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modified Abs were then incubated with 500 µL of the AgNP 
solution (4.9 x 1011 AgNPs/mL) for 1 h. In this step, the 
microcentrifuge tubes were pre-blocked with superblock 
blocking buffer (SBB) to prevent non-specific binding of 
Abs and AgNPs on the walls of the tubes. These tubes were 
covered with aluminum foil to protect the AgNPs from light. 
Following incubation, 50.0 µL of 10.0 µM mPEG-SH were added 
and incubated for another 20 min. Finally, three 
centrifugation (25 min, 4 °C, 16,600 g) steps were 
performed to remove unbound material, followed by 
resuspension into 500 µL SBB.180,106 
 
A4. Preparation of the MµB-Ab conjugate 
First, 50.0 µL of 1.0 µm-diameter streptavidin-coated 
magnetic beads (MµB) were placed into a 0.6 mL PCR tube and 
washed by magnetic separation. The washing was carried out 
as follows: the tube was held up to the magnet so that the 
MµBs collected on the side of the tube (~30.0 s), and then 
the supernatant was removed. The MµBs were resuspended in 
100 µL of PBS, vortexed, and gently centrifuged to pull the 
solution back into the bottom of the tube. The tube was 
then held up to the magnet again, and the supernatant was 
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removed. This was repeated four times. The MµBs were 
resuspended in 20.0 µL of PBS, and then 30.0 µL of 4.7 µM 
of the biotinylated 15C4 Ab were added. The tube was 
incubated at RT for 30 min on the tube revolver at 40 rpm. 
Finally, the MµBs were gently centrifuged back into the 
bottom of the tube and washed as previously described using 
SBB.184 The final MµB-Ab conjugate was then resuspended in a 
final volume of 50.0 µL of SBB.  
 
Protocol A5. Synthesis of AgNCs 
The AgNCs were synthesized using a slightly modified version 
of a previously reported method.224,221 Briefly, 5.0 mL of 
100% EG in a 50 mL round-bottom flask were heated to 150 °C 
using an oil bath, and then 60.0 µL NaSH (3.0 mM in EG) 
were added. After 2 min, 0.50 mL HCl (3.0 mM in EG) and 
1.25 mL polyvinylpyrrolidone (20.0 mg/mL in EG) were added. 
After another 2 min, 0.40 mL CF3COOAg (282 mM in EG) was 
added. The reaction was stopped after 30 min by cooling the 
flask in an ice bath. The products were washed with acetone 
and DI water using centrifugation at 12,000 g, dispersed in 
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